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SUMMARY
The initial aim of the thesis was the production of monoclonal antibodies for 
use in the development of an assay for PTH (1-84). The response to 
immunisation, using chemically synthesised PTH peptides as immunogen, was 
species and strain specific with DA rats consistently responding with high titre 
antibodies to PTH (1-34). Five monoclonal antibodies were produced to PTH 
(1-34), three of which (3B3, 4G3 and 6E3) were considered to be of potential 
use in assay systems.
A two-site immunometric assay specific for PTH (1-84) has been developed 
using 3B3 and a C-terminal monoclonal antibody - ESQ1. The assay 
development studies revealed 3B3 to be sensitive to the oxidation state of PTH. 
Hydrogen peroxide is therefore included in the assay to convert endogenous 
PTH (1-84) to the oxidised form prior to measurement. The validation studies 
confirmed the assay to be unaffected by PTH fragments. The assay has a 
minimum detection limit of 0.5 pmol/1, sufficient to measure PTH (1-84) in all 
normal subjects, and a range of 1.5-250 pmol/1 with an intra-assay CV of less 
than 10% (2.8-250 pmol/1 less than 5% CV). Studies on clinical samples 
indicate good discrimination between normal subjects (mean 2.1; range 1.0-5.0 
pmol/1) and patients with primary hyperparathyroidism (mean 21.0; range 5.8- 
100 pmol/1) who in turn are well separated from patients with hypercalcaemia 
of malignancy (14/18 <0.5 pmolA).
The measurement of PTH(l-84) over a 24 h period has shown the existence of 
circadian rhythm, characterised by an early evening rise and a broad peak 
through the night, in normal subjects which is absent in patients with primary 
hyperparathyroidism. The physiological significance of this observation is 
reflected in the presence of parallel changes in nephrogenous cyclic adenosine 
monophosphate in the normal subjects which are also absent in the
hyperparathyroid patients. Although transient falls in calcium were observed 
these studies the changes in PTH (1-84) over the 24 h period could not be fully 
accounted for by changes in serum adjusted calcium concentrations. An 
important observation from these studies was that discrimination between 
normal subjects and patients with primary hyperparathyroidism is time 
dependent. Thus for optimal discrimination between normal subjects and 
patients with primary hyperparathyroidism PTH (1-84) samples should be 
taken, and reference ranges established, between 1000 and 1600 h. The most 
significant finding of the circadian studies was that PTH (1-84) concentrations 
in normal subjects over a 24 h period show a stronger temporal correlation with 
other circadian hormones, notably prolactin, than with adjusted calcium 
concentrations. This observation suggests that factors other than plasma 
ionised calcium are involved in the tonic control of PTH (1-84) secretion.
4. PTH (1-84) concentrations in the circulation vary in a manner consistent with 
pulsatile secretion. The estimates of pulsatility obtained in normal subjects, 
pulses every 10-15 minutes, are in agreement with the frequency of pulsatility 
previously reported for bioactive PTH. This supports the concept of PTH (1- 
84) being the major bioactive form of PTH in the circulation. The response to 
an acute lowering of serum calcium confirms that, in common with other 
hormones, modulations of the amplitude and frequency of pulses are an integral 
part of the control of PTH (1-84) secretion. However, the pattern of 
pulsatility observed, at the frequencies studied, appears to be characteristic of 
the individual and does not correlate with the presence of primary 
hyperparathyroidism.
5. The response to treatment, with the bisphosphonate Pamidronate, was 
compared in patients with either Paget's disease of bone or hypercalcaemia 
associated with malignancy. In the patients with Paget's disease therapy with 
Pamidronate produced a small but significant drop in serum adjusted calcium
which was sustained throughout the study. This was accompanied by a 
significant rise in PTH (1-84). The concentration of PTH (1-84) continued to 
rise progressively despite no further fall in serum calcium. In patients with 
hypercalcaemia of malignancy Pamidronate produced the expected and 
prolonged decrease in serum adjusted calcium such that at the end of the study 
the mean calcium in these patients was within the reference interval. The PTH 
(1-84) concentrations rose progressively throughout the study to a mean 
concentration above the reference interval. More interestingly the initial 
increase occurred when the mean adjusted calcium was above the reference 
interval with no patient hypocalcaemic. The results suggest a resetting of the 
'trigger' point for PTH (1-84) secretion in patients with hypercalcaemia of 
malignancy. An important conclusion from this study is that in the assessment 
of PTH (1-84) concentrations in the hypercalcaemic patient samples should be 
obtained prior to treatment being initiated.
A study of the treatment of patients with secondary hyperparathyroidism 
undergoing haemodialysis demonstrated the ability of the assay to measure 
PTH (1-84) specifically in the presence of large amounts of C-terminal PTH 
fragments. The study also showed that in patients with moderately severe 
secondary hyperparathyroidism, even after many years of renal replacement 
therapy, medical treatment can achieve marked parathyroid suppression. A 
combination of high oral doses of Calcitriol and low calcium dialysate was well 
tolerated and achieved higher concentrations of 1,25 dihydroxy vitamin D 
without causing hypercalcaemia than oral Calcitriol therapy alone. There was 
evidence of the direct effect of 1,25 dihydroxyvitamin D on the parathyroid 
gland since PTH (1-84) concentrations fell significantly during the first month 
of active treatment despite static serum calcium concentrations. An additive 
suppressive effect of PTH (1-84) secretion was observed when the serum 
calcium increased with higher doses of Calcitriol. Thrice weekly Calcitriol
was shown to be as effective as daily therapy which may allow simplification 
of therapy regimes.
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CHAPTER 1 : INTRODUCTION 
1 BACKGROUND TO THE PROJECT
The Endocrinology Section at Glasgow Royal Infirmary has had a strong interest in 
the measurement of parathyroid hormone (PTH) for many years. The measurment of 
PTH has been central to the routine laboratory assessment of patients with disorders 
of calcium metabolism and to studies on the physiology and pathophysiology calcium 
homeostasis. The present project was conceived at the time when the PTH 
immunoassay method was based on a unique polyclonal antiserum raised in a 
guinea pig - AS 211/32. While the assay had been a significant improvement on 
previous methods it was cumbersome by today's standards (7 day incubation), had 
limitations in its ability to measure PTH (sensitivity and specificity), but more 
importantly the antiserum was in increasingly restricted supply. The time was 
appropriate, therefore, for a project to design and develop an assay for PTH.
2 INTRODUCTION TO PTH
2.1 Biosynthesis and structure
PTH in man and in other species studied is comprised of 84 amino acids in a single 
peptide chain (Potts et al 1982). PTH is secreted by the chief cells of the parathyroid 
glands and within the parathyroid cell the biosynthetic pathway is known to conform 
to that of other secretory peptides .
The biosynthesis of PTH is shown diagramatically in Figure 1.1. PreproPTH (115 
amino acids) is the primary translation product of the PTH mRNA. The preproPTH 
is synthesised on the ribosome then transported across the membrane of the 
endoplasmic reticulum with concomitant cleavage of the pre or signal sequence to 
yield the proPTH form (90 amino acids). The cleavage is so rapid that very little 
intact preproPTH is found in parathyroid cells. The relatively more stable proPTH is
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Figure 1.1
S c h e m e  depicting th e b io sy n th esis  of PTH (1-84) (from H abener et al, 1977).
31
the major precursor protein. After a lag of several minutes, the proPTH moves to the 
Golgi apparatus where the prohormone is converted to PTH (1-84). The mature 
hormone PTH (1-84) is then packaged in secretory granules and leaves the cell by 
exocytic fusion of the granule with the plasma membrane (Habener et al 1977, Cohn 
and Elting 1983).
The PTH gene is represented only once in the haploid genomes of humans, rats and 
cows. The human PTH gene is located on the short arm of chromosome 11 and is 
closely linked to the b-globin gene. The PTH gene contains two introns. The first 
intron (3400 bp) comes 5 base pairs before the sequence encoding the preproPTH 
sequence. The second intron (103 bp) interrupts the codon encoding the fourth amino 
acid of the 'pro' sequence. The PTH gene introns therefore roughly separate discrete 
functional domains, the first separates the 5' noncoding region from the rest of the 
gene and the second separating the precursor specific 'prepro’ region from that of 
mature PTH (1-84). A similar pattern of intervening sequence has been found in a 
number of genes encoding hormones such as gastrin and insulin (Kronenberg et al 
1986).
The base sequences for the entire coding regions of the gene for human, bovine and 
rat PTH have been determined utilizing complementary deoxyribonucleic acid 
(cDNA) sequences to mRNA isolated from parathyroid cells (Vasicek et al, 1983, 
Heinrich et al 1984, Weaver et al, 1984). These analyses have confirmed the 
sequences for PTH obtained by amino acid sequencing techniques (Keutmann et al, 
1978, Potts et al, 1982, Rosenblatt 1982). The primary structure of human 
preproparathyroid hormone is shown in Figure 1.2. The mature PTH (1-84) 
hormone contains no carbohydrates but there is evidence that up to 2 0 %  of hormone 
extracted from parathyroid glands is phosphorylated on the serine residues at 
positions three and seventeen (Goltzman et al, 1986).



























o Human PTH B ovine PTH
Figure 1.2
Primary structure of hum an preproparathyroid horm one. Also sh ow n  are the d ifferences in 
primary structure b etw een  hum an and bovine PTH (from Potts e t al, 1982).
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2.2 Structure-Function Relationships
The biological activity of PTH (1-84) is associated with the N terminal third of the 
molecule. The sequence 1-27 is the minimum required for detectable biological 
activity (Cohn and Elting 1983). Deletion of residues 1 and 2 destroys the biological 
activity but not receptor binding such that the modified peptides 3-34 and 7-34 are 
competitive inhibitors of PTH action in  v i tr o  (Potts et al 1982, Horiuchi et al 1983). 
The interaction of PTH (1-34) with its receptor is also altered by oxidation of the 
methionine residues at positions 8 and 18 (Tashijian et al, 1964). Studies on the 
effects of oxidation on the biological activity of PTH peptides in animals have 
indicated either total inactivation (Galceran et al, 1984) or an alteration in the 
spectrum of biological activity (Pang et al, 1983). More recent work has indicated 
that oxidation alters the secondary structure of PTH (Zull et al, 1990).
The investigation of the secondary structure of PTH revealed two domains of 
secondary structure, one corresponding to the N-terminal region and the other to the 
C-terminal region, connected by a 'stalk' sequence in the region of residues 30-40 
(Brewer et al 1975, Fiskin et al 1977). Using circular dichroism Zull et al (1990) 
have shown most of the secondary structure in PTH (1-84) to be associated with the 
N- terminal region. Within PTH (1-34) they showed that the secondary structure to 
be primarily generated by the first 18 residues. Further it was shown that oxidation 
of the methionine residues, particularly at position 8 , was accompanied by a change 
in secondary structure and a reduction in affinity for PTH receptors. Deletion of 
residues from 1 through to 6  did not affect the secondary structure. Thus it was 
concluded that secondary structure is important for receptor binding and that 
oxidation alters the biological activity of PTH (1-84) by modifying the secondary 
structure. As deletion of residues 1 and 2 did not alter the secondary structure or 
receptor binding, but results in a loss of activity, it was concluded that these residues 
are important in the activation of the PTH receptor.
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2.3 Mechanism of Action
PTH interacts with specific receptors on distinct cell types in target tissues. 
Classically the PTH-receptor complexes have been shown to stimulate cell function 
through coupling to adenylate cylase to produce the second messenger, cAMP, and 
subsequent phosphorylation of regulatory proteins by protein kinases (Chase and 
Aurbach 1967). The activation of adenylate cyclase is mediated through the guanine 
nucleotide coupling proteins - the G proteins. Two G proteins are involved in the 
regulation of adenylate cyclase, one stimulatory, Gs, and the other inhibitory, Gi 
(Hurley et al, 1984).
Recently PTH has been shown also to activate phospholipase C and act via the 
second messengers, inositol triphosphate (IP-3) and diacylglycerol (DAG) (Hruska 
et al, 1987). Both type 1, cAMP mediated, and type 11, IP-3 and DAG mediated, 
receptors have been described in various cells (Hesch et al, 1986, Hruska et al 1986, 
Hruska et al, 1987). The mechanism by which PTH and its receptor couple to both 
adenylate cyclase and phospholipase C may involve preferential activation of the Gi 
protein (Hruska 1987).The biological role for the interaction of these signals and 
remains to be established.
2.4 Control of secretion from the parathyroid glands
There is general agreement that the plasma concentration of calcium is the dominant 
regulator of PTH secretion. PTH secretion is increased in response to low calcium 
and decreased in the face of high calcium. There are at least two major mechanisms 
that control the secretion of PTH, one involving intracellular calcium, the other 
intracellular accumulation of cAMP.
The precise mechanism whereby calcium exerts its effects on PTH secretion is not 
fully established. It appears to be mediated in part through a decrease in the cAMP 
content of the cell (Brown 1982). Calcium does not acutely alter the rate of synthesis
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of proPTH or its conversion to PTH but affects hormone production through 
enhancing intracellular degradation of PTH within the parathyroid cell. The major 
products of intraglandular degradation of PTH (1-84) are the C-terminal peptides 
PTH (34-84) and PTH (37-84). These C-terminal fragments are secreted with intact 
PTH (1-84) in a molar ratio of 2:1, indicating that the bulk of newly synthesised 
PTH (1-84) is degraded (Cohn and Elting 1983). The inabilty to find substantial 
amounts of N-terminal fragments in glandular secretion suggests that these fragments 
are further degraded within the gland probably by a mixture of enzymes including 
cathepsin B (MacGregor et al, 1979).
The availability of cDNA probes for preproPTH mRNA has made possible the study 
of the control of PTH synthesis together with its secretion. Acute experiments (4-7 h) 
on the effects of high extracellular calcium on bovine parathyroid cells showed 
changes in PTH secretion with no detectable change in mRNA concentrations 
(Heinrich et al 1983, Brookman et al 1986), whilst longer incubation periods (16-24 
h) resulted in a decrease in mRNA in addition to a fall in secretion (Russel et al, 
1983, Brookman 1986). Studies on human parathyroid adenomata in culture also 
showed suppression of mRNA in response to high calcium although this was not 
accompanied by a fall in PTH secretion (Farrow et al, 1988). A two-stage control of 
PTH synthesis and secretion has been proposed on the basis of these studies. Long 
term regulation would involve changes in mRNA concentrations within the cell while 
acute control would involve alterations in post-transcriptional events (Farrow et al, 
1988). This model is consistent with the concept, discussed above, of acute changes 
in calcium controlling PTH secretion by altering intraglandular degradation of PTH 
(Cohn and Elting 1983).
Parathyroid glands are known to contain receptors for 1,25 dihydroxy vitamin D3 
(Mason et al 1980). Studies in  v iv o  have indicated that that administration of 1,25 
dihydroxyvitamin D3 decreases parathyroid activity (Oldham et al, 1979). It was not 
clear, however, whether the parathyroid gland was a target tissue for 1,25
dihydroxyvitamin D3 or whether suppression was as a result of raised circulating 
concentrations of calcium produced by the administration of 1,25 dihydroxyvitamin 
D3 . Recent studies, using a cDNA probe, have indicated that 1,25 dihydroxyvitamin 
D 3 regulates parathyroid gland activity by suppressing preproPTH mRNA 
concentrations and PTH secretion (Karmali et al, 1989). The receptor for 1,25 
dihydroxyvitamin D3 has now been shown to bind directly to the 5’-flanking region 
of the bovine parathyroid hormone gene (Farrow et al, 1990).
Magnesium inhibits PTH in a similar way to calcium although the affinity of 
magnesium for the inhibitory site is less than is the case for calcium. In addition 
profound hypomagnesaemia interferes with PTH secretion (Brown 1982). The 
monovalent ions lithium and potassium stimulate secretion (Brown et al, 1982). 
Sodium-potassium ATPase may also be involved in controlling secretion in that 
ouabain, an inhibitor of the ATPase, inhibits secretion (Brown et al, 1983).
In addition adrenergic agents, dopamine, secretin, prostaglandins, and several 
classes of drugs are also capable of influencing PTH secretion (Heath 1980, Brown
1982). Parathyroid cells contain the adenylate cyclase system and PTH secretion is 
intimately related to the cAMP content of of parathyroid tissue (Abe and Sherwood 
1972, Dufresne and Gitelman 1972). Evidence from in  v i tr o  studies indicate that 
agents capable of altering the cAMP content of the parathyroid cell will alter the rate 
of PTH secretion. There is a linear relationship between measured total cAMP and 
the rate of PTH release regardless of which stimulator or inhibitor is applied (Brown 
et al, 1978).
Although the intracellular cAMP concentration is clearly an important modulator of 
PTH secretion calcium appears to be the more significant physiological regulator of 
secretion. Calcium is capable of completely suppressing PTH secretion regardless 
of the cAMP concentration within the cell. However, higher concentrations of 




Intact PTH (1-84) is rapidly cleared from the circulation (half life of less than 4 
minutes) mainly by liver and kidney (Oldham et al, 1978, Martin et al, 1979, 
Bringhurst et al, 1988). In the liver, Kupffer cells metabolise PTH (1-84) by 
cleaving it at the region containing amino acids 33-41 (Bringhurst et al, 1982). In 
addition the kidney also clears PTH (1-84) from the circulation where both 
peritubular uptake and glomerular filtration are important. Inactive C-terminal 
fragments are then released into the circulation (Bringhurst et al, 1988). Liver and 
kidney cathepsin-like enzymes have been identified that are capable of cleaving PTH 
(1-84) at or near residues 33-44 and 36-57 (Bringhurst et al, 1982). Whether the N- 
terminal fragments are degraded, sequestered in tissue or secreted in  v iv o  has not 
been completely resolved but most studies agree that if N-terminal fragments circulate 
then their concentration is much lower than that of PTH (1-84) (Goltzman 1986, 
Bringhurst et al, 1988).
Glomerular filtration is the main mechanism for removing inactive C-terminal 
fragments from the circulation. Impaired renal function prolongs the half-life of both 
intact PTH (1-84) and fragments. The concentration of the inactive C-terminal 
fragments is particularly affected as the half-life can be extended from less than an 
hour to days (Hruska et al, 1981).
In addition bone cells and skeletal tissue may metabolise PTH (1-84) and contribute 
to the heterogeneity of circulating PTH (Freitag et al, 1979).
2.6 Heterogeneity of Circulating PTH
As described in Sections 2.4 and 2.5 the metabolism of PTH (1-84) within the 
parathyoid gland and in liver, kidney and bone all contribute to the final heterogeneity 
of PTH in the circulation (see Figure 1.3). Generally less than 5% to 25% of total
Heterogeneity of circulating PTH
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Figure 1 .3
S c h e m e  depicting the secretion , m etabolism , c learan ce  and circulating form s of PTH.
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immunoreactive PTH is the major glandular form PTH (1-84) and the predominant 
circulating immunoreactive form consists of inactive C-terminal fragments (Bennet et 
al, 1981). In addition the presence of mid-molecule fragments in the circulation has 
been described (Roos et al, 1981, Marx et al, 1981). The available evidence suggests 
that, if present in the circulation, the concentration of N-terminal fragments is low 
relative to PTH (1-84) (Bringhurst 1988) although it may be increased in end stage 
renal failure (Goltzman 1986). These studies emphasise the dominant role of intact 
PTH (1-84) as the major biologically active form of the hormone in  v iv o  .
3 PHYSIOLOGY OF PTH
3.1 Actions of PTH on the Kidney
Sites of action
The actions of PTH in target tissue are mediated by interaction with specific receptors 
on distinct cell types. The nephron represents a series of distinct cell types bearing 
receptors for several different hormones. PTH receptors are distributed in the cortical 
regions of proximal as well as distal tubules.In the proximal tubule sites are found in 
the cortical early convoluted as well as the ‘bright’ portions. In the distal tubule, 
PTH sensitive adenylate cyclase is found in the granular portion and the cortical 
ascending limb (Morel et al, 1982). The distribution found for PTH sensitive 
adenylate cyclase agrees with the physiological findings that PTH influences 
phosphate transport at proximal and distal tubular sites (Khlar and Peck 1980).
Calcium reabsorption
PTH directly affects reabsorption of calcium from the glomerular filtrate. Under the 
influence of PTH there is a decreased calcium clearance at any given calcium load, 
reduction in circulating PTH concentrations leads to an increased calcium clearance. 
The physiological mechanisms whereby calcium transport in the kidney is regulated 
by PTH have been delineated only partially. It is known that calcium and sodium
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transport are coupled in the proximal tubule and that PTH can influence sodium 
transport in that segment of the nephron. However the major physiological effect of 
PTH on calcium reabsorption occurs beyond the proximal tubule in the thick 
ascending and granular portions of the distal tubule (Dennis and Brazy 1982). Direct 
effects of PTH on this segment have been identified in  v i tr o  and have been shown to 
be mediated through cAMP (Bordeau and Burg 1980).
Phosphaturic Effect
A rapid increase in the urinary excretion of phosphate was one of the first 
physiological effects of increased PTH secretion to be recognised. This action 
represents the effects of the hormone at two distinct loci within the nephron. 
Infusion of PTH reduces reabsorption of sodium and phosphate in the proximal 
tubule. Further, PTH reduces phosphate reabsorption in the distal tubule (Agus et al, 
1981).
The effect of PTH on phosphate reabsorption in the proximal tubule may be 
secondary to its effect on sodium reabsorption. Dibutyryl cAMP has a similar 
influence on sodium and phosphate, and cAMP is known as a regulator of sodium 
transport in a number of tissues (Strewler et al, 1977). It has also been suggested that 
phosphaturia may be secondary to changes in intraluminal pH or proximal transport 
of bicarbonate. Increases in pH would change the ratio of HP0 42‘ to H2PO4’ and 
consequently decrease the rate of phosphate reaborption as monvalently charged 
phosphate is more readily translocated across cell membranes than is divalently 
charged phosphate.
Other effects on the kidney
PTH causes a net inhibition of bicarbonate reabsorption in the proximal tubule. The 
mechanism is not clear. In conditions of excessive PTH secretion, such as marked 
hyperparathyroidism, proximal tubular acidosis can develop (Aurbach et al, 1985).
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The effects of PTH on renal bicarbonate clearance may be one of the factors causing 
the phosphaturia discussed above.
Isotonic fluid reabsorption in the proximal tubule is also impeded by PTH. This may 
be secondary to decreased sodium transport in the proximal tubule. The sodium thus 
excluded from reabsorption in the proximal tubule gives rise to a net increase in 
sodium delivery to the distal tubule carrying with it an increase in associated water. 
The sodium is reabsorbed in the distal tubule leaving the water to be excreted. This is 
reflected an an increase in the free water clearance (Aurbach et al, 1985).
3.2 Actions of PTH on Bone
Early and late effects
The effect of PTH in mobilising calcium from bone occurs in two phases. The early 
phase represents mobilisation of calcium from areas of bone and the enhanced 
transfer of this calcium into the ECF; this effect does not require protein synthesis. 
The later phase is associated with an increase in in synthesis of bone enzymes, 
particularly lysosomal enzymes that promote bone resorption and influence bone 
remodelling. Bone remodelling, the resorption of older regions of bone (osteons) 
and subsequent replacement with new bone formation, is due to degradation of bone 
by osteoclasts and the subsequent infiltration of osteoblasts that synthesise new 
collagen and allow remineralisation of replacement osteons (Aurbach 1988). The 
inital effect of PTH on bone is increased resorption. This is reflected in reduced 
osteoblast function and enhanced osteoclast activity. Later, new bone formation is 
enhanced. Bone growth factors are likely to be involved in mediating the new bone 
formation which occurs in response to the earlier phases of enhanced bone resorption 
(Tam et al, 1982).
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Action of PTH on bone cells
PTH added to bone fragments causes enhanced bone resorption by increasing the 
activity of osteoclasts and initially by inhibition of osteoblast activity. PTH stimulates 
RNA synthesis in osteoclasts, increases the number of nuclei per osteoclast and 
increases the number of osteoclasts. These changes are accompanied by increases in 
the release of lysosomal enzymes which are dependent on new protein synthesis. 
Lysosomal enzymes are released rapidly from bone activated by PTH. Other effects 
of PTH on bone include enhanced synthesis of hyaluronate, inhibition of citrate 
decarboxylation, inhibition of collagen synthesis and changes in alkaline phosphatase 
activity (Aurbach 1988). Despite the importance of the increase in osteoclastic 
resorption by PTH studies in  v i t r o  indicate that PTH does not interact directly with 
the osteoclast. The primary target of PTH appears to be a mononuclear bone cell, 
thought to be the osteoblast. Osteoblasts in turn release factors which activate the 
osteoclast (Cohn and Wong 1978).
3.3 Action of PTH on gastrointestinal calcium absorption
The gastrointestinal tract responds indirectly to PTH as a consequence of the 
activation of the la  hydroxylase system for vitamin D metabolites in the kidney. The 
enhanced gastrointestinal absorption of calcium induced by PTH is secondary to the 
action of 1,25-dihydroxyvitamin D formed in the kidney and acting on cells in the gut 
(Aurbach 1988).
3.4 Role of PTH in calcium homeostasis
The most significant physiological role of PTH is to control the concentration of 
calcium in the extracellular fluid (ECF) (Talmage and Meyer 1976). Calcium is the 
most abundant mineral in the human body. The average adult body contains 25,000 
mmol (1 kg) of which 99% is in bones and teeth with less than 0.1% in the ECF. 
Numerous cell and organ functions are dependent on the maintenence of calcium
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concentration in the ECF within narrow limits. These include the excitabilty of nerve 
function and neural transmission; proteolysis; exocytosis; blood coagulation; muscle 
contraction; membrane stability; enzyme regulation and mineralisation of bone 
(Aurbach et al, 1985).
Plasma calcium after correction for variations in plasma proteins shows little variation 
throughout the day, although the changes in protein levels induced by postural 
changes in blood volume are sufficiently large that correction for them may introduce 
errors that would obscure significant changes in the concentration of free calcium 
ions. Small changes have been observed in normal subjects in the concentration of 
adjusted clacium (Markowitz et al, 1988, Mallette 1989, Logue et al, 1990c) and 
ionised calcium (LoCascio et al, 1982) although the significance of these changes is 
not clear.
The concentration of calcium in the plasma is controlled by the coordination of the 
fluxes of calcium which occur between the plasma and the gut, bone and kidney. 
Figure 1.4 shows in diagramatic form the average fluxes in calcium per day in a 
normal adult. Bone is not metabolically inert, some of its calcium is rapidly 
exchangeable with the ECF, the turnover between bone and ECF being 
approximately 500 mmol/day. In the kidneys ionised calcium is filtered by the 
glomeruli and almost totally reabsorped in the tubules. Gastrointestinal secretions 
contain calcium some of which is reabsorbed together with dietary calcium. Since 
calcium in the ECF pool is exchanged through the kidneys, gut and bone about 
thirty-three times every 24 h a small change in any of these fluxes will have a 
profound effect on the concentration of calcium in the ECF and, therefore, in plasma. 
These fluxes in calcium are controlled by the co-ordinated action of the three major 
calcitropic hormones - PTH, 1,25-dihydroxyvitamin D and calcitonin.
The hormonal control of the fluxes between plasma and gut, kidney and bone is 
shown in Figure 1.5. At the gut level 1,25-dihydroxy vitamin D acts to increase
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calcium absorption. PTH and calcitonin have no recognised effects on gut absorption 
by the intestine.
Bone remodelling is influenced by each of the three main calcitropic hormones. The 
effects of PTH are complex involving a balance between an anabolic effect (on the 
osteoblast) and a catabolic effect (on the osteoclast). In  v i v o , the balance between the 
anabolic and catabolic effects of PTH may be critically determined by dose and 
timing, with continuous high levels of PTH enhancing bone resorption and 
intermittent exposure enhancing the osteoblast-stimulating effects (Tam et al, 1982). 
The major effect of calcitonin is to inhibit osteoclastic bone resorption. The acute 
inhibition of osteoclastic activity allows the continuing osteoblastic activity to 
increase net bone uptake of calcium into bone (Talmage et al, 1983). 1,25- 
dihydroxyvitamin D also has dual effects on bone, it increases bone resorption by 
increasing the metabolic activity of the osteoclast especially at high concentrations 
(Malluche et al, 1986). 1,25-dihydroxy vitamin D also plays major role in facilitating 
bone formation but this is probably mediated by its maintenance of a normal calcium 
phosphate product (Underwood and De Luca 1984).
At the kidney PTH and 1,25-dihydroxyvitamin D promote tubular reabsorption of 
calcium: calcitonin tends to inhibit this process although probably to a minor degree 
in humans (Mallette 1989).
Several hormones other than those directly involved in calcium homeostasis, PTH, 
vitamin D and calcitonin, exert effects on bone and calcium metabolism. Growth 
hormone, adrenal glucocorticoids, thyroid hormones and the sex hormones are 
necessary for the normal growth and maintenance of bone balance. The precise 
cellular events which underly these effects are not fully understood; thyroid 
hormones, glucocorticoids and insulin appear to act directly on bone cells; growth 
hormone exerts its effects through growth hormone dependent intermediary 
compounds, somatomedins; and sex steroids appear to act indirectly but the
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mechanisms involved have not been identified. For a review see Adams (1989).
Therefore, the physiological actions of PTH are in general directed to raise the 
concentration of calcium in the ECF. The actions of PTH on the kidney and bone in 
effecting calcium transfer are direct whereas the transfer of calcium from the gut to 
the ECF is indirect and secondary to the influence of PTH in enhancing the formation 
of 1,25-dihydroxyvitamin D from 25 hydroxyvitamin D in the kidney. In addition 
however, since activation of osteoclastic bone resorption is thought to be the primary 
step in the initiation of bone remodelling at each site, increasing the number of 
osteoclasts serves to maintain bone turnover at a higher rate. Thus, PTH under 
normal conditions plays a major role in the maintenance of bone turnover.
4 MEASUREMENT OF PTH
4.1 Assay of function
Bioassay
It is in the nature of the scientific investigation of endocrine systems that hormones 
are first discovered and initially defined by their physiological function. PTH was 
first prepared as an active extract of parathyroid glands by Collip (1925). The 
original bioassay for PTH was based on the rise in serum calcium observed in dogs 
injected with gland extract (Collip 1925). Subsequent in  v iv o  bioassays utilised, rats, 
chicks or quail (Aurbach 1985). In general in  v iv o  bioassays based on the ability of 
PTH to induce hypercalcaemia or phosphaturia or to stimulate urinary cAMP have 
not been sufficiently sensitive to measure circulating concentrations of PTH (Zanelli 
and Parsons 1980) and have largely been replaced by in  v i tr o  bioassay methods. A 
number of more sensitive in  v i tr o  systems based on measuring the cAMP response of 
the adenylate cyclase systems of the renal membrane (Nissenson et al 1981, Niepel 
et al, 1983) or the rat osteosarcoma cell (Klee et al, 1988) have been described. 
While these methods can be adapted to measure PTH concentrations in the
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circulation, by concentration of the sample, they are not sufficiently sensitive to 
differentiate low, normal and elevated concentrations in sera (Armitage 1986).
Ultrasensitive cytochemical bioassays have been developed which allow the 
determination of PTH bioactivity in the circulation (Chambers et al, 1978, Goltzman 
et al, 1980). The cytochemical bioassay method is based on the PTH-mediated 
stimulation of glucose-6 -phosphate dehydrogenase activity in guinea pig renal 
capsule segments. The end product, reduced neotetrazolium, is quantitated in 
sections by microdensitometry (Chambers et al, 1978). This assay has been shown 
to allow discrimination of normal subjects from patients with either 
hypoparathyroidism or hyperparathyroidism (Fenton et al, 1978, Allgrove et al,
1983).
Although bioassays, particularly the cytochemical bioassay, can provide clinically 
useful measurements they are cumbersome to perform and unsuited to processing 
large numbers of samples. Thus bioassays remain valuable research tools but are not 
practicable for routine use.
Indirect Measurements of PTH Function 
Urinary cAMP
The discovery of the PTH-sensitive adenylate cyclase in renal cortex was followed 
by the demonstration that PTH rapidly increased the urinary excretion of cAMP 
(Chase and Aurbach 1967). This increase was due to enhanced renal production of 
cAMP rather than to a change in filtered load. The urinary excretion of cAMP was 
therefore used as an indirect assessment of circulating PTH activity. However, 
differences in methods of specimen collection and data expression limited the use of 
this test (Marcus 1989). Standardisation of the urinary cAMP measurement was 
achieved by Broadus et al, (1977) who normalised the excretion data for glomerular 
filtration rate and described a simple approach to estimate the renal contribution or
‘nephrogenous’ cAMP. The calculation is made by subtracting the plasma cAMP 
from the total urinary cAMP excretion:-
NcAMP = Urinary cAMP x serum creatinine - plasma cAMP
urinary creatinine
The use of nephrogenous cAMP as an index of PTH function has centered on its 
ability to identify excess PTH function, as in primary hyperparathyroidism. While 
the calculation of NcAMP provides the best index of cAMP excretion, and there is a 
positive correlation between NcAMP and the degree of hypercalcaemia, the utility of 
this test in mild disease has been questionable (Marcus 1989).
Urinary Phosphate
The rapid increase in urinary phosphate excretion that follows PTH administration 
was one of the first described effects of PTH. The kidneys handle phosphate by a 
saturable reabsorption process with no apparent tubular secretion in humans. In 
considering the efficiency of phosphate reabsorption, in addition to the urinary 
phosphate excretion, factors that determine the load presented to the nephron should 
be taken into account - the plasma phosphate concentration and the glomerular 
filtration rate. Classical indices such as the tubular reabsorption of phosphate do not 
fully allow for these. The concept of a ‘tubular maximum’ for phosphate was 
defined, therefore, as the maximal tubular reabsorption of phosphate divided by the 
glomerular filtration rate (TmP/GFR) (Walton and Bijvoet 1975). This value 
estimates the set point for the serum phosphate concentration taking into account the 
serum phosphate concentration and the glomerular filtration rate (Broadus and 
Rasmussen 1981). Like NcAMP the sensitivity and specificity of this test, in the 
assessment of excess PTH function, has proved to be variable (Marcus 1989).
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4.2 Assay of structure 
Immunoassay
Immunoassay since its first description (Yalow and Berson 1960, Ekins 1960) has 
become the foremost method in the routine endocrine laboratory for the measurement 
of hormones. The technique is based on the inherent specificity and avidity of the 
binding of an antibody to its antigen. For the clinical laboratory the major advantages 
of immunoassay methods lie in the abilty to develop sensitive assays for a wide range 
of hormones and the applicabilty of the methods to the processing of large numbers 
of samples.
Radioimmunoassay
Radioimmunoassay (RIA) is the simplest example of saturation analysis (Ekins 
1960). In RIA methods a fixed but limiting amount of antibody is reacted with a 
fixed amount of radioactively labelled antigen and a variable amount of antigen, either 
standard or unknown sample. At equilibrium the antibody binding sites are saturated 
with labelled antigen and antigen in proportion to their relative concentrations in the 
assay tube (Figure 1.6). Theoretically, from consideration of the Laws of Mass 
Action, it can be shown that for an RIA the maximal sensitivity is directly 
proportional to the antibody affinity, and that the optimal antibody concentration to 
maximise sensitivity approaches zero. In practice the optimal antibody concentration 
will dependent on the specific activity and level of non-specific binding of the 
labelled antigen. It is also demonstrable that incubation times must be extended in the 
direction of infinite time (Ekins 1981). Thus the development of sensitive RIA 
methods requires the production of high affinity antisera and high specific activity 
labelled antigen.
Since the first development of an RIA method (Berson et al, 1963), the PTH assay 



















































































































































































































































































development of RIA methods for PTH has been problematic due the heterogeneity of 
circulating PTH, its poor immunogenicity and the scarcity of suitable human PTH for 
immunisation and use as radiolabel. Until recently most antisera were heterologous, 
utilising antisera raised to porcine or bovine PTH purified from parathyroid glands. 
The antisera were then selected for the ability to recognise human PTH, although in 
many cases this was with reduced sensitivity. In addition preparations of 
radiolabelled PTH were labile and had inherent high non-specific binding (Endres et 
al, 1989).
Later methods employed preparations of human PTH or synthetic fragments as 
immunogen thus producing homologous antisera (Fischer et al, 1974, Hendy et al, 
1979). A further refinement was the use of fragments of PTH as radiolabel in 
conjunction with homologous polyclonal antisera to produce sequence specific 
assays (Marx et al, 1971, Mallette et al, 1982).
In general PTH RIA methods can be categorised in terms of their specificity into one 
of four groups:-
N-terminal assays: methods based on antisera to PTH (1-34), the biologically active 
region of PTH (Silverman et al, 1973, Arnaud et al, 1974, Woo and Singer 1974, 
Potts et al, 1983). As PTH (1-34) fragments, if present in the circulation, are 
thought to be in low concentration the N-terminal immunoreactivity measured in 
these assays is presumably predominantly intact PTH (1-84). It should be noted 
however, that many polyclonal antisera with predominantly N-terminal specificity, 
but raised to extracts of PTH, may well recognise additional C-terminal epitopes 
(Mallette 1980).
C-terminal assays: methods based on antisera to the C-terminal region PTH (53-84) 
(Silverman et al, 1973, DiBella et al, 1978b, Simon et al, 1980, Roos et al, 1981, 
D'Amour et al, 1984). These methods measure the intact PTH (1-84) and the 
biologically inactive C-terminal fragments. However the C-terminal fragments have a
longer half life than either intact or PTH (1-34) and are present in higher 
concentrations, therefore these assays measure mainly the C-terminal fragments.
Mid-molecule assays: The availability of synthetic fragments of PTH for 
immunisation and use as radiolabel has allowed the development of assays to the 
middle region (44-68) of the PTH molecule (Roos et al, 1981, Marx et al, 1981, 
Mallette et al, 1982). In general these assays detect fragments which contain the 
middle region and the intact hormone. In addition mid-molecule assays detect an 
additional fragment in the circulation which contains the mid-region but not the C- 
terminal region (Roos et al, 1981, Marx et al, 1981). This fragment is similar in size 
and immunochemical characteristics to the mid-region fragment found in parathyroid 
gland extracts. It has been proposed that this fragment is a specific marker for 
increased PTH secretion as it is absent from basal samples from normal subjects 
(Roos et al, 1981).
Intact PTH: At the time of considering this project there were two approaches to the 
measurement of intact PTH. The first was the production of antisera to the region in 
which PTH is proteolytically cleaved. Mallette (1983) raised antisera to PTH (28-48) 
and the resulting assay detected the intact hormone and the PTH (28-48) fragment but 
not hormone fragments thought to be formed in  v iv o . However the assay was not 
sufficiently sensitive to measure intact PTH concentrations in normal subjects. The 
second approach was to use sequential immunoextraction of N-terminal fragments 
followed by a mid-molecule assay (Lindall et al, 1983). Using this assay intact PTH 
was detectable in all normal subjects tested.
Immunoradiometric Assay
This technique, using an excess of labelled antibody (rather than a fixed amount of 
labelled antigen) was introduced by Miles and Hales (1968) (Figure 1.7). 
Theoretically, in comparison to the sensitivity in the limited reagent RIA method, the 






































































































































































consequence incubation times tend towards zero. The limiting sensitivity in the 
labelled antibody technique is determined to a large extent by the non-specific binding 
of the labelled antibody (Ekins 1981). The two main advantages of the use of this 
technique in a PTH assay would therefore be a potential increase in sensitivity and, 
in view of the problems in obtaining suitable PTH material for iodination and the 
lability of iodinated PTH, the use of a labelled antibody.
Initially antisera were raised to extracts of bovine PTH and selected for recognition of 
human PTH. A bovine PTH immunoadsorbent was used used to remove the residual 
antibody (see Figure 1.6 ) producing an assay for total immunoreactive PTH in the 
circulation (Addison etal 1971). The assay was further refined by raising 
anti sera to partially purified human PTH (1-84) and by the use of a PTH (1-34) or 
PTH (53-84) immunoadsorbent, homologous immunoradiometric assays were 
produced to N-terminal (Manning et al, 1980) and C-terminal (Manning et al, 1981) 
PTH respectively.
These assays while providing a rugged estimate of N-terminal or C-terminal PTH 
were not widely developed probably because of the difficulties in maintaining the 
large volumes of antisera required. In addition the N-terminal assay was not 
sufficiently sensitive to measure detectable PTH in sixty percent of normal subjects 
(Papapoulos et al, 1980).
4.3 Utility of PTH assays in the laboratory investigation of patients 
with disorders of calcium homeostasis
In the laboratory assessment of patients with disorders of calcium metabolism the 
major application of PTH assays is in the differential diagnosis of hypercalcaemia 
and in the monitoring of secondary hyperparathyroidism in renal failure. 
Hypercalcaemia and particularly primary hyperparathyroidism is a common 
differential diagnostic problem. Many patients are either asymptomatic or have only 
vague non-specific symptoms (Heath 1989). There are differences in the incidence
and causes of hypercalcaemia between the general population, or unselected 
outpatients, and hospital inpatients. The incidence of hypercalcaemia in the general 
population has been reported as 0 .1 % to 1 .6 %, while in hospital inpatients the 
incidence ranged from 0.5 to 3.6% (Fiskin et al, 1980). Primary 
hyperparathyroidism was the most common cause of hypercalcaemia in the general 
population while in the hospital inpatients hypercalcaemia was most commonly 
associated with malignancy. In primary hyperparathyroidism increased PTH 
secretion due to adenoma, hyperplasia or carcinoma of the parathyoid gland results 
in increased calcium in serum (Clark and Duh 1989). In hypercalcaemia associated 
with malignancy the release of humoral factors by the tumour such as parathyroid 
hormone related peptide, prostaglandins, transforming growth factors, cytokines or 
1,25-dihydroxy vitamin D may cause an increase in osteoclastic bone resorption, 
increased renal tubular absorption of calcium or increased absorption of calcium from 
the gut leading to hypercalcaemia. (Mundy 1988). Secondary hyperparathyroidism is 
a consistent feature of advanced renal failure. The concentration of PTH in the 
circulation rises early in renal disease and often continues to increase in as renal 
function declines. Many patients develop progressive secondary hyperparathyroidism 
and eventually require subtotal parathyroidectomy (Arnaud 1973, Fuss et al, 1976)
In primary hyperparathyroidism, which is characterised by oversecretion of PTH, it 
would be expected that assays of PTH function if sufficiently sensitive, would 
correlate strongly with the clinical status of the patient. Only the most sensitive 
bioassay, the cytochemical bioassay (Chambers et al, 1978), has been shown to 
reliably discriminate between normals and either hypoparathyroid or 
hyperparathyroid patients (Allgrove et al, 1983). In hypercalcaemia of malignancy in 
which PTH secretion is suppressed, as a consequence of the humoral induced 
hypercalcaemia, the assay of PTH function (bioassays, NcAMP and TmP/GFR) 
provides a less specific assessment of circulating PTH than do immunoassay 
methods due to the ability of parathyroid-like peptides to interact with the PTH
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receptor and initiate a biological response (Stewart et al, 1983). Indeed it has been as 
a consequence of careful consideration of the discrepancy between the estimates of 
immunoreactive PTH and the those of PTH function in hypercalcaemia of 
malignancy that the presence of parathyroid hormone-related peptide was identified 
(Stewart et al 1983), isolated and sequenced (Suva et al, 1987) and immunoassay 
methods for its measurement developed (Burtis et al, 1990, Henderson et al, 1990).
N-terminal immunoassays measure the biologically active region of PTH and 
therefore might be expected to be the most useful for clinical purposes. However the 
evaluation of early N-terminal immunoassays had shown variable discrimination 
between normal subjects and patients with primary hyperparathyroidism (Armitage 
1986). This probably reflects the limited sensitivity of these methods in which most 
normal sera have undetectable PTH concentrations. Improved discrimination between 
these groups, with up to 90% of patients with primary hyperparathyroid patients 
having elevated PTH concentrations, has been obtained with more sensitive N- 
terminal assays (Manning et al, 1980, Potts et al, 1983, Hawker et al, 1984) 
although they are not sufficiently sensitive to measure circulating PTH in normal 
subjects. N-terminal assays are useful in the investigation of hypercalcaemia of 
malignancy as PTH concentrations are low or suppressed (Armitage 1986). The half- 
life of the immunoreactive N-terminal PTH is similar to that of intact PTH and 
therefore these assays can be applied to the study of acute changes in PTH secretion. 
As N-terminal immunoreactive PTH is less affected than C-terminal fragments by 
diminished renal clearance these assays are also useful in monitoring patients with 
renal failure.
Paradoxically C-terminal and mid-molecule assays which measure predominantly 
biologically inactive fragments assays have provided clearer discrimination between 
normal and abnormal parathyroid function (Armitage 1986). It has been suggested 
that the results of C-terminal PTH assays correlate well with parathyroid gland 
activity because, with the longer half-lives of the C-terminal fragments, these assays
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provided an indication of the integrated secretory activity of the parathyroid glands 
(Arnaud et al, 1974). The finding that the small mid-region fragment reflects 
parathyroid activity has given the importance to mid-molecule assays (Roos et al, 
1981). An assay has been developed with an antiserum to mixed C-terminal and mid­
molecule activity (Hawker et al, 1984). Although mid-molecule and C-terminal 
assay have been shown to provide good discrimination of normal from 
hyperparathyroid patients these assays are markedly affected by renal function and 
give consistently detectable values in patients with hypercalcaemia of malignancy 
(Armitage 1986).
At the time of considering this project the procedure for intact PTH (1-84) had 
recently been developed and data available on the clinical validation of this method 
was limited. Initial studies suggested that the method could measure circulating PTH 
(1-84) in normal subjects and gave good discrimination between the normals and 
patients with primary hyperparathyroidism (Lindall et al, 1983). However, this 
method requires an immunoextraction step and may not be suited to processing large 
numbers of specimens.
In summary, therefore, no one method for the assay of circulating PTH is optimal for 
the clinical laboratory. The cytochemical bioassay while providing valuable clinical 
information is technically complex and therefore the method remains a reference 
method rather than a routine procedure. Immunoassay methods are ideally suited to 
the processing of large numbers of samples and will remain the method of choice for 
the clinical laboratory. At this time, the mid-molecule and C-terminal assays provide 
the best discrimination between normal and hyperparathyroid patients. However, it is 
probable the development of more sensitive assays for the biologically active N- 
terminal PTH and more particularly specific assays for intact PTH (1-84) will 
produce methods with the discrimination required for the laboratory investigation of 
patients with disorders of calcium metabolism and which will be applicable to all 
clinical samples. In addition the ability to measure directly changes in circulating
PTH (1-84) would allow the study of the physiology of PTH (1-84) secretion.
5 STRATEGY FOR THE MEASUREMENT OF PTH (1-84) 
5.1 Objectives
From consideration of the review of the PTH assay methods and their clinical utility I 
decided that the proposed assay should be specific for the major circulating bioactive 
form of PTH - intact PTH (1-84). The assay should not measure and should be free 
of interference from N-terminal or C-terminal fragments and therefore be applicable 
to samples from patients with renal failure. In the initial assay design parameters I 
included the following general characteristics:-
a) The assay should be capable of measuring circulating PTH in all normal 
subjects. Given this requirement then, from the estimates available (Lindall et 
al, 1983), the assay will be required to measure low picomolar concentrations 
of PTH (1-84).
b) The estimates of circulating PTH concentrations obtained from the assay 
should allow good discrimination between normal subjects and patients with 
either primary hyperparathyroidism or hypercalcaemia of malignancy i.e. the 
assay should be of use in the differential diagnosis of hypercalcaemia.
c) The assay should be suitable for use in the routine clinical biochemistry 
laboratory in that it should being capable of processing large numbers of 
specimens and be applicable to samples from all patients groups including 
patients with advanced renal failure.
5.2 Two-site Immunometric Assay
As the proposed assay was to be applicable to the clinical laboratory I judged 
immunoassay to be the method of choice. Further, given the aims for specificity and 
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This technique is a modification of the immunometric, or labelled antibody, assay in 
which two antibodies are combined to provide the signal (Figure 1.8). This technique 
combines the advantages of the excess labelled antibody methods, (increased 
sensitivity, precision and working range), with the defined specificity inherent in 
employing two antibodies, raised to different but complementary epitopes on the 
molecule to be measured. The use of labelled antibody also avoids the problems 
associated with the production and storage of radiolabelled PTH.
5.3 Monoclonal antibody production
The development of a two-site immunometric assay (IRMA) specific for for PTH 
(1-84) would require two antibodies, one with absolute specificity for N-terminal 
PTH, the other with absolute specificity for C-terminal PTH. The antibodies would 
be either coupled to a solid-phase support or radiolabelled and therefore would be 
required in large quantities and in purified form.
The development of the techniques to produce monoclonal antibodies (Kohler and 
Milstein 1975) has had a major impact on the development of two-site IRMA 
methods. The classical disadvantage of having to maintain large volumes of antisera 
and the problems inherent in radiolabelling polyclonal antisera have been to a large 
extent circumvented as monoclonal antibody (Mab) technology enables the 
production of gram quantities of purified antibodies of defined specificity.
The principle underlying the successful production of monoclonal antibodies is 
outlined in Figure 1.9. Lymphocytes from immunised animals will not themselves 
grow in v i t r o  but they may be immortalised by fusion with myeloma cell lines. The 
resulting hybrid myeloma (hybridoma) cells retain the important properties of both 
cell types involved in the fusion. Thus they not only grow indefinitely as tumour 
cells like the myeloma but also continue to secrete the antibody characteristic of the 
lymphocyte. The key to this success was the careful choice of fusion partners, these 
being not only from the same species (originally from mouse) but also of the same
Production of monoclonal antibodies
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basic cell type. As an essential refinement the myeloma cells were engineered to have 
an enzyme (hypoxanthine-guanine phosphoribosyltransferase) deficiency. Thus, 
after cell fusion, hybrids but not parental cells survive to grow in selective medium 
containing hypoxanthine, aminopterin and thymidine (HAT). This is important as the 
efficiency of fusion is low (of the order of 1 in 1 0 ,0 0 0  cells) so that hybrids are 
initially vastly outnumbered by myeloma cells. Hybrid cells may be cloned and 
individual colonies, each secreting a different homogeneous, defined antibody, can 
be grown in tissue culture or as tumours in animals, for antibody production. Cells 
can be maintained indefinitely in culture or stored frozen until required.
Thus I proposed that the production of large quantities of purified antibodies of 
defined specificity by monoclonal antibody technology was to be central to the 
strategy for the development of the two-site IRMA for PTH (1-84).
5.4 Chemically synthesised PTH peptides as immunogen
At the time of initiating this work the above approach of two-site immunometric 
assay based on monoclonal antibodies was begining to be applied to the measurement 
of hormones. Two-site IRMA's had been successfully developed for human 
chorionic gonadotrophin (HCG), alphafoetoprotein (AFP) and luteinising hormone 
(LH) (Shimizu et al, 1982, Hunter et al, 1982, Hunter et al, 1983) These assays had 
confirmed the theoretical predictions of improved sensitivity, precision and working 
range over the corresponding RIA methods. However these molecules are highly 
immunogenic and material for immunisation was readily available.
For monoclonal antibody production it is possible to use a crude extract of an 
antigen, which is immunogenic, and then select for the hydridoma clones with the 
appropriate specificity - the approach successfully adopted for HCG, AFP and LH. 
Nevertheless it would also be possible to use defined preparations of the antigen and 
therefore ensure antisera of defined specificity. PTH is a poor immunogen and 
human material for immunisation was not available at the outset of this project. I
proposed therefore to utilise the available chemically synthesised peptide sequences 
of PTH which had been used to raise polyclonal antisera but not monoclonal 
antibodies, useful in diagnostic systems.
The use of synthetic human PTH peptide sequences offered several potential 
advantages - a) the synthetic peptide sequences were readily available in sufficient 
quantities; b) by immunising with only either the N-terminal or C-terminal sequence 
it would be improbable that antibodies raised would recognise both regions, thus 
ensuring totally N or C-terminal specific antisera; and importantly, c) as PTH is a 
poor immunogen it was hoped that immunisation with parts of the PTH (1-84) 
molecule would raise antisera to epitopes not normally immunogenic as part of the 
whole molecule (Lemer 1982).
6 AIMS FOR THE WORK OF THE THESIS
The primary aim at the outset of this project was to develop an assay for circulating 
PTH (1-84) which would supersede- the existing RIA method which was based on 
the predominantly N-terminal specific antibody AS 211/32. The secondary aim of the 
work of this thesis was the application of the assay to a re-examination of the 
physiology and pathophysiology of PTH secretion. It was was hoped the assay , by 
virtue of increased specificity and sensitivity, would be able to measure changes 
within the reference range for normal subjects with confidence and thus provide a 
clearer insight into the control of PTH secretion particularly with regard to dynamic 
changes in circulating PTH concentrations.
Thus the aims and proposed strategy for the work of this thesis can be summarised 
as follows:-
1) The production of monoclonal antibodies of defined specificity using 
chemically synthesised peptide sequences of PTH.
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2) The development and validation of a two-site IRMA specific for intact PTH 
d-84).
3) The application of the assay developed to the physiology and pathophysiology 








CHAPTER 2 : MATERIALS AND METHODS 
1 MATERIALS
BioGelPIO
Bovine serum albumin (BSA)
Carbonyldiimidazole 
Cell culture plastics
Cell culture reagents 
Cysteine hydrochloride 
Dimethyl Sulphoxide (DMSO)
Donkey anti-sheep gamma globulin
ECDI (ethyl-dimethyl-aminopropyl carbodiimide)
Freund's adjuvant
Glutaraldehyde (electron microscopy grade) 
Mouse/Rat strains
Non-immune bovine and ovine serum 














Sigma Chemical Co. 
Bantam and Kingman UK 
SAPU











Sepharose 6 B 
Sepharose CL-4B 
Sheep anti-mouse gamma globulin 



















All other reagents and chemicals were Analar grade from BDH.
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2 IMMUNISATIONS AND SERUM ANTIBODY EVALUATION
2.1 N-terminal PTH Immunogens
(a) Synthetic human PTH (1-34) peptide.
(b) Synthetic human PTH (1-34) conjugated to albumin. PTH (1-34) was 
coupled to bovine serum albumin in the initial experiments by the 
carbodiimide method and latterly by the glutaraldehyde method both as 
described by Orth (1979) except that the quantities were scaled down to 
allow coupling of 400 qg peptide batches:-
Carbodiimide: Reagents were dissolved in 0.04 molA potassium phosphate 
buffer pH 4.5. ECDI (0.1 ml; 3.7 mg/ml) was added to a solution of 
bovine serum albumin (0.4 ml; 3.6 mg/ml) in a polystyrene test tube (55 x 
75 mm) and incubated for 60 minutes at room temperature with mixing. 
The PTH peptide (0.4 ml; 400 |ig) was added to the reaction mixture in 4 
x 0.1 ml aliquots over the next 60 minutes with continued mixing. This is 
equivalent to a molar ratio of peptide to albumin to ECDI of 1: 0.1: 100. 
The conjugate was purified by by dialysis against 0.05 mol/1 sodium 
phosphate buffer pH 7.4 in a microdialysis system (Bethesda Research 
Laboratories). Incorporation of peptide was monitored by the inclusion of 
radiolabelled peptide (1 0 ,0 0 0  cpm/tube).
Glutaraldehyde: Reagents were dissolved in 0.05 mol/1 sodium phosphate 
buffer pH 7.4. PTH peptide (0.4 ml; 400 (ig) was added to a solution of 
bovine serum albumin (0.4ml; 3.6 mg/ml). Glutaraldehyde (0.025 %  v/v) 
was then added to the mixture in 4 x 0.05 ml aliquots over 60 minutes 
with stirring. The conjugate was purified by dialysis against 0.05 mol/1 
sodium phosphate buffer pH 7.4 in a microdialysis system (Bethesda 
Research Laboratories). Incorporation of peptide was monitored by the
inclusion of radiolabelled peptide (1 0 ,0 0 0  cpm/tube).
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(c) Synthetic human PTH (1-10) conjugated to keyhole limpet haemocyanin 
(KLH). PTH (1-10) was custom synthesised and conjugated to KLH, 
using a bis-diazotised tolidine linkage that produced a C-terminally bound 
peptide, by Cambridge Research Biochemicals.
2.2 C-terminal PTH Immunogens
(a) Synthetic human PTH (53-84).
(b) Synthetic human PTH (53-84) conjugated to albumin. PTH (53-84) was 
coupled to bovine serum albumin in the initial experiments by the 
carbodiimide method and latterly by the glutaraldehyde method both 
described by Orth (1979) as in Section 2.1 above.
(c) Synthetic human PTH (74-84) conjugated to keyhole limpet haemocyanin. 
PTH (74-84) was custom synthesised and conjugated to KLH, using a 
bis-tolidine linkage that produced an N-terminally bound peptide, by 
Cambridge Research Biochemicals.
2.3 Preparation of Immunogens
Immunogens were prepared as water-in-oil emulsions. One volume of 
immunogen in buffer and three volumes of adjuvant, in separate glass syringes, 
were emulsified by repeated passage through a 19 g needle fitted with twin Luer 
hubs.
2.4 Immunisation Schedules
Mice: Groups of six female mice (six to eight weeks old) were given primary 
immunisations of peptide or conjugate administered intraperitoneally (ip) 
followed by up to four secondary immunisations (also ip) at intervals of two
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weeks.
Rats: Groups of six female rats (150 to 200 g) were given primary 
immunisations of peptide or conjugate followed by up to five secondary 
immunisations at intervals of two weeks. Immunisations were administered 
subcutaneously using the multi-site method (Vaitukaitus et al 1971).
Sheep: Groups of two Suffolk wethers were given a primary immunisation 
with peptide or conjugate followed by secondary immunisations at monthly 
intervals. Immunisations were administered intramuscularly and subcutaneously 
using the multi-site method (Vaitukaitus et al 1971).
2.5 Blood Spot Sampling
Mice and rats were anaesthetised with ether, the ventral vein punctured with a 
sterile 23 g needle and the exuding blood absorbed onto filter paper card to form 
a discrete spot. The blood spot was allowed to dry and a 6  mm disc punched out 
into 1.0 ml 0.9% saline.
2.6 Iodination of PTH Peptides
PTH peptides were iodinated by the solid-phase lactoperoxidase method of 
Karonen et al (1975).
To PTH peptide (2 (ig) the following additions were made:-
10 |il 0.5 molA sodium phosphate pH 7.4
1 0  jil solid-phase lactoperoxidase (prepared locally)
10 jj.1 1^5 carrier-free (1 mCi).
10 jil hydrogen peroxide (30% w/v stock diluted 1:20,000 in distilled water). 
The reaction was terminated by the addition of 200 |il of column buffer,
0.1 mol/1 sodium acetate buffer pH 4.0 containing 0.1% BSA. The solution 
was then applied to a column (30 x 1 cm) of Biogel P10 and eluted in the 
column buffer. The iodinated peptide peak was then pooled and aliquots stored 
at -20°C.
2.7 Preparation of Sepharose Linked Second Antibodies
Sheep anti-mouse, sheep anti-rat and donkey anti-sheep gamma globulin 
antisera were coupled to Sepharose CL-4B by the carbonyldiimidazole method 
of Chapman and Ratcliffe (1982).
A calibrated solution of Sepharose C1-4B in distilled water (200 ml; equivalent 
to 100 ml settled gel) was transferred to a sintered glass funnel (porosity 3) and 
dehydrated by washing the gel successively with 500 ml aliquots of distilled 
water, 30%, 50%, 70% and 100% acetone. The dehydrated gel slurry was 
resuspended in acetone to a volume of 200 ml to which was added 4.87 g of 
carbonyldiimidazole (0.15 mol/1). The solution was incubated for 60 minutes 
with stirring, then transferred to the sintered glass funnel and rehydrated by 
washing with 500 ml aliquots of acetone, 30%, 50%, 70% and 100% distilled 
water. The gel was then washed with 500 ml coupling buffer (0.1 mol/1 EPPS 
pH 8.0 containing 0.05% sodium azide). The gel was transferred to a 
polycarbonate bottle containing 25 ml of the appropriate antiserum to be 
coupled, the volume adjusted to 2 0 0  ml by the addition of coupling buffer, and 
the solution incubated for 18-24 h with mixing.
The gel solution was then centrifuged, the supernatant containing uncoupled 
protein retained for further use and the gel washed, recovered by centrifugation 
(5 minutes at 1,200 g), according to the procedure of Wide (1969).
The gel was washed with 100 ml aliquots o f :
(a) 0.5 mol/1 sodium bicarbonate buffer pH 8.0, mix for 20 minutes
(b) repeat sodium bicarbonate wash as in (a)
(c) 0.1 mol/1 sodium acetate buffer pH 4.0, mix for 60 minutes
(d) 0.1 mol/1 sodium acetate buffer pH 4.0. mix for 18-24 hours
(e) 0.9% saline, mix for 20 minutes
(f) repeat saline wash as in (e).
The gel was then stored in isotonic saline at 4°C until required.
2.8 Antibody Screening Assay
The screening assay diluent was 0.05 mold sodium barbitone buffer pH 8 .6 , 
containing 0.1% BSA.
Dilutions of serum or blood spot eluate collected from immunised animals were 
incubated (0.1 ml) with iodinated PTH peptide(10,000 cpm/tube) overnight at 
room temperature. Sheep anti-mouse/anti-rat or donkey anti sheep gamma 
globulin coupled to Sepharose CL-4B was then added (1 mg/tube) and the assay 
incubated with shaking for 2 h at room temperature. The assay was then washed 
(x3) with 2 ml 0.9% saline/Tween 20 (0.2% v/v) by centrifugation and 
aspiration.
3 PRODUCTION OF MONOCLONAL ANTIBODIES
3.1 Myeloma Cell Medium
To 100 ml RPMI 1640 media containing 20 mmol/1 HEPES the following were 
added:
1 0  ml foetal bovine serum (heat inactivated)
1 ml glutamine ( 2 0 0  mmol/1)
2 ml Penicillin/Streptomycin (100 U/ml, 100 |ig/ ml respectively)
1 ml Fungizone (250 g/ ml)
3.2 Hybridoma Cell Medium
To 100 ml RPMI 1640 media containing 20 mmol/1 HEPES the following were 
added:
2 0  ml foetal bovine serum (heat inactivated)
1 ml glutamine (2 0 0  mmol/1)
2 ml Penicillin/Streptomycin (100 U/ml, 100 |ig/ ml respectively)
1 ml Fungizone (250 [ig/ ml)
4 ml Hypoxanthine, Aminopterin, Thymidine (HAT) solution (100, 0.4 and 16 
pmolA respectively)
3.3 Maintenance of Myeloma Cell Lines
Aliquots (10 x 10^ cells/ml) of the myeloma cell lines X63.Ag8.653 (mouse) 
and Y3 Ag 1.2.3 (rat) were stored in liquid nitrogen (-196°C) until required. 
In preparation for hybridisation experiments an aliquot of myeloma cell line was 
thawed rapidly by immersion in a water bath at 37 °C and the cells transferred 
aseptically to a sterile universal container (20 ml). The cells were then washed 
(x3) in prewarmed myeloma cell medium.
The concentration of cells was then adjusted to 200,000 cells/ml with further 
myeloma cell medium and the cells incubated in a stoppered flask at 37 °C. The 
myeloma cells were maintained in logarithmic growth (minimum and maximum 
densities of 2.5 x 10^ and 1.5 x 1 0 ^ cells/ml; doubling time 16-24 h). Cells 
were counted and their viability assessed using a haemocytometer and the
trypan blue dye exclusion method.
3.4 Myeloma Cells
The volume of medium required to provide 150 x 10^ myeloma cells was 
centrifuged at 800 rpm for 5 minutes and the supernatant discarded. The cell 
pellet was washed and resuspended in 15 ml RPMI. As each hybridisation 
experiment consisted of three separate fusion events the cells were split into 3 x 
5 ml aliquots of 50 x 10^ myeloma cells.
3.5 Spleen Cells
The spleen from an immunised mouse was removed under sterile conditions and 
placed in a petri dish (5.5 cm diameter) containing 10 ml RPMI. The spleen was 
dissected free of fatty tissue and the spleen cells carefully teased from the 
capsule with scalpel blades. The cell suspension was transferred to a universal 
container and allowed to settle. The supernatant cells were removed, centrifuged 
at 800 rpm for 10 minutes and the cells resuspended in 15 ml RPMI. The cells 
were counted and split into three aliquots of 50 x 10^ cells.
3.6 Polyethylene Glycol (PEG) 1500
PEG (10 g) was weighed into a 20 ml measuring cylinder and 5 ml RPMI 
added. The PEG was dissolved by heating in water bath at 50 °C. The pH was 
then adjusted to 7.0 with NaOH (0.1 mold). The volume was then made to 
20 ml with pre-warmed RPMI. The PEG solution was then sterilised by 
membrane filtration (0 .2 2  pm).
3.7 Peritoneal Macrophages (feeder cells)
Balb/c mice (3) were killed and the peritoneal cavity washed with 5 ml RPMI 
using a syringe with a 19 g needle. The three peritoneal washings were pooled 
into a universal container, centrifuged at 800 rpm for 5 minutes, resuspended




The hybridisation protocol employed is based on that of Fazekas De Groth and 
Scheidegger (1980).
Each hybridisation experiment consisted of three fusion events.The 3 x 5 ml 
aliquots of spleen and myeloma cells were mixed and centrifuged for 1 0  minutes 
at 800 rpm. The supernatants were then decanted and the containers with the cell 
pellets placed in a beaker of water at 37 °C. The PEG solution (0.8 ml) was 
added dropwise over 60 seconds, after a further 60 seconds 1 0  ml warmed 
RPMI was added over 5 minutes. The mixture of cells was centrifuged for 10 
minutes at 800 rpm, washed in RPMI and suspended in 60 ml pre-warmed 
hybridoma cell medium.
3.9 HAT Selection
The hybridisation products were plated out into 5 x 96 well microtitre plates (0.2 
ml/well) containing peritoneal macrophages. Plates were sealed with sellotape 
and incubated at 37°C for 10-14 days before examination for growing hybrids 
and subsequent screening for antibody production.
3.10 Cloning of Hybridoma Lines
Hybridoma cells were cloned by limiting dilution. A dilution was made in 
hybridoma cell medium to a concentration 800 cells/ml. Doubling dilutions 
were then performed across the 12 columns of a 96 well plate containing 
peritoneal macrophages. The plates were sealed with sellotape and incubated at 
37°C for 10-14 days before examination for hybridoma growth and screening 
for antibody production. The cells growing from the highest dilution (lowest
starting cell numbers) and identified as producing antibody were selected for 
further cloning. Cell lines were cloned at least twice before expansion and ascitic 
fluid production.
3.11 Screening for PTH Antibody
All wells with growing hybrids were screened for antibody production. Cell 
culture supernatant (0.1 ml) was incubated with iodinated PTH peptide (10,000 
cpm/tube) diluted in 0.05 mol/1 barbitone buffer pH 8 .6  containing 0.5% BSA, 
overnight at room temperature. Sheep anti-mouse, or anti-rat gamma globulin 
coupled to Sepharose CL-4B was then added (1 mg/tube) and the assay 
incubated with shaking for 2 h at room temperature. The assay was then washed 
(x3) with 2 ml 0.9% saline/Tween 20 (0.2% v/v) by centrifugation and 
aspiration.
3.12 Assessment of Immunoglobulin Class of Antibodies
Rat monoclonal antibody typing kits (Serotec) were used to assess the 
immunoglobulins produced by the hybridoma lines. The test entails diffusing 
six antisera, directed against rat IgGl, IgG2a, IgG2b, IgG2c, IgA and IgM, 
against neat culture supernatants in immunodiffusion plates.
3.13 Expansion of Hybridoma Lines
Selected hybridoma lines were transferred from the 0.2 ml wells of the clone 
plates to 2  ml wells and allowed to expand before seeding in 25 ml and 100 ml 
flasks. Feeder cells were present at each stage and cell densities in flasks were 
maintained at lO^-lO^ cells/ml.
3.14 Cell Freezing
All cells were stored frozen in liquid nitrogen. Cells were centrifuged and 
resuspended at 1 -5  x 1 0 ^ cells/ml by the drop wise addition of ice cold foetal
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bovine serum containing 10% DMSO. Aliquots (1ml) containing 5-10 x 1 0 ^ 
cells were dispensed into cryovials and frozen slowly overnight in a polystyrene 
box at -70 °C . The cells were then transferred to liquid nitrogen for long term 
storage.
3.15 Bulk Production of Monoclonal Antibody
Congenitally athymic (Nu/Nu; nude) mice were used for the production of 
ascitic fluid and were maintained under sterile conditions in a laminar flow 
hood. The nude mice were primed by the intraperitoneal injection of 0.5 ml 
pristane 7 days before the injection of 5 xlO^ hybridoma cells, which had been 
washed and resuspended in 5 ml RPMI. Ascitic fluid was tapped at intervals of 
2-3 days from anaesthetised nude mice using a 19 g needle allowing the fluid to 
to drain from the abdomen under gravity.
IgG was purified from ascitic fluid using the method of Steinbuch and Audran 
(1969). Ascitic fluids of the same tap number were pooled to a volume of 20 
ml and adjusted to pH 5.0 with acetic acid (0.1 mol/1). N-octanoic was added 
dropwise with stirring (1.76 ml/20 ml ascitic fluid). After stirring for 30 minutes 
the solution was centrifuged at 1500 g for 20 minutes and the supernatant 
containing the IgG retained. The pellet was washed (x2) with 20 ml 0.1 mol/1 
sodium bicarbonate pH 8.0. The supernatants were pooled and dialysed against 
0.01 mol/1 sodium bicarbonate pH 8.0 and stored at -50 °C .
3.16 Protein Estimation
Protein estimations were carried according to the method of Schacterle and 
Pollack (1973), based on the original work of Lowry et al (1951).
Reagents:
(a) Alkaline copper reagent: 20 g Na2 CC>3 , 4 g NaOH, 200 mg sodium 
tartrate and 1 0 0  mg copper sulphate (5H20) were dissolved and made up
to a final volume of 2 0 0  ml with distilled water.
70
(b) Folin-Ciocalteau reagent: a 1:25 dilution of the pre-prepared stock solution 
in distilled water.
(c) Protein standards: a stock solution of 50 mg BSA in 50 ml distilled water 
was double diluted (x4) prior to use.
Protocol:
Standard, buffer blank or test solution (0.2 ml) was mixed with reagent (a), 
vortexed and allowed to stand for 10 minutes at room temperature. Reagent (b) 
(1.0 ml) was then added, the solution vortexed, incubated at 55°C for 5 
minutes, cooled and the absorbance measured at 650 nm.
4 DEVELOPMENT OF PTH (1-84) IRMA
4.1 Iodination of Monoclonal Antibodies
PTH Mab's were iodinated by the solid-phase lactoperoxidase method of 
Karonen et al (1975).
To PTH Mab (25 p.g) the following additions were made:
10 pi 0.5 mol/1 sodium phosphate pH 7.4
1 0  |il solid-phase lactoperoxidase (prepared locally)
10 pi 125i , carrier-free (1 mCi).
10 |il hydrogen peroxide (30% w/v stock diluted 1:20,000 in distilled water).
The reaction was terminated by the addition of 200 p.1 of column buffer, 
0.1 mol/1 sodium phosphate buffer pH 7.0 containing 0.1% BSA. The solution 
was then applied to a column (30 x 1 cm) of Sepharose 6 B and eluted in the 
column buffer. The iodinated antibody peak was then pooled and aliquots stored
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at -20°C.
4.2 Preparation of Solid-phased Monoclonal Antibodies 
Mab coupled to Sepharose CL-4B
Mab IgG was coupled to Sepharose CL-4B by the carbonyldiimidazole method 
of Chapman and Ratcliffe (1981) as described for second antibodies. Mab IgG 
(70 mg) was added to the activated Sepharose CL-4B gel and the procedure 
followed as in methods Section 1.7 above.
Mab coated to Microtitre Plates
Mab IgG was coated to microtitre plates using the following procedure: the Mab 
IgG (0.2 ml) diluted in coating buffer (0.05 mol/1 TAPS buffer pH 8 .6 ) to a 
concentration of 100 |ig/ ml was incubated overnight at 37°C in 96 well 
microtitre plates (0.2 ml wells). The IgG solution was aspirated and the wells 
washed (x4) with coating buffer containing 0.5 % BSA (0.2 ml) . The plates 
were stored at 4°C in the presence of coating buffer containing 0.5% BSA until 
required.
4.3 Oxidation/reduction of PTH Peptides
PTH peptides were oxidised/reduced by the method of Tashijian et al (1964).
Oxidation: stock aliquots (2 |ig) of PTH peptide were diluted with 1 ml sodium 
acetate buffer pH 3.8 (0.1 mol/1) and incubated with hydrogen peroxide (0.1 
molA) for 3 hours at room temperature.
Reduction: stock aliquots (2 fig) were diluted with 1 ml sodium acetate buffer 
pH 3.8 (0.1 mol/1) and incubated with cysteine hydrochloride (0.12 mol/1) for 3 
hours at 80°C.
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5 COMPARISON OF PTH (1-84) METHODS 
5.1 Protocol for Allegro** M ethod
The Allegro1* method (Nichols Institute Diagnostics, San Juan Capistrano, CA 
92675) for intact PTH method is a two-site immunoradiometric assay for the 
measurement of PTH (1-84). It is based on two goat polyclonal antibodies to 
human PTH which have been affinity purified to be specific for mid-region and 
C-terminal PTH (39-84) respectively. The C-terminal specific antibody is 
immobilized onto plastic beads and the N-terminal antibody radiolabelled.
Sample, standard or control (0.2 ml) is incubated simultaneously with 
radiolabelled antibody (0 .1  ml; 2 0 0 ,0 0 0  cpm/tube) and antibody coated bead for 
22 hours at room temperature. The tubes are washed (x2) with 2.0 ml of the 
wash solution provided and the radioactivity counted for one minute.
5.2 Protocol for Magic-Lite** Method
The Magic-LiteR method (Ciba Coming Diagnostics Limited, Essex, UK C09 
2DX) is a two-site chemiluminometric assay employing an acridinium ester 
labelled sheep anti-human PTH (1-34) and a mouse monoclonal anti-human 
PTH (44-68) covalently coupled to paramagnetic particles.
Sample, standard or control (0.2 ml) is incubated with acridinium ester labelled 
N-terminal antibody, vortexed and incubated for 18 hours at room temperature. 
The solid-phased C-terminal monoclonal antibody is added (0.5 ml) and 
incubated for 1 hour at room temperature. The assay is washed with 1.0 ml 
distilled water. Separation is achieved using magnetic separation racks and 
decantation of the supernatants. Distilled water (0.1 ml) is added and tubes 
vortexed prior to counting for 2 seconds in the Magic-LiteR Analyzer.
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CHAPTER 3 : PRODUCTION OF MONOCLONAL ANTIBODIES 
1 INTRODUCTION
Since the first development of a radioimmunoassay (Berson and Yalow, 1963), the 
measurement of PTH has played a central role in the differential diagnosis of 
hypercalcaemia (Boyd and Ladenson 1984). However, the low picomolar 
concentrations and molecular heterogeneity of circulating PTH have remained 
significant obstacles for the analyst and compromised the clinical utility of PTH assay 
development (Armitage, 1986). Classically, these problems have been addressed by 
attempting to develop sensitive limited reagent assays of defined specificity for PTH 
fragments. This requires the production of high avidity antisera, of defined 
specificity for PTH fragments (Segre et al, 1975).
The source of immunogen for the production of antibodies to PTH has also caused 
difficulty. PTH is not stored in large quantities in the parathyroid glands (Cohn and 
Elting 1983). Therefore supplies of PTH, especially human, are limited. Bovine 
parathyroid glands have been used as a source of immunogen, either partially 
purified extracts or purified PTH (1-84) (Nussbaum et al, 1981). Similarly 
adenomatous and hyperplastic human parathyroid tissue have been used as a source 
of immunogen (Di Bella et al, 1978a).
In general, limited reagent assays based on antisera to the N-terminal region of PTH, 
classically raised to purified bovine PTH (1-84) preparations in guinea pigs, chicken 
and goats, have lacked the sensitivity to measure circulating concentrations in the 
plasma of normal subjects (Amaud et al, 1974, Martin et al, 1980, Beastall et al, 
1983). In addition, these assays could not be guaranteed to be totally N-terminal 
specific. For example, the N-terminal antiserum AS 211/32, commercially available, 
and one of the most widely used in human studies was found to react also with C- 
terminal epitopes (Mallette, 1980).
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The limited reagent assays based on antisera specific for the biologically inactive mid 
or C-terminal regions raised to extracts of parathyroid tissue (Di Bella et al, 1978b, 
Simon and Cuan 1980) while able to measure circulating concentrations, present at 
up to tenfold greater concentrations than N-terminal fragments or intact PTH, were at 
best an index of chronic parathyroid hormone secretion and markedly influenced by 
renal function.
The advantages of excess reagent immunometric assays, have been extensively 
reviewed (Miles and Hales, 1968, Woodhead et al, 1974, Ekins, 1981). 
Theoretically the immunometric assay can achieve greater sensitivity, for an antibody 
of a given avidity than limited reagent systems. Further, by using the two-site or 
sandwich technique assays of defined specificity can be developed (Addison and 
Hales 1971, Miles et al, 1974). The principles of immunometric assays were first 
elucidated in 1968 (Miles and Hales, 1968). However, practical difficulties - the 
large volumes of antisera required, high blanks in the single antibody immunometric 
assay which limited the sensitivities realised and the requirement for affinity 
purification of antibodies for labelling in the two-site assay - restricted the general 
application of these methods. It was with the development of the techniques for the 
production of monoclonal antibodies (Mab) (Kohler and Milstein, 1975) that the 
immunometric assays came of age. The Mab technology made available for the first 
time milligram to gram quantities of purified antibody.
Generally, Mab’s tend to be of lower avidity than polyclonal antisera and so 
unsuitable for sensitive limited reagent assays (Siddle, 1985). However, using 
excess reagent principles in the immunometric assays greater sensitivities can be 
achieved than using limited reagent systems even with Mab of lower avidity, in the 
range 109 - 1011 (Ekins, 1981). Thus the combination of Mab technology and 
immunometric two-site assay principles offered the potential for the development of 
sensitive and specific assays for hormones circulating low concentrations. This
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approach has been applied to a wide range of hormones and proteins, eg, TSH, LH,
FSH and HCG - for a review see Siddle (1985).
The aim of this project was to raise Mab’s of defined specificity to N-terminal and to 
C-terminal PTH which could be combined in an immunometric two-site assay system 
with the sensitivity and specificity to measure intact PTH (1-84).
The production of Mab’s of defined specificity posed the combined problems as to 
the source of material for the immunogen and the poor immunogenecity of PTH. 
The availability of synthetic peptide sequences of PTH offered a ready source of 
milligram quantities of immunogen and importantly of guaranteed purity. The 
studies on the generation of an antibody response to an immunogen (Young et al, 
1983) and on the ‘tapping of the immune repertoire’ (Lerner, 1984) had shown that 
small synthetic peptide sequences from a larger molecule could generate an antibody 
response. Further, it was shown that antibodies could be generated in response to 
the small sequence epitopes that would not generate a response as part of the intact 
molecule (Schmitz et al, 1983). Thus the aims of this project were fully defined as: 
the production of monoclonal antibodies of defined specificity to PTH, using 
synthetic peptide sequences as immunogen, which would form the basis of a two-site 
immunometric assay for intact PTH (1-84).
2 IMMUNOGEN AND IMMUNISATION SCHEDULES
2.1 N-terminal PTH Peptide Immunogens
Three preparations of N-terminal immunogens were employed:
(i) Synthetic human PTH (1-34) peptide
(ii) Synthetic human PTH (1-34) peptide conjugated to bovine serum albumin
(iii) Synthetic human PTH (1-10) conjugated to keyhole limpet haemocyanin (KLH)
The source of peptides and preparation of the peptide-protein conjugates is described 
in Methods (Chapter 2; Section 2.1).
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2.2 C-terminal PTH Peptide Immunogens
Three preparations of C-terminal immunogen were employed:
(i) Synthetic human PTH (53-84)
(ii) Synthetic human PTH (53-84) conjugated to bovine serum albumin
(iii) Synthetic human PTH (74-84) conjugated to keyhole limpet haemocyanin (KLH)
The source of peptide and preparation of the peptide-protein conjugates is described 
in Methods (Chapter 2; Section 2.2).
2.3 Immunisation Schedules
For all primary immunisations a solution of peptide/conjugate was emulsified in 
Complete Freund’s adjuvant. For secondary immunisations Incomplete Freund’s 
adjuvant was employed, (see Methods, Chapter 2; Section 2.3).
(a) Mice: Groups of six female mice of six different strains, were given a primary 
immunisation of peptide/conjugate administered intra-peritoneally (i.p.) followed by 
up to four secondary immunisations (also i.p.) at intervals of two weeks.
(b) Rats: Groups of three female rats were given a primary immunisation of 
peptide conjugate followed by up to five secondary immunisations at intervals of two 
weeks. Immunisations were administered subcutaneously using the multi-site 
method (Vaitukaitus et al, 1971).
(c) Sheep: Groups of two sheep were given a primary immunisation followed by 
up to six secondary immunisations at monthly intervals. Immunisations were 
administered subcutaneously and intra-muscularly using the multi-site method 
(Vaitukaitus et al, 1971).
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3 RESPONSE TO IMMUNISATION SCHEDULES
A summary of the responses to the PTH peptide immunogens obtained in sheep, 
mice and rats is shown in Table 3.1.
3.1 Antibody Screening Procedure
Blood samples taken by venesection were collected either in glass tubes (sheep) or 
absorbed on to filter paper (mice, rats). Serum or blood-spot eluate was diluted in 
barbitone buffer pH 8.6 (0.05 mol/1, 0.5% BSA) and incubated with radiolabelled 
peptide (either PTH (1-34) or PTH (53-84)) overnight at 4°C. Second antibody 
(either anti-sheep or anti-rat/mouse IgG) coupled to Sepharose C1-4B was added, the 
assay shaken for 2 h at room temperature, then washed (x2) in Saline/Tween 20 
(0.2% v/v) and counted.
3.2 Response in Sheep
There was a brisk response in Suffolk wethers to immunisation with unconjugated 
PTH (1-34) and PTH (53-84) peptides (50 pg primary and secondary 
immunisations). Antibody titres were detected at one month post primary 
immunisation in 2/2 and 1/2 sheep immunised with PTH (1-34) and PTH (53-84) 
peptides, respectively. Similar results were obtained in Suffolk wethers using PTH 
(1-34) and PTH (53-84) conjugated to albumin as immunogens (100 pg conjugate; 
equivalent to 11 pg peptide for primary and secondary immunisations). Maximum 
titres of 1:64,000 and 1:18,000 for PTH (1-34) and PTH (53-84) were achieved 
(Figures 3.1 and 3.2).
3.3 Response in Mice
No antibody titres were detected in balb/c mice in response to immunisation with 
unconjugated PTH (1-34) and PTH (53-84) peptides at 10, 20 or 50 pg primary and 
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Figure 3.1
Serum  titre of PTH (1-34) antibodies in sh e e p  108 following 
im munisation with PTH (1 -34) peptide.
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Figure 3 .2
Serum  titre of PTH (53-84) antibodies in sh e e p  109 following im m unisation  
with PTH (53-84) peptide.
and PTH (53-84) conjugated to albumin at 100 |LLg conjugated (equivalent to 11 (ig 
peptide) or 200 |ig primary and secondary immunisations.
Immunisation with PTH (1-10) and PTH (74-84) conjugated to KLH (100 |ig 
conjugate; equivalent to 30 jig peptide, primary and secondary immunisations) also 
failed to produce a detectable antibody titre.
The above immunisation experiments were also carried out in the following strains of 
mice considered likely to be higher antibody responders than the balb/c strain - NZB, 
balb/c NZB FI hybrids, SWR and SJL, however no antibody titre was detected.
Following publication of the work of Nussbaum et al, (1985), on the genetic control 
of the generation of an immune response to PTH, the CBA strain of mouse was 
immunised as above. No antibody titre was detected.
3.4 Response in Rats
DA and Lou strains of rats were immunised with PTH (1-34) and PTH (53-84) 
peptides (50 jig primary and secondary immunisations). No antibody titres were 
detected in the Lou rats or in DA rats immunised with PTH (53-84) peptide. In 
contrast a consistent response was detected in DA rats immunised with PTH (1-34) 
(50 |ig primary and secondary immunisations) with 6/6 DA rats responding with 
serum titres of 1:3,000 - 1:5,000 at one month post primary immunisation. 
Maximum titres of 1:50,000 were detected after a primary and five secondary 
immunisations (Figure 3.3).
4 PRODUCTION OF HYBRIDOMA LINES
4.1 Mouse Spleen Cell/Mouse Myeloma Cell Fusions
Despite the failure to detect an antibody titre three fusion experiments were 
undertaken using the spleen cells from balb/c mice immunised with either PTH (1- 
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Figure 3 .3
Serum  titre of PTFI (1-34) antibodies in a  DA rat following 
im m unisation with PTH (1-34) peptide.
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The mouse myeloma line X63 Ag 8.653 was chosen for the fusion experiments. The 
fusion protocol was based on that of Fazekas de Groth and Scheidegger, (1980), 
using 50% polyethylene glycol 1500 and a myeloma cell to spleen cell ratio of 1:1. 
Each fusion experiment consisted of three separate fusion events with the spleen cells 
recovered being split into three aliquots of approximately 50 x 106 cells. Each of the 
fusion events was plated-out into five microtitre plates (96 x 0.2 ml wells) (Methods, 
Chapter 2; Section 3.9). In addition to the immunisation schedule detailed above an 
intravenous dose of 10 Jig peptide was administered via the tail vein three days prior 
to fusion.
In each of the experiments growing hybridoma lines were seen in greater than 70% 
of wells. However, no cell lines were detected to be secreting anti-PTH antibody.
4.2 Rat Spleen Cell/Rat Myeloma Cell Fusions
Three fusion experiments were undertaken with the spleen cells from the DA rats 
found to be positive for serum antibody following immunisation with PTH (1-34). 
In addition to the immunisation schedule described above, an intravenous dose of 50 
jig PTH (1-34) was administered intrajugularly via the pectoral muscle three days 
prior to fusion. The Y3 Ag 1.2.3 rat myeloma cell line (Galfre et al, 1979) was 
obtained through Dr A Campbell, Department of Biochemistry, University of 
Glasgow. Fusion experiments were carried out using the same protocol as for the 
mouse myeloma system (Section 4.1 above; Methods , Chapter 2; Section 3.8).
No growing hybrids survived for longer than seven days in the fusion experiments 
using the rat myeloma line.
4.3 Rat Spleen Cell/Mouse Myeloma Cell Fusions
Using the same protocol as the mouse spleen/mouse myeloma experiments (Section 
4.1; Methods, Chapter 2; Section 3.8). Spleen cells from the DA rats found to have
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anti-PTH (1-34) serum titres were fused with the myeloma cell line x63 Ag 8.653. 
The DA rats were given a 50 pg dose of PTH (1-34) administered intrajugularly via 
the pectoral muscle four days prior to fusion.
In three fusion experiments growing hybrids were seen in greater than 70% of wells. 
A total of 39 wells were identified as positive for anti-PTH (1-34) antibodies. The 
distribution of binding in the positive wells is shown in Figure 3.4. Five hybridoma 
lines were stabilised and remained secreting anti-PTH (1-34) antibodies through 
cloning (x2) by limiting dilution. The initial binding in the wells from which the five 
lines 1D1, 3B3, 4G3, 6E3 and 9E3 were stabilised, is also shown in Figure 3.4.
4.4 Initial Assessment of Hybridoma Lines
Culture fluid from the five hybridoma lines was used for isotype analysis and initial 
displacement studies using PTH (1-34) peptide and a PTH (1-84) preparation from 
NIBSC (75/549). Of the five lines, four producing IgG and one IgM Mab, the best 
displacement with PTH (1-34) was observed with 9E3, then 4G3, 6E3, 3B3 and 
1D1. However, 1D1 and 9E3 appear specific for PTH (1-34) in that only 3B3, 6E3 
and 4G3 show displacement with PTH (1-84) (MRC 75/549), having displacements 
of 0.96, 0.90 and 0.43 for PTH (1-84) relative to that obtained with PTH (1-34) 
respectively (Table 3.2).
5 BULK PRODUCTION OF MAB
On the basis of the displacement experiments (Table 3.2) the three cell lines which 
recognised PTH (1-84), 3B3, 4G3 and 6E3, were chosen for bulk production of 
Mab. As the hybridoma lines are mouse/rat hybrids, and not histocompatible with 
balb/c mice, congenitally athymic (Nu/Nu; nude) mice were used for the production 
of ascitic fluid. For each hybridoma line six nude mice were pristane primed and 
inoculated with 5 x 10  ^cells intra-peritoneally. All nude mice responded with ascites 
production. Taps of ascitic fluid showed anti PTH (1-34) antibody titres of 1:105 at
Fusion Experiments for PTH(1-34) Mab's 
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Figure 3 .4
Distribution of binding in w ells found to b e  positive for PTH (1-34) 
antibodies. A lso show n are the binding levels  in the w ells from which 
the Mab lines 1 D 1, 3B 3, 4G 3, 6E 3 and 9E 3 w ere isolated.
Table 3.2
Isotope analysis and initial displacement studies on culture fluid from 
the mouse/rat hybridoma lines
Hybridoma Line Isotype of Mab Concentration of 
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9E3 IgM 0.6 -
!;;.n 7 . 9  X '?•
- C 'UiUUK ; n  • : i l  >p;  T L P P s
PTH i I - iv). None -4 the vA.r- v xhev.- .P. t;;^a=Gcaiu ds 
. uP'to ■ ■
81
20 days post inoculation ranging to >1:1010 at 40 days (Figure 3.5).
Mab IgG was purified from ascitic fluid by n-octanoic acid precipitation (Methods, 
Chapter 2; Section 3.15). Typical recoveries of IgG from ascitic fluid are shown in 
Table 3.3. Total protein concentrations for the ascitic fluids were in the range 64.3 - 
75.2 mg/ml with 20.4% to 31.1% of the protein being recovered as IgG.
6 ASSESSMENT OF ANTIBODIES TO PTH
6.1 Sheep Polyclonal Antisera
(i) Sheep 108 anti-PTH (1-34).
The displacement with PTH (1-34) and the Scatchard analysis of the data are shown 
in Figure 3.6. The avidity constant estimated for the highest avidity component of 
the antiserum is 1.6 x 1010 L/M.
(ii) Sheep 109 anti-PTH (53-84)
Despite reaching a titre of 1:18,000 the antiserum showed no significant displacement 
even at nanomolar concentration of PTH (53-84) (data not shown).
6.2 Mab’s to PTH (1-34)
(i) Displacement with PTH (1-34)
The displacement obtained with PTH (1-34) and the Scatchard analysis of the data 
for the Mab’s 3B3, 4G3 and 6E3 are shown in Figure 3.7, 3.8 and 3.9. The avidity 
constants were estimated as 5.9 x 10 ,^ 3.0 x 1010 and 1.1 x 10  ^L/M for 3B3, 4G3 
and 6E3 respectively.
(ii) Displacement with PTH (1-10)
In an attempt to localise the epitope in PTH (1-34), the Mab’s were tested for 
displacement with PTH (1-10). None of the Mab’s showed significant displacement 
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Figure 3 .5
Titre of PTH (1-34) antibodies in ascitic fluid from pristane-primed  
congenitally athymic m ice inoculated with 5 x 10 6 cells of the hybridoma 
line 6E 3.
Table 3.3
Purification of Mab IgG (3B3) from ascitic fluid
TAP: Aspiration Interval
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Figure 3 .6
PTH (1-34) standard curve obtained with sh e e p  108 antiserum  (top). The 
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Figure 3 .7
PTH (1-34) standard curve obtained with Mab 3B 3 (top). The  
Scatchard analysis of the data is a lso  show n (bottom).
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Figure 3 .8
PTH (1-34) standard curve obtained with Mab 4G 3 (top). The  
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Figure 3 .9
PTH (1-34) standard curve obtained with Mab 6E 3 (top). The  
Scatchard analysis of the data (bottom).
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(iii) Displacement with PTH (1-84)
The displacements with PTH (1-84) for the Mab’s 3B3, 4G3 and 6E3 are shown in 
Figure 3.10. The Mab’s 3B3 and 6E3 show essentially equipotent displacement with 
PTH (1-34) and PTH (1-84) consistent with the initial displacement studies (Table
3.2). 4G3 however shows little displacement even at high nanomolar concentrations 
of synthetic PTH (1-84). This is contrary to the initial displacement studies (Table
3.2) which indicated that 4G3 recognised PTH (1-84) with approximately 50% 
potency of PTH (1-34). It is probable that the impure standard preparation used in 
the initial displacement studies contained significant amounts of PTH (1-34).
7 DISCUSSION
Studies on the immunogenicity of peptide sequences have varied in their conclusions. 
Some reports have indicated that an antibody response can be obtained to peptides of 
6 to 35 residues even without conjugation to a protein carrier (Lerner, 1984, 
Schmidtz et al, 1983, Young et al, 1983). Others have maintained that only 
hydrophilic peptide sequences of at least 15 residues conjugated to protein carriers 
are consistently immunogenic (Hopp and Woods, 1981, Delmas et al, 1985).
Palfreyman et al (1984) reviewed the literature on 103 peptide sequences, up to 20 
residues long, which had been used as immunogen to generate antisera specific for 
the intact proteins of which they represented small fragments. The guidelines from 
this study were that for successful antibody production peptide sequences should be 
a minimum of 10 residues and coupled to a carrier protein. Highest success rates, 
approaching 100%, were achieved with sequences from the N- and C-terminal 
regions of proteins. This was ascribed to the suggestion (Walter, 1980) that the 
terminal sequences of polypeptides may be conformationally less constrained and 
more likely to be on the available surface of proteins than internal sequences. While 
the immunogens used in the present study conform to the above guidelines the 
success rate was less than predicted for N- and C-terminal peptide sequences. This
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undoubtedly reflects the choice of species for immunisation. The authors compiling 
the review were concerned with production of polyclonal antisera and therefore 
selected an animal for immunisation appropriate to the antigen of interest. The main 
aim of this project was the production of monoclonal antibodies and therefore it was 
essential to produce an antibody response in an animal compatible with the myeloma 
lines used for fusion experiments i.e. mice, ideally balb/c mice, failing this Lou or 
DA rats.
The pattern of responses obtained in this study - all mouse strains tested and Lou rats 
negative, 6/6 DA rats positive for PTH (1-34) antibodies, 2/2 sheep positive for PTH 
(1-34) and 1/2 sheep positive for PTH 53-84) antibodies - is consistent with a 
species and strain specific response. In previous attempts to produce monoclonal 
antibodies mice have been shown to be poor responders to bovine PTH (1-84) with 
only low avidity IgM Mab’s obtained (Nussbaum et al, 1981, Van de Walle et al, 
1983). Studies on the immunoresponsivity to human PTH (1-34) in inbred mice 
indicated that the response was under genetic control of Ir genes located in the IA and 
IE subregions of the major histocompatability complex (Nussbaum et al, 1985). 
Balb/c mice were also confirmed as genetic non-responders and the CBA mouse 
strain found to be high responders to PTH (1-34). Despite this no response was 
detected in the CBA mice immunised in this project.
The fusion experiments with the spleen cells from the DA rats, positive for PTH 
(1-34) antibodies, produced a total of 39 positive hybrids, representing 0.64% of the 
wells screened, of which 5 lines survived cloning. This is a low yield compared to 
the results obtained for highly immunogenic proteins eg, TSH, LH, FSH and AFP 
(Siddle and Soos 1981, Stevenson et al, 1987) where positive rates of 60-80% can 
be obtained. However, it is similar to the results obtained with the poorly 
immunogenic peptide hormone ACTH (White et al, 1985). The assessment 
experiments on the monoclonal antibodies produced indicate that 3B3 and 6E3 are of 
the required avidity and specificity to be of use in a two-site immunometric assay for
84
PTH (1-84). 4G3 having the highest avidity for PTH (1-34) but not recognising 
PTH (1-84) may well be of use in a two-site assay for PTH (1-34) perhaps in 
combination with either 3B3 or 6E3 Mab’s.
The polyclonal antisera produced were found not to be of sufficiently high avidity to 
be of use in an assay system for PTH (1-84). Useful antisera to both N- and C- 
terminal PTH have been produced in sheep and goats (Brown et al, 1987, Nussbaum 
et al, 1987). This may indicate that the PTH peptide conjugates prepared for this 
project were not highly immunogenic and explain the failure to produce a response in 
CBA mice. Further work is required to produce a C-terminal Mab compatible with 
either 3B3 or 6E3. In a study on the importance of hydrophilic sequences in C- 
terminal PTH, the sequence 49-53 was identified as an important epitope for the 
production of antibodies in mice, sheep and goats (Delmas et al, 1985). Continued 
immunisations with peptides containing the PTH (49-53) sequence eg, PTH (39-84) 
or PTH (44-68) would seem to offer the best chance of success.
The immediate development of the assay for PTH (1-84) would continue by a search 
for C-terminal Mab’s available either from other research groups or commercially 
which would be compatible with 3B3 or 6E3.
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CHAPTER 4 : DEVELOPMENT OF A TWO-SITE IMMUNOMETRIC 
ASSAY FOR PTH (1-84)
1 INTRODUCTION
The strategy adopted for the production of Mab’s to PTH peptides had yielded two 
Mab’s (3B3, 6E3) directed to the N-terminal region of PTH which were of the 
requisite specificity and avidity to be of potential use in a two-site immunometric 
assay for PTH (1-84). As Mab’s to the C-terminal region were not obtained it was 
decided to search for Mab’s available from other research groups which would be 
compatible with 3B3 and 6E3. Two Mab’s were located which were C-terminal 
specific and reacted with intact PTH (1-84).
(a) EioAio; specific for the 44-68 region (Ka 5.0 x 108 L/M). Produced by Dr J S 
Woodhead, Department of Medical Biochemistry, University of Wales College 
of Medicine.
(b) ESQ1; specific for the 74-84 region (Ka 1.1 x 1010 L/M). Produced by Dr K 
James, Department of Surgery, University of Edinburgh.
Samples of the Mab's were kindly supplied by the producers in order to assess their 
compatibility with 3B3 and 6E3 in a two-site immunometric assay system.
2 ASSESSMENT OF MAB COMPATIBILITY IN A TWO-SITE IRMA
2.1 Iodination of M ab’s
IgG aliquots (25 |ig) of each of the four Mab’s 3B3, 6E3, and ESQ1 and EioAio 
were iodinated by the lactoperoxidase method (Methods section 4.1). The iodination 
mixture was then applied to a Sepharose 6B column (1.6 x 70 cm) and run overnight 
at 10 ml/h 0.05 mol/1 phosphate buffer pH 7.0,0.5% BSA.
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The profile for iodinated Mab ESQ1 run on a S ep h a r o se  6B colum n (1.6 x 70 cm) 
in 0 .0 5  mol/l p h osp h ate  buffer pH 7 .0 , 0.05%  BSA  (10  ml/h).
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profiles for 3B3, 6E3 and EioAio show clean protein peaks while the ESQ1 protein 
peak has a ‘shoulder’ of higher molecular-weight material. This probably reflects the 
IgG purification procedure; 3B3, 6E3 and EioAio IgG fractions were prepared by 
the n-octanoic acid method (Methods section 3.15) while ESQ1 was received as an 
IgG prepared by a sodium sulphate precipitation method.
The specific radioactivities calculated from the percentage incorporation of iodine12^  
into the protein peaks were 18.2, 17.9, 17.2 and 18.7 (iCi/|ig IgG for 3B3, 6E3, 
EioAio and ESQ1, respectively. These were close to the target value of 20 |iCi/|ig.
2.2 Assessment of Mab’s in Microtitre Plate-Based IRMA
Preparation of Plates
IgG fractions from each of the Mab’s 3B3, 6E3, EioAio and ESQ1 were coated onto 
micro-titre plates (0.2 ml x 96 well, Removastrips, Dynatech). The IgG fractions 
were diluted in 50 mmol/1 TAPS buffer pH 8.6 to a protein concentration of 100 
pg/ml and a 200 fil aliquot incubated in the wells overnight at 37°. The wells were 
then washed (x4) in 50 mmol/1 TAPS buffer pH 8.6 containing 0.5% BSA prior to 
use.
Assessment of Mab Combinations
(i) Mab to N-terminal PTH coated on plate.
Wells (x4) coated with either 3B3 or 6E3 were incubated with 200 (il PTH (1-84) 
standard (0, 500, 1,000 pmol/l) in 0.05 mol/1 barbitone buffer pH 8.6, 0.5% BSA 
overnight at room temperature. The wells were then washed (x2) with barbitone 
buffer pH 8.6, 0.5% BSA and incubated with radiolabelled C-terminal Mab, either 
E 10A io or ESQ1 (100,000 cpm/well) overnight at room temperature. Wells were 
then washed (x4) in barbitone buffer pH 8.6, 0.5% BSA prior to counting.
The results obtained with the N-terminal Mab’s coated on plates are shown in Figure
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4.5. In the 3B3 coated plate responses were obtained with both ESQ1 and EioAio 
radiolabelled C-terminal Mab’s. The responses obtained at both PTH (1-84) 
concentrations were greater with ESQ1 than with EioAio. A similar trend is seen in 
the plate coated with 6E3 (Figure 4.5(b)). However, the responses obtained were in 
each case lower than those in the 3B 3 coated plate.
The response levels even with the best combination of 3B3 coated and ESQ1 
radiolabel were not particularly encouraging (8% counts added bound at 1,000 pmol/l 
and 0.8% bound at 500 pmol/l PTH (1-84)) although the assay system had not been 
optimised at this point.
(ii) Mab to C-terminal PTH coated on plate:
Wells coated with C-terminal Mab, either EioAio ESQ1, were incubated with 
radiolabelled N-terminal Mab, either 3B3 or 6E3, according to the protocol in (i) 
above.
The results are shown in Figure 4.6. Responses were obtained in the ESQ1 coated 
plate with both radiolabelled N-terminal Mab’s 3B3 and 6E3. The responses with 
3B3 were greater than those with 6E3. Similar results were obtained in the EioAio 
coated wells (Figure 4.6(b)) but the responses were lower than in the ESQ1 coated 
wells in each case.
The results confirm the previous experiments in concluding ESQ1/3B3 as the 
combination of Mab’s giving best results. The responses with Mab’s used in this 
orientation (ESQ1 coated, 3B3 radiolabelled) were greater than in the previous 
experiment (3B3 coated, ESQ1 radiolabelled) with 14.0 versus 8.2% of counts 
bound at 1,000 pmol/l and 8.0 versus 0.8% at 500 pmol/l PTH (1-84).
Dose response curves using ESQ1 and 3B3 in both orientations were set up using the 
above protocols. The results are in agreement with the above experiments (Figure 
4.7). The combination of 3B3 coated with ESQ1 radiolabelled gives an insensitive
A ssessm en t of Mab's : N-terminal Mab on plate
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Figure 4 .5
R e sp o n se s  obtained in the microtitre plate b a sed  IRMA with (a) 3B 3 and (b) 6E3  
Mab coated  on the plate. W ells (x4) w ere incubated (18 h at room temperature) 
with PTH (1-84) standard, w ashed  and then incubated (18 h at room temperature) 
with either ESQ1 or E1 0A 10  radiolabelled Mab.
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Figure 4 .6
R e sp o n se s  obtained in the microtitre plate b a sed  IRMA with (a) ESQ1 and (b) 
E iq A io  Mab coated  on plate. W ells w ere incubated (18 h at room tem perature) 
with PTH (1-84) standard, w ash ed  then incubated (18 h at room tem perature) with 
either 3B 3 or 6E 3 radiolabelled Mab (100 ,000  cpm /well).
R e sp o n se  Curves in Microtitre Plate IRMA
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Figure 4 .7
D o se  resp o n se  curves obtained for com binations of ESQ1 and 3B 3 M ab’s in the 
microtitre plate b a sed  IRMA. W ells coated  with either ESQ1 or 3B 3 Mab w ere 
incubated (18 h at room tem perature) with PTH (1-84) standard, w a sh ed  then  
incubated (18 h at room tem perature) with either 3B 3 and ESQ1 radiolabelled  
Mab (1 0 0 ,0 0 0  cpm /well).
response curve which even with extensive optimisation would probably not have 
been useful in measuring low picomolar concentrations of PTH (1-84). The 
combination of ESQ1 coated and 3B3 radiolabelled gave a substantially more 
sensitive response curve.
On the basis of these results it was decided to investigate the ESQ1/3B3 combination 
on the high capacity solid-phase support Sepharose CL-4B both in an attempt to 
increase the response levels obtained and also to develop an assay system with 
maximum capacity for C-terminal Mab in an attempt to minimise the influence of the 
high concentrations of C-terminal PTH fragments present in patient samples.
2.3 Assessment of Mab’s in Sepharose CL-4B Based IRMA
Coupling of Mab’s to Sepharose CL-4B
IgG fractions from Mab’s ESQ1 and 3B3 were coupled to Sepharose CL-4B gel by 
the carbonyldiimidazole method of Chapman and Ratcliffe 1981 (Methods section
4.2). Using 12 mg of Mab IgG the estimated mean uptake of IgG onto 10 ml of 
Sepharose CL-4B gel was 46.6% (range 32.1-60.8%, n=5). This is equivalent to a 
mean ratio of 15 pg IgG/mg gel (range 14-18 |ig/mg).
Assessment of ESQ1/3B3 Combinations
(i) Protocol 1
This protocol was devised to be equivalent to that employed in the plate based assay 
(Section 2.2). Mab, either 3B3 or ESQ1, coupled to Sepharose CL-4B (200 pi; 1 
mg gel) was incubated with PTH (1-84) standard (200 pi; 1,000 pmol/l) in 0.05 
mold barbitone buffer pH 8.6, 0.5% BSA overnight at room temperature with 
shaking. The tubes were then washed (x2) in barbitone buffer pH 8.6, 0.5% BSA 
and incubated with radiolabelled Mab either ESQ1 or 3B3 (200 pi, 100,000 cpm) 
overnight at room temperature. The tubes were then washed (x4) with barbitone 
buffer pH 8.6, 0.5% BSA prior to counting.
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(ii) Protocol 2
Radiolabelled Mab either 3B3 or ESQ1 (100 |il, 100,000 cpm) was incubated 
overnight at room temperature with PTH (1-84) standard (200 p,l, 1,000 pmol/l). 
Mab coupled to Sepharose CL-4B either ESQ1 or 3B3 (100 pi, 1 mg gel) was added 
and the mixture incubated overnight at room temperature with shaking. The tubes 
were then washed (x4) in 0.05 mol/1 barbitone buffer pH 8.6, 0.5% BSA prior to 
counting.
The results obtained with 3B3 coupled to Sepharose CL-4B and radiolabelled ESQ1 
are shown in Figure 4.8(a). The response obtained in both protocols (6.0-8.2% of 
counts bound) are equivalent to those achieved in the plate-based assay for these 
Mab’s used in this orientation. The blanks (response at 0 pmol/l PTH (1-84)) are 
however significantly higher.
The results obtained with ESQ1 coupled to Sepharose CL-4B and 3B3 radiolabel are 
shown in Figure 4.8(b). The responses obtained were a significant improvement 
from the plate-based assay with 35.2% and 40.3% of counts bound at 1,000 pmolA 
PTH (1-84) for protocols (i) and (ii) respectively.
A response curve using ESQ1 coupled to Sepharose CL-4B and radiolabelled 3B3 in 
protocol (ii) is shown in Figure 4.9. These results confirmed the choice of ESQ1 as 
the Mab on the Sepharose CL-4B solid-phase support and the use of 3B3 as the 
radiolabelled Mab. The response curve even though the assay conditions were not 
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R e sp o n s e s  obtained for com binations of 3B 3 and ESQ1 Mab in S ep h a ro se  CL- 
4B  b a sed  IRMA. PTH (1-84) standard w as pre-incubated (18 h at room  
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Figure 4 .9
R e sp o n se  curve obtained using Mab’s  ESQ1 and 3B 3 in S ep h a ro se  b a sed  
IRMA. Radiolabelled 3B3 w a s pre-incubated with PTH (1-84) standard then  
E S Q 1-S ep h arose  added and incubated for a further 18 h at room tem perature.
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3 OPTIMISATION OF PTH (1-84) IRMA SYSTEM
3.1 Introduction
The previous section on the assessment of the compatibility of the Mab’s had shown 
clearly that the use of radiolabelled N-terminal Mab 3B3 with the C-terminal Mab 
ESQ1 on the Sepharose CL-4B support was the only combination of real potential in 
an assay system (Section 2). In the light of this information and previous discussion 
on the performance characteristics required of an assay capable of measuring 
circulating PTH (1-84) concentrations, the optimisation experiments were aimed 
primarily:
(i) to develop as sensitive a system as possible, ie. to maximise the response and 
precision at low picomolar concentrations.
(ii) to maximise the specificity of the system for PTH (1-84) by minimising any 
possible interference from C-terminal fragments and to a lesser extent N- 
terminal fragments.
3.2 Preliminary Optimisation Studies
The assay protocol shown in Table 4.1 was chosen as baseline to the preliminary 
optimisation studies.
Optimisation of ESQl-Sepharose Incubation
(i) Time
Synthetic PTH (1-84) standard (0, 25, 250, 500 pmol/1) was incubated with 
radiolabelled 3B3 according to the initial protocol in Table 4.1. ESQl-Sepharose 
was added (1 mg Sepharose/100 |il/tube) and the assay shaken for times varying 
between 0.5 and 4.0 h, prior to washing by centrifugation and aspiration using 4 x 
2 ml 0.9% saline/Tween 20 (0.2% v/v). The response increased across the
Table 4.1
Initial protocol adopted as baseline to the preliminary assay 
optimisation studies
Assay Tubes 55 x 12 mm polystyrene (Sarstedt 55.484).
Assay Diluent 0.05 mol/1 barbitone buffer pH 8.6 (0.1 mol/1 
NaCl, 0.5% BSA). Previously employed in 
the antibody screening and assessment 
studies.
PTH (1-84) Standard Synthetic PTH (1-84) (Peninsula) diluted in 
assay diluent to concentrations covering the 
expected assay range (0 - 500 pmol/1).
Radiolabelled 3B3 N-terminal Mab 3B3 iodinated to a specific 
activity of approximately 20 pCi/pg by 
lactoperoxidase method.
(Methods section 4.1).
1st incubation 200 pi PTH (1-84) standard
100 pi radiolabelled 3B3 (100,000 cpm)
incubated at 22 h (overnight) at room 
temperature.
ESQl-Sepharose C-terminal Mab ESQ1 coupled to Sepharose 
CL-4B using carbonyldiimadazole (Methods 
section 4.2) approximately 12-17 pg IgG/mg 
gel.
/ d  ai 1 p<r ad«5 Wf?.s' aJdrd and ;;‘aY:
4 r  i  m l s a i m e A  w e e n . 2 0  ( 0 .2 %  v 7 y t
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concentration range with time as shown in Figure 4.10. The 2 h shaking time was 
selected as optimal as the increase in the blank level (the response at 0 pmol/1 PTH 
(1-84)) seen at 4 h was considered potentially detrimental to the potential sensitivity 
of the final assay system.
(ii) Mass of ESQl-Sepharose
ESQl-Sepharose was added at 0.5, 1.0 or 2.0 mg per tube to a range of PTH (1-84) 
concentrations previously incubated overnight with radiolabelled 3B3 as above. The 
assay was shaken for 2 h prior to the 4 x 2 ml saline/Tween 20 (0.2% v/v) wash 
procedure.
The response curves at 0.5 and 1.0 mg ESQl-Sepharose per tube were similar as 
shown in Figure 4.11. There was however, a significant increase in the blank level 
at 2.0 mg ESQl-Sepharose per tube which was considered undesirable.
The addition of 1.0 mg ESQl-Sepharose was adopted in order to minimise possible 
interference from C-terminal fragments by using as high a mass of ESQ1 Mab per 
tube as practicably possible. Given the coupling ratios achieved this approximates to 
12-17 |ig ESQl-IgG per tube.
Optimum pH of Assay Diluent
(i) Buffer system alone
The effect of pH on the PTH (1-84) response curve was investigated by using a 
variety of buffer systems (acetate pH 6.0, phosphate pH 7.0 and pH 7.5, bicarbonate 
pH 8.0, barbitone pH 8.5 and pH 9.0). All buffers were 0.05 M and final assay 
diluents contained 0.1 M NaCl and 0.5% BSA. For each of the diluents PTH (1-84) 
standards were incubated overnight at room temperature with radiolabelled 3B3 
(100,000 cpm). ESQl-Sepharose at 1 mg per tube was added and the assay shaken 
for 2 h prior to washing with 4 x 2 ml saline/Tween 20 (0.2% v/v).
The results are shown in Figure 4.12. The response curves decreased across the
PTH(1-84) IRMA: Time of So l id -Phase  Incubation
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Figure 4 .1 0
Optimisation of the tim e of incubation with ESQ1 cou p led  to S ep h a r o se  CL-4B. 
R adiolabelled 3B 3 w a s pre-incubated with PTH (1-84) standard, E S Q l-  
S ep h a ro se  w a s then  added  and incubated at room tem perature with shaking for 
periods of 0 .5  - 4  h.
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Figure 4.11
Optim isation of the am ount of ESQ1 cou p led  to S ep h a r o se  CL-4B added  per 
tube. Radiolabelled 3B 3 w a s pre-incubated with PTH (1-84) standard and ESQ1 
S ep h a r o se  corresponding to 0 .5 , 1.0 or 2 .0  mg S ep h a r o se  per tube w a s  added  
and the a ssa y  shaken for 2 h at room tem perature.
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PTH (1-84) concentration range with increasing pH. The blank levels followed the 
same trend apart from the blank at pH 8.5, which was lower than would be expected 
from the pH trend. This is possibly because the isoelectric point of the Mab IgG is 
close to this pH.
Analysis of this data as a ratio of signal (response) to blank indicates pH 8.5 
followed by pH 7.0 as the diluent systems giving maximum specific response. It 
was also noted that the actual blank levels in this experiment at 1,000-3,000 counts 
per 120 s were higher than previously encountered, perhaps due to ageing of the 
labelled 3B3 preparation in use at the time.
(ii) Buffer system with serum
The selection of the pH 8.5 diluent system as giving best specific response was 
mainly determined by the lower than expected blank at this pH. The final assay 
system would however contain 50% serum (assuming a 200 |il serum sample). The 
response curves in pH 8.5 and pH 7.0 diluents were repeated as per the protocol 
above but with the PTH (1-84) standard prepared and added in 200 |il 
hypoparathyroid serum. The results are shown in Figure 4.13. The blanks at pH 
8.5 and pH 7.0 are reduced to the same level by the inclusion of serum. The greater 
response at higher PTH (1-84) concentrations at pH 7.0 is however maintained. The 
signal to blank ratio in the pH 7.0 diluent is therefore greater across the PTH (1-84) 
concentration range. The phosphate pH 7.0 diluent system with the inclusion of a 
200 (il semm sample was adopted for further experiments.
Performance of Prelim inary PTH (1-84) IRMA System
Figure 4.14 shows a typical response curve and associated precision profile. The 
error relationship was derived from the measurement of synthetic PTH (1-84) 
standard curves (140 duplicate pairs) in the preliminary optimised protocol (Table
4.2). The assay has a detection limit of 0.5 pmol/1 estimated from the 22% CV on 
the precision profile (McConway et al, 1989). The intra-assay CV is less than 10%
PTH(1-84) IRMA : Effect of pH and Serum
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Figure 4 .1 3
T he effect of a s s a y  buffer pH in the p resen ce  of serum . PTH (1-84) resp o n se  
curves w ere se t  up in p hosp hate (pH 7.0) and barbitone (pH 8.5) a s sa y  buffers 
with added serum  (50% v/v) corresponding to a 200  jil sam p le s ize .
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Figure 4 .1 4
A typical PTH (1-84) resp on se curve and asso c ia ted  precision profile. The error 
relationship w a s  derived from the m easurem ent of PTH (1-84) standard (140  
duplicate pairs) in the preliminary optim ised protocol.
Table 4.2
Preliminary optimised PTH (1-84) Assay Protocol
Assay Diluent 0.05 mol/1 phosphate buffer pH 7.0 
(0.1 mol/1 NaCl, 0.5% BSA).
1st incubation 200 pi PTH (1-84) in hypoparathyroid serum 
100 pi radiolabelled 3B3 (100,000 cpm)
22 h at room temperature.
2nd incubation 100 pi ESQl-Sepharose (1 mg/tube)
2 h at room temperature with shaking.
Wash 4 x 2 ml 0.9% saline/Tween 0.2% (v/v).
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between 1.5 and 250 pmol/1 PTH (1-84) giving the assay an acceptably wide 
working range. Thus far, however, only synthetic PTH (1-84) standard had been 
measured in the assay system.
3.3 Measurement of Endogenous PTH (1-84) in Preliminary Assay 
System
Clinical Groups
Serum samples were taken, separated within 30 min of venesection, from a group of 
normal subjects (10) and patients with either primary hyperparathyroidism (10), 
hypercalcaemia of malignancy (10) or hypoparathyroidism (5). Samples were stored 
at -70°C until assay for PTH (1-84). Initially 2/10 samples from the group of normal 
subjects gave responses in the assay of 80% binding indicating PTH (1-84) 
concentrations well in excess of 500 pmol/1. As this seemed unlikely in normal 
subjects the possibility of the presence of heterophilic antibodies (Boscato and Stuart 
1988) in these sera was suspected. The samples were re-assayed with the inclusion 
of 1% (v/v) rat serum in the assay diluent. The responses in the samples were then 
consistent with the rest of the samples in the normal subject group. Thereafter, rat 
serum at 1 % (v/v) was incorporated into the assay diluent as routine.
The PTH (1-84) concentrations measured in the groups are shown in Figure 4.15. 
Also indicated are the detection limit of the assay (0.5 pmol/1) and a tentative 
reference range for PTH (1-84) in normal subjects (1.0-10 pmol/1) predicted from the 
literature (Papapoulos etal, 1980, Roos et al, 1981,Lindall et al, 1983). Eight of 
the ten samples from normal subjects had PTH (1-84) concentrations less than 0.5 
pmol/1. The two measurable PTH (1-84) concentrations were both 0.6 pmol/1 which 
is close to the assay detection limit.
The PTH (1-84) concentrations in the patients with primary hyperparathyroidism 
were as a group higher than those in normal subjects. The group mean was 0.8
PTH(1-84) IRMA Preliminary Optimisation : Clinical Groups 
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Figure 4 .1 5
PTH (1-84) concentrations obtained in the preliminary o p tim iiid  IRMA 
for serum  sa m p les from normal subjects (10) and patients with either 
primary hyperparathyroidism (10), hypercalcaem ia of m alignancy (HCM) (10) 
or hypoparathyroidism  (5), S h ad ed  area represen ts the predicted reference  
range for normal subjects.
94
pmol/1 with a range 0.6-1.1 pmol/1 (one result <0.5 pmol/1).
All patients in the hypercalcaemia of malignancy and hypoparathyroid groups had 
PTH (1-84) concentrations less than 0.5 pmol/1.
Therefore, although the ranking of the PTH (1-84) results appeared consistent with 
predicted concentration for these groups, i.e. hypoparathyroid and HCM patients 
< normal subjects < hyperparathyroid patients - the discrimination between the 
groups was very poor. In addition with eight out of ten normal subjects giving 
undetectable PTH (1-84) concentrations and only one result above 1.0 pmol/1 in the 
hyperparathyroid group, all results were much lower than predicted.
Oral Calcium Load
This study was organised by Dr I Gunn, Consultant Clinical Biochemist at Law 
Hospital, Carluke, Lanarkshire. Twenty normal volunteers had serum samples 
withdrawn immediately prior to and 2 h post taking a 1 g oral calcium load. The 
samples were separated within 30 minutes of venesection and stored at -70° (prior to 
assay for PTH (1-84)). The results shown in Figure 4.16 were consistent with the 
previous experiment on the clinical groups. Most normal subjects had PTH (1-84) 
less than 0.5 pmol/1 with no change seen post-calcium load.
Summary
The experiments on the measurement of endogenous PTH (1-84) in the preliminary 
assay system had indicated lower than predicted PTH (1-84) concentrations. 
Despite an apparent minimum detection limit of 0.5 pmol/1 as assessed using 
synthetic PTH (1-84) (Figure 4.14), most normal subjects had undetectable PTH (1- 
84) concentrations. Discrimination between the clinical groups on the basis of the 
measured PTH (1-84) was also very poor.
It appeared therefore that if the PTH (1-84) concentrations predicted for the normal
PTH(1-84 ) IRMA Preliminary Optimisation: 















Figure 4 .1 6
PTH (1-84) concentrations obtained with the preliminary optim ised IRMA for 
sa m p les from a  group of normal subjects (20), pre- and post- oral calcium (1 g) 
load. S h a d ed  area  represen ts the predicted reference range for normal subjects.
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subjects from the literature were in the right order of magnitude i.e. 1-10 pmol/1 then
the sensitivity of the assay system of 0.5 pmol/1 as assessed using synthetic PTH
(1-84) standards was not reflected in the measurement of endogenous PTH (1-84).
Two possible explanations for these results were considered for further investigation:
(i) The synthetic PTH (1-84) standards were calibrated incorrectly. If the actual 
PTH (1-84) concentrations in the standards were very much higher than the 
concentrations calculated from the dilution factor and the nominal weight of 
PTH (1-84) in the vial then the assay would appear to have a lower limit of 
detection for the synthetic PTH (1-84) standard than for endogenous PTH (1- 
84).
(ii) The assay system was able to distinguish between synthetic PTH (1-84) and 
endogenous PTH (1-84) and detected the latter much less effectively.
3.4 Investigation of PTH (1-84) Standard Preparations
Standard Preparations
Three preparations of PTH (1-84) standard were compared:
(1) Synthetic PTH (1-84) (Peninsula). This preparation had been used in the 
optimisation experiments thus far. The PTH (1-84) vial had been reconstituted 
in 2 ml acetic acid (0.1 mold) and stock aliquots of 2 fig stored at -70°C. Initial 
dilutions were made in 0.05 mol/1 barbitone buffer pH 8.6, 0.5% BSA prior to 
dilution in hypoparathyroid serum.
(2) Synthetic PTH (1-84) (Peninsula). A new vial of PTH (1-84) was purchased 
and assayed immediately upon reconstitution (as above). Stock aliquots of 2 
(ig in acetic acid (0.1 molA) were also stored at -70° C.
(3) Human PTH (1-84) (NIBSC 79/500). The first international preparation (IRP) 
of human parathyroid hormone was reconstituted in 0.05 mol/1 barbitone buffer
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pH 8.6, 0.5% BSA according to the recommended procedure (Caygill 1977). 
The human PTH (1-84) was then diluted in hypoparathyroid serum prior to 
assay.
S tandard Comparison
The comparison of standards is shown in Figure 4.17. There was a marked 
difference in potency between ‘old’ and ‘new’ synthetic PTH (1-84) preparations. 
The new synthetic PTH (1-84) having a potency of 10% relative to the old standard. 
The IRP of human PTH had a potency of 66% relative to the old standard.
These results appeared contradictory. The difference in potency between the old and 
new synthetic PTH (1-84) standard preparations could have been consistent with an 
error in the previous calibration and therefore account for the observed apparent 
difference in potency between synthetic and endogenous human PTH (1-84). 
However, the human PTH standards prepared from the IRP 79/500 although not 
equipotent with old synthetic PTH (1-84) standard had a relative potency of 66%. 
This was considered close to the expected value given that the IRP is calibrated by 
biological activity and the estimate of actual mass of PTH (1-84) in the IRP is 
approximate (Zanelli and Gaines-Das 1980). Other workers have since reported a 
potency by mass of 59% for the IRP 79/500 relative to synthetic PTH (1-84) (Brown 
et al, 1987).
Therefore although the PTH (1-84) assay system measured human PTH (1-84) in the 
IRP similar to the old synthetic PTH (1-84) standard, endogenous human PTH (1- 
84) when in serum appeared to have a low potency similar to that of the new 
synthetic PTH (1-84) standard. However, both the old and new synthetic PTH (1- 
84) standard preparations, although different batches, were from the same source. In 
addition, endogenous PTH (1-84) and the IRP material were of human origin 
although the latter had undergone extensive purification.
Assay Development: 
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Figure 4 .1 7
Com parison of PTH standard preparations in the preliminary optim ised PTH (1-84) 
IRMA. R esp o n se  curves w ere se t up with the synthetic PTH (1-84) u sed  for the  
optim isation experim ents (old standard), a fresh batch of synthetic PTH (1-84) 
(new  standard) and the 1st International R eferen ce Preparation of Parathyroid 
H orm one 7 9 /5 0 0  (IRP).
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It was postulated that the PTH (1-84) assay system was sensitive to a conformational 
aspect of PTH (1-84) which had altered on reconstitution and storage of the old 
synthetic PTH (1-84) standard and also in the IRP material during the purification 
procedure.
Effect of Storage on Synthetic PTH (1-84) Standards
The postulate on the conformation of PTH (1-84) (above) was investigated. PTH is 
known to contain a greater degree of ordered helical structure at pH 7.5 than at pH
2.1 (Brewer et al, 1975). It has also be reported that the PTH molecule is more 
compact at alkaline pH (Cohn et al, 1974). A number of experiments were 
performed over a period of seven days in an attempt to affect the conformation of 
PTH (1-84) in solution and thereby alter the relative potencies of the three standard 
preparations in the PTH (1-84) assay system.
No change in the relative potencies of the standard preparations was achieved by a 
change of pH (4.0, 6.0, 7.0, 8.5 and 9.5) or by the addition of either EDTA (0.025, 
0.05 mol/1) or mercaptoethanol (0.01, 0.1 mol/1) (data not shown in the interests of 
brevity). A small but significant increase in specific binding was observed, 
however, in all response curves on the addition of 0.05 mol/1 EDTA which was 
subsequently incorporated into the PTH (1-84) assay diluent as routine.
While none of the above measures achieved an alteration from control curves within 
any one experiment the relative potencies of the old and new synthetic PTH (1-84) 
standards was observed to change over the seven day period. Figure 4.18 shows the 
control response curves for both preparations from the reconstitution of the new PTH 
(1-84) standard at day 0 through the seven day period of the experiment. The 
potency of the new PTH (1-84) standard was observed to rise steadily from the 10% 
estimate at day 0 to become indistinguishable from that of the old standard 
preparation after seven days storage.
Assay Development: Change in standard 
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Figure 4 .1 8
C om parison of the potency  of the synthetic PTH (1-84) standard u sed  in the initial 
optimisation experim ents (old standard) and the n ew  batch of synthetic PTH (1- 
84) im m ediately on reconstitution (New:day 0) and for se v e n  d ays post 
reconstitution (days 2-7).
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It was concluded that synthetic PTH (1-84) was altering on storage in acid at -70°C 
and that the PTH (1-84) assay system recognised the altered form preferentially.
3.5 Specificity of N-Terminal MAB’s for Oxidised/Reduced PTH
Background
Early studies on the stability of bovine PTH indicated that the PTH molecule is 
susceptible to oxidation on storage. It was also shown that the PTH molecule lost 
biological activity on oxidation with hydrogen peroxide and that on subsequent 
reduction a complete restoration of biological potency occurred (Rasmussen 1959).
Further studies on the alkylation and oxidation of bovine PTH concluded that both 
alkylation with iodoacetate and oxidation with hydrogen peroxide involved only the 
methionine residues in PTH (Tashijian et al, 1964). Human PTH (1-84) has only 
two methionine residues both in the 1-34 N-terminal region of the molecule at 
positions 8 and 18 (Figure 4.19). The effect of oxidation and reduction on the ability 
of the N-terminal Mab’s 3B3, 4G3 and 6E3 to recognise synthetic PTH (1-84) and 
PTH (1-34) was therefore investigated further.
Oxidation/Reduction Procedures
Preparations of oxidised PTH and reduced PTH were produced by the method of 
Tashijian et al, 1964:-
Oxidation: Stock aliquots (2 fig) of synthetic PTH (1-84) and PTH (1-34) were 
diluted with 1 ml acetate buffer pH 3.8 and incubated with hydrogen peroxide (0.1 
mol/1) for 3 h at room temperature.
Reduction: Stock aliquots (2 |ig) of synthetic PTH (1-84) and PTH (1-34) were 
diluted with 1 ml acetate buffer pH 3.8 and incubated with cysteine hydrochloride 
(0.12 mol/1) for 3 h at 80°C.
The Primary Structure of Preproparathyroid Hormone
Lys Y Ala Y Pro Y lie  Y Met
1 _1 ( L y s10 _
Leu
Glu T TrpX l^ 11
Leu )( Ala Y Val Y Phe I  Asn Y His I  Val X AspX Gin
A laY A sp X V alX A sn Y V alX L cu Y T h rY L ysY A laY L ysY S erY G ln
Figure 4 .1 9
The primary structure of human pre- pro-parathyroid horm one (residu es -31-84) 
incorporating the structure of PTH (1-84) (resid u es 1-84) and highlighting the 
positions of th e m ethionine resid u es (8,18) the site  of oxidation.
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Displacement Studies
The specificity of the N-terminal Mab’s for oxidised/reduced PTH was investigated 
using the conditions employed in the initial characterisation and specificity studies 
(Chapter 3, Section 6.2). Displacement curves for oxidised/reduced PTH (1-84) and 
PTH (1-34) were set up with limiting dilutions of 3B3 (1:4,000), 4G3 (1:4,000) and 
6E3 (1:1,000) culture fluid in barbitone buffer using PTH (1-34) as radiolabel. The 
assay was incubated overnight at room temperature and separated with solid-phase 
sheep anti-rat IgG.
The displacement curve for 3B3 (Figure 4.20) confirms previous data that this Mab 
reacts with PTH (1-84) and PTH (1-34) on an essentially equimolar basis. The data 
also show that 3B3 recognises oxidised PTH peptides preferentially. The reduced 
PTH peptide having a potency of 10% relative to oxidised PTH in this system. 
Figure 4.21 shows the displacement curves for 4G3 which confirm that this Mab 
does not recognise PTH (1-84). 4G3 also recognises oxidised PTH (1-34) in 
preference to reduced PTH (1-34) which is twofold less potent with this Mab.
6E3 (Figure 4.22) reacts with PTH (1-84) and PTH (1-34) equally and also shows a 
preference for oxidised PTH by a factor of two.
In summary therefore, the N-terminal Mab’s 3B3, 4G3 and 6E3 react preferentially 
with oxidised PTH. The Mab chosen for the development of the PTH (1-84) IRMA 
shows a tenfold preference for oxidised PTH (1-84).
The PTH molecule is known to oxidise on storage (Rasmussen 1959, Tashijian et al, 
1964) and the synthetic PTH (1-84) has been demonstrated to increase in potency on 
storage (Section 3.4). It was concluded therefore that the difference in potency 
between synthetic PTH (1-84) and circulating endogenous PTH (1-84) observed in 
the PTH (1-84) IRMA reflected a difference in the oxidation state of the PTH 
molecule.
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Figure 4 .2 0
D isp lacem ent stud ies on Mab 3B 3 with oxid ised  and reduced PTH peptides. 
S tu d ies w ere carried out at a 1 ,4 0 0 0  dilution (in barbitone buffer pH 8.6 , 0.5%  
BSA) of 3B 3 culture fluid with iodinated PTH (1-34) a s  radiolabel.
Effect of Oxidation/Reduction of PTH S tandards
Monoclonal Antibody 4G3







10 100 1000 100001
PTH pmol/l
Figure 4.21
D isp lacem ent stud ies on Mab 4G 3 with oxid ised  and reduced PTH p ep tid es. 
S tu dies w ere carried out at a 1 ,4000  dilution (in barbitone buffer pH 8 .6 , 0.5%  
BSA) of 4G 3 culture fluid with iodinated PTH (1-34) a s  radiolabel.
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Figure 4 .2 2
D isp lacem ent stud ies on  Mab 6E3 with oxid ised  and redu ced  PTH p ep tid es. 
S tu d ies w ere carried out at a  1 ,000  dilution (in barbitone buffer pH 8 .6 , 0.5%  
BSA) of 6E 3 culture fluid with iodinated PTH (1-34) a s  radiolabel.
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However, the assay development data indicated that provided endogenous PTH (1- 
84) could be oxidised then the measurement of circulating concentrations could be 
achieved. Therefore the development of an assay system based on these reagents 
required investigation of the oxidation of circulating PTH (1-84).
3.6 Oxidation of Endogenous PTH (1-84)
Clinical Groups
Serum samples from normal subjects (5), patients with primary hyperparathyroidism 
(5) and patients with hypercalcaemia of malignancy (5) were treated with hydrogen 
peroxide (0.1 M) for 2 h at room temperature prior to measurement in the PTH (1- 
84) IRMA.
Figure 4.23 shows a comparison of the responses obtained in the PTH (1-84) IRMA 
for the oxidised aliquots of the above samples compared with that obtained for an 
untreated aliquot for each sample. The responses obtained for the untreated aliquots 
(shown shaded) were low, similar to previous experiments. Oxidation (shown as 
shaded + open) increased the responses in all samples. The predicted reference range 
(Section 3.3) is also indicated on Figure 4.23. The oxidised aliquots from normal 
subjects had responses falling within the predicted range; in the hyperparathyroid 
patients the responses were elevated; and in the HCM group the responses were 
below the reference range. Thus the oxidation of samples prior to assay had 
increased the response in all samples, but more importantly, dramatically improved 
the discrimination between the clinical groups. This was consistent with the 
postulate that the PTH (1-84) IRMA recognised oxidised PTH (1-84) preferentially 
and hydrogen peroxide treatment converts endogenous PTH (1-84) to the oxidised 
form.
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Figure 4 .2 3
E ffect of oxidation  of e n d o g e n o u s  PT H (1-84). Serum  sa m p le s  from normal 
su b jec ts  and patients with either primary hyperparathyroidism  (hyperpara) or 
h ypercalcaem ia of m alignancy (HCM) w ere treated  with hydrogen peroxide (0.1 
mol/l) prior to m easu rem en t. R e s p o n s e s  are sh ow n  for the u ntreated  (pre­
oxidation) and the hydrogen peroxide treated  (post oxidation) aliquots for each  
sam p le. T he dotted lines indicate the r e sp o n se s  corresponding to the lower and  
upper en d s of the exp ected  reference range for normal subjects.
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Optimisation of Hydrogen Peroxide Concentration in PTH (1-84) 
IRMA
As the protocol for the PTH (1-84) IRMA included an overnight incubation it was 
hoped that the addition of hydrogen peroxide to the solution of radiolabelled 3B3 
would be effective rather than have a separate pre-treatment step for each sample.
Patient Samples
Aliquots of samples from patients with various disorders of calcium metabolism were 
assayed in the PTH (1-84) IRMA with hydrogen peroxide (final assay concentration 
0-0.25 mol/1) to the solution of radiolabelled 3B3.
Figure 4.24 shows the results of the hydrogen peroxide optimisation with patient 
samples. All responses were increased over the control (no hydrogen peroxide 
added) on the addition of hydrogen peroxide. The response in all samples had a 
plateau around 0.1 mol/1 hydrogen peroxide. It appeared that on the higher 
concentration (0.25 mol/1) the responses may decrease.
Synthetic PTH (1-84) Standards
The above experiment was repeated with synthetic PTH (1-84) standard diluted in 
horse serum (Figure 4.25). The responses with synthetic PTH (1-84) also had a 
plateau around 0.1 mol/1 hydrogen peroxide added. There was no significant 
difference from control (no hydrogen peroxide added) up to 0.125 mol/1 - the 
synthetic standard having oxidised on storage. Responses decreased at 0.25 mol/1 
hydrogen peroxide.
The experiments on the optimisation of hydrogen peroxide concentration in the PTH 
(1-84) IRMA confirmed the use of 0.1 mol/1 hydrogen peroxide in the oxidation 
procedure as described by Tashijian et al, 1964. The addition of hydrogen peroxide 
to the solution of radiolabelled 3B3 obviates the requirement for treatment of samples
PTH(1-84) IRMA : O p t im isa t io n  of H y d ro g e n
P e r o x id e  C o n c e n t r a t i o n  in P a t ie n t  s a m p l e s
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Figure 4 .2 4
Optim isation of the hydrogen peroxide concentration for the m easu rem ent of 
e n d o g en o u s PTH (1-84). S am p les from patients with hypercalcaem ia of 
m alignancy (HCM), vitamin D deficiency (Vit D Def); chronic renal failure (CRF) and 
primary hyperparathyroidism (Prim hyper 1, 2) w ere a ssa y e d  at a range of 
hydrogen peroxide concentrations (0 - 0 .25  mol/l) which w a s added directly to the 
a s s a y  in the solution of radiolabelled 3B 3.
PTH(1-84) IRMA: Optimisation of Hydrogen
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Figure 4 .2 5
Optimisation of the hydrogen peroxide concentration for the m easu rem ent of 
synthetic PTH (1-84). Solutions of PTH (1-84) standard ( 0 ,1 0  & 250  pmol/l) w ere  
a ssa y e d  at a range of hydrogen peroxide concentrations (0 - 0 .25  mol/l) which  
w a s added directly to the a ssa y  in the solution of radiolabelled 3B 3.
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prior to assay.
3.7 PTH (1-84) IRMA - Preparation of Standards and Quality 
Control Pools
Selection of Matrix for Standards
Serum from a patient with hypoparathyroidism had been employed as the matrix for 
the PTH (1-84) standards in the optimisation studies. As this was in limited supply, 
possible alternative sources of suitable matrix material were investigated prior to final 
validation of the assay and application to clinical samples.
Figure 4.26 shows a comparison of the response curves for synthetic PTH (1-84) 
standard in assay buffer, serum from the hypoparathyroid patient, equine serum, 
bovine serum and porcine plasma. The response curves diverge from the assay 
buffer curve at low PTH (1-84) concentrations. This is consistent with the previous 
findings of higher blanks in the assay buffer at pH 7.0 (Section 3.2). There was no 
significant difference between the response curves in human, equine or bovine serum 
or porcine plasma. As equine serum was readily available in large batches, this was 
chosen as the matrix for PTH (1-84) standards.
Preparation of Standards
Synthetic PTH (1-84) was the most readily available source of material for primary 
standardisation. In view of the possible instability of PTH (1-84) in serum it was 
decided to store initial dilutions of the synthetic PTH (1-84) in 0.05mol/l barbitone 
buffer pH 8.6 containing 0.5% BSA. These were then diluted into the equine serum 
matrix prior to assay according to the protocol in Table 4.3.
Preparation of Quality Control Pools
Initially quality control pools were prepared by the addition of known amounts of 
synthetic PTH (1-84) to equine serum. However these proved unstable over the first
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Figure 4 .2 6
S election  of matrix for standards. R esp on se  curves for dilutions of PTH (1 -84) 
standard in a s sa y  buffer (buffer), equine serum , bovine serum , porcine serum  and 
serum  from a  patient with hypoparathyroidism (hypopara).
Table 4.3
Preparation of PTH (1-84) standards
(A) Concentrated Standard
1 vial 20 pg PTH (1-84) (Peninsula) made up in 2 ml 0.05 mol/1 barbitone buffer pH 
8.6, 0.5% BSA.
Aliquots stored at -70°C = 1 pg/100 pi.
(B) Stock Standard
100 pi of concentrated standard (A) made up to 10 ml barbitone buffer pH 8.6, 0.5% 
BSA.
Aliquots stored at -70°C = 10 ng/100 pi.
(C) Working Standard (Made up fresh for each assay)
100 pi stock standard (B) plus 1.9 ml horse serum = 500 pmol/l.
(D) Standard Curve (Diluted fresh for each assay)
(i) 1 ml working standard (C) + 1 ml equine serum = 250 pmol/l
(ii) 200 pi (i) + 600 pi equine serum = 62.5 pmol/l
(iii) 200 pi (ii) + 600 pi equine serum = 15.6 pmol/l
(iv) 200 pi (iii) + 600 pi equine serum = 3 .9  pmol/l
(v) 200 pi (iv) + 600 pi equine serum = 0.98 pmol/l
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month of usage (Figure 4.27). The measured value in these pools dropped by 30% 
on average over the 30 day period. Subsequently the quality control pools were 
prepared by diluting serum from a patient with primary hyperparathyroidism in 
equine serum. These pools showed no sign of deterioration over a three month 
period (Table 4.4).
4 VALIDATION OF THE PTH (1-84) IRMA 
4.1 PTH (1-84) IRMA Finalised Protocol
The protocol for the PTH (1-84) IRMA derived from the antibody 
characterisation/compatibility studies and the subsequent optimisation experiments is 
shown in Table 4.5.
4.2 Potency of Oxidised/Reduced PTH (1-84)
Given the sensitivity of the assay system to the oxidative state of PTH (1-84) the 
assessment of the potency of oxidised PTH (1-84) and reduced PTH (1-84) was an 
important validation criterion.
Preparations of oxidised and reduced PTH (1-84) were produced from the same 
stock aliquot of synthetic PTH (1-84) by the method of Tashijian et al, (1964) 
(Section 3.5). The preparations were then diluted for assay according to the protocol 
for assay standards (Section 3.7). Figure 4.28 shown the response curves obtained 
for the oxidised and reduced standard preparations compared to the routine standard 
curve. The potency of both oxidised and reduced PTH (1-84) is essentially identical 
across the reference range of the standard curve (0-250 pmol/l).
4.3 Specificity for PTH (1-84); interference from PTH Fragments
Circulating PTH fragments may be present in excess in serum and competitively 
inhibit reagent binding. The effect of adding excess PTH fragments to the standard 
curve was investigated.
PTH(l-84) Concentration in QC Pools 
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Figure 4 .2 7
PTH (1-84) concentrations m easured in quality control pools, prepared by the 
addition of synthetic PTH (1-84) peptide to equine serum, for 30 days post 
preparation.
Table 4.4
Assessment of PTH (1-84) assay performance using quality control 
pools prepared from endogenous PTH
Month 1 Month 2 Month 3
QC1 Mean: 2.8 2.9 2.6
SD: 0.33 0.40 0.37
CV: 11.7 13.7 12.6
n: 10 10 10
QC2 Mean: 10.6 11.7 11.6
SD: 0.94 1.0 1.1
CV: 8.8 8.5 9.4
n: 10 10 10
QC3 Mean: 17.6 17.8 17.7
SD: 1.6 1.9 1.3
CV: 9.1 10.6 7.3
n: 10 10 10
Mean CV: 9.9% 10.9% 9.8%
Table 4.5
Optimised PTH (1-84) assay protocol
Assay Diluent 0.05 mol/1 phosphate buffer pH 7.0 
containing NaCl (0.1 mol/1), EDTA (0.05 
mol/1), BSA (0.5% w/v) and rat serum (1% 
v/v).
1st incubation 200 p.1 sample or standard 100 p.1 
radiolabelled 3B3 (100,000 cpm) diluted in 
assay diluent containing 0.4 mol/1 H2O2 .
overnight at room temperature.
2nd incubation 100 pil ESQl-Sepharose CL-4B (1 mg/tube). 
2 h at room temperature,with shaking.
Wash 2 ml 0.9% saline/Tween 20 (0.2% v/v). 
Centrifuge and aspirate (x4).
Count 120 secs.
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Figure 4 .2 8
P oten cy  of ox id ised  and reduced PTH (1-84). The resp on se curves for oxid ised  and  
redu ced  synthetic PTH (1-84) prepared by the m ethod of Tashijan 1964 (Section  3.5) 
are show n com pared  to the PTH (1-84) standard curve in routine u se.
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The response curve was unaffected by up to a 200 molar excess of C-terminal 
fragments PTH (53-84) (Figure 4.29). The N-terminal fragment PTH (1-34) caused 
a saturation of binding at high PTH (1-84) concentration at a fifteenfold molar excess 
(Figure 4.29).
The tolerance of a 200 molar excess of C-terminal fragments should prevent 
interference even in samples from patients with established renal failure where gross 
elevations of C-terminal fragments can occur. The level of interference by PTH (1- 
34) is unlikely to be a major problem in clinical samples as recent evidence indicates 
that circulating levels of PTH (1-34) are low (Bringhurst et al, 1988).
4.4 Reference Interval and Clinical Groups
Serum samples (separated within 30 minutes of venepuncture) were collected for 
assay in the PTH (1-84) IRMA from the following groups:
Normal subjects: A group of 57 apparently healthy laboratory staff with mean age 
30.3 years (range 20-53 years). All samples contained detectable PTH (1-84) 
concentrations (Figure 4.30). The mean PTH (1-84) concentrations was 2.21 pmolA 
(absolute range 0.8-5.0 pmol/l). The reference interval was estimated as 1.0-4.4 
pmol/l (range containing 95% of results).
Primary hyperparathyroidism: A group of 27 patients with appropriate biochemistry 
and surgically proven hyperparathyroidism gave values in the range 5.8-100 pmol/l 
(mean 21.0 pmol/l).
Hypoparathyroidism: Six patients with established hypoparathyroidism post radical 
neck surgery gave undetectable (<0.5 pmol/l) PTH (1-84) concentrations.
Hypercalcaemia associated with malignancy (HCM): Fourteen of 18 samples from 
patients with HCM gave undetectable (<0.5 pmol/l) PTH (1-84) concentrations. Of 
the four samples with detectable PTH (1-84), two (0.8, 0.9 pmol/l) were from
PTH(1-84) IRMA : Assessment of 
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Figure 4 .2 9
M easurem ent of PTH (1-84) in the p resen ce of PTH fragm ents. The resp on se  
cu rves for PTH (1-84) is shown com pared to the curves obtained for PTH (1-84) 
with an added 200  molar e x c e s s  of PTH (53-84) and for PTH (1-84) with an added  
15 molar e x c e s s  of PTH (1-34).
Optimised PTH(1-84) IRMA : Clinical Groups
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Figure 4 .3 0
PTH (1-84) concentrations m easured using the optim ised IRMA in normal 
subjects, patients with primary hyperparathyroidism (prim hyper), hypercalcaem ia  
of m alignancy (HCM) or hypoparathyroidism (hypo). The sh aded  area represents 
the reference interval estim ated from the normal subjects. Also represented as  
the d a sh e d  line is the minimum detection limit of the a ssa y  (cf Figure 4.15).
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patients with some degree of renal failure. A third (2.7 pmol/l) was from a patient 
who was found to have an elevated urinary cAMP concentration. The fourth sample 
gave a result at the detection limit of the assay (0.5 pmol/l).
The PTH (1-84) concentrations in these groups are compared in Figure 4.30. The 
results from patients with hyperparathyroidism (5.8 - 100 pmol/l) were all above the 
reference interval (1.0 - 4.4 pmol/l) estimated from the normal subjects. Six of the 
patients with hyperparathyroidism however, had results in the range 5.2 - 7.0 pmol/l, 
close to the upper limit of the reference interval indicating there may be some overlap 
between PTH (1-84) concentrations in normal subjects and patients with 
hyperparathyroidism. The results in hyperparathyroid patients were well separated 
from those in patients with HCM.
These results confirmed that the PTH (1-84) IRMA was capable of measuring 
PTH (1-84) in normal subjects and gave good discrimination between 
hyperparathyroid patients, normal subjects and patients with HCM.
Oral Calcium Load
The samples from the study described in Section 3.3 were re-analysed in the 
optimised PTH (1-84) IRMA. The PTH (1-84) concentrations in the twenty normal 
volunteers pre and post oral calcium load (1 g) are shown in Figure 4.31. All 
subjects pre calcium load had detectable PTH (1-84) concentrations; mean 1.8 pmol/l 
(range 1.0 - 3.6 pmolA). There was a reduction in PTH (1-84) concentrations in all 
subjects 2 h post oral calcium, mean 0.92 pmol/l which was significant on a paired 
difference t-test (p <0.0001). The results confirm the ability of the PTH (1-84)
IRMA to measure detectable PTH (1-84) concentrations in normal subjects and to 
detect changes in PTH (1-84) concentrations within the reference interval.
4.5 Recovery of PTH (1-84) added to Human Serum
Intra-assay recovery: Synthetic PTH (1-84) (10 pmol/l) was added to ten serum
Optimised PTH(1-84) IRMA: 
Oral Calcium Load (1g)
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PTH (1-84) concentrations m easured using the optim ised IRMA in normal 
su bjects pre (0 min) and post (120 min) an oral calcium load (1 g). (cf Figure 
4 .1 6 ) .
samples (4 normal subjects, 3 hyperparathyroid patients and 3 patients with chronic 
renal failure). The results are shown in Table 4.6(i).
Inter-assay recovery: Pooled normal human serum was spiked with 5, 10 and 20 
pmol/l synthetic PTH (1-84) and assayed in the PTH (1-84) IRMA (x5). The results 
are shown in Table 4.6(ii).
Recovery of human PTH (1-84) (IRP 79/500): The experiment in (ii) above was 
repeated using the IRP 79/500 human PTH as both the added recovery material and 
for the assay standard curve. The results are shown in Table 4.6(iii).
The recovery experiments indicated that the optimised PTH (1-84) IRMA gave good 
recovery of both synthetic and human PTH (1-84) from human serum. There is a 
slight over-recovery (107-110%) at 10 pmol/l added which appears to increase at 20 
pmol/l added (116 - 120%). This level of recovery was not expected to compromise 
the clinical utility of the assay. The results however indicate that the equine serum 
adopted for the routine production of standards is perhaps not the ideal matrix for the 
standard curve.
4.6 Dilution of Patient Samples
Serum samples from a patient with primary hyperparathyroidism (PTH (1-84) 
80 pmol/l) and three patients with elevated PTH (1-84) concentrations (50, 80, 
100 pmol/l) and varying serum creatinine concentrations (690, 830 and 1300 p.mol/1 
respectively) due to chronic renal failure were analysed at various dilutions. The 
responses were plotted against the theoretical PTH (1-84) value and compared to the 
synthetic PTH (1-84) standard response curve (Figure 4.32).
All samples diluted essentially parallel to the synthetic PTH (1-84) response curve 
with no evidence of interference from PTH fragments.
Table 4.6
Recovery of PTH (1-84) added to human serum
(i) Intra-assay recovery: synthetic PTH (1-84)
Basal + 10 pmol/l PTH (1-84)
Mean
PTH (1-84)
6.9 pmol/l 17.6 pmol/l




Mean recovery 107% (98 - 110%)
(ii) Inter-assay recovery: synthetic PTH (1-84)
PTH (1-84) (SD) 
pmol/l
Recovery % (range)
Basal 2.04 (0.23) -
+5 7.44 (0.57) 108 (88-124)
+10 12.72 (1.13) 107 (94-118)
+20 25.24 (2.43) 116(112-124)
(iii) Recovery of human PTH (1-84) (IRP 79/500)
PTH (1-84) (SD) 
pmol/l
Recovery %  (range)
Basal 4.5 (0.46) -
+5 10.0 (0.91) 110 (91-124)
+10 15.9 (1.49) 114(86-127)
+20 28.4 (3.00) 120(115-128)
Optimised PTH(1-84) IRMA : 
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Figure 4 .3 2
M easurem ent of en d ogen ou s PTH (1-84) in pathological sam p les. R esp o n se  
curve for synthetic PTH (1-84) standard com pared with th o se  for dilution of 
sa m p les from patients with primary hyperparathyroidism (PHP) or with chronic 
renal failure with a serum  creatinine of 600 pmol/l (CRF 600), 830  pmol/l (CRF 
830) and 1300  pmol/l (CRF 1300).
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5 STABILITY OF PTH (1-84) IN BLOOD SAMPLES
As a final assay validation prior to initiating studies on circulating PTH (1-84) 
concentrations the stability of PTH (1-84) in blood samples and the comparability of 
the results obtained with the PTH (1-84) assay developed in this study with those of 
published assays was investigated.
For the measurement of immunoreactive PTH it had been recommended that samples 
were obtained in the morning ( 0700-0900 h) after an overnight fast followed by 
rapid separation and storage at -20°C (Stitch 1980, Di Bella and Hawker 1982). With 
the development of assays for intact PTH (1-84) the stability of PTH (1-84) in blood 
samples has been re-examined both during assay validation (Brown et al 1987) and 
more extensively during method evaluation (Newman and Ashby 1988).
These studies reported a gradual loss (18-30%) of both synthetic and endogenous 
PTH (1-84) in whole blood or serum incubated overnight at room temperature and 
have recommended rapid separation and freezing of samples. Endogenous PTH (1- 
84) was found to be stable on storage at -20°C. The present study therefore aimed 
merely to confirm these data with the in-house assay and is therefore of limited 
scope rather than an extensive investigation of PTH (1-84) stability.
Blood from a normal subject and a patient with primary hyperparathyroidism was 
taken into plain, lithium heparin and lithium heparin with aprotinin (4000 KIU;
0.2ml Trasylol) containing tubes. Aliquots were separated within 30 minutes of 
venesection and incubated at either room temperature or 4°C for up to 24h.
The PTH (1-84) concentrations measured in the samples from the normal subject and 
the patient with primary hyperparathyroidism are shown in Figures 4.33 and 4.34 
respectively. There was a drop in PTH (1-84) concentrations over the 24 h period in 
the samples from both the normal subject (mean 23.9%) and the patient with 
hyperparathyroidism (mean 39.2%). There was no significant difference observed in
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Figure 4 .3 3
T he stability of en d ogen ou s PTH (1-84) in sam ples from a normal subject. 
Aliquots of serum  or plasm a w ere incubated at either room temperature (RT) or 
4°C (4C) then stored at -50°C prior to a ssay  (within 4  days).
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Figure 4 .3 4
T h e stability of en d ogen ous PTH (1-84) in sam p les from a patient with primary 
hyperparathyroidism. Aliquots of serum  or plasm a were incubated at either room  
tem perature (RT) or 4°C (4C) then stored at -50°C prior to a ssa y  (within 4  days).
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the PTH (1-84) concentrations between serum and plasma samples or with the 
temperature of incubation. The addition of aprotinin had no effect on the decrease in 
PTH (1-84) concentrations over the incubation period (data not shown).
The results confirm a gradual loss of endogenous PTH (1-84) concentrations on 
incubation at 4°C and room temperature. The stability of endogenous PTH (1-84)
(from a patient with hyperparathyroidism) stored over a period of several months 
at -20°C was demonstrated during the preparation of quality control pools. While 
this study involves samples from a limited number of subjects the results are are in 
agreement with published data ( Brown et al 1987, Newman and Ashby 1988).
Thus whereas short delays in separations and freezing would not normally have 
major affects on the clinical value of PTH (1-84) concentrations there is the 
possibility that misclassification of patients with mild primary hyperparathyroidism 
may occur. Therefore for clinical and physiological studies samples were separated 
within 30 minutes of venepuncture and stored frozen at -20°C.
6 CORRELATION WITH PUBLISHED PTH (1-84) METHODS
At the time of initiating the studies on the circulating concentrations of PTH (1-84) 
two methods for the measurement of intact PTH (1-84) were available commercially.
The assay validation studies (above) had shown the performance of the in-house 
assay developed in this study to be comparable to the published data from these 
assays in terms of sensitivity, precision and discrimination between clinical groups.
It was of further interest to assess the correlation between the in-house PTH (1-84) 
assay and each of these methods on the same clinical samples. Thus the study was 
aimed to investigate briefly the degree of correlation between these methods and was 
not designed to be an extensive comparison of methods.
The PTH (1-84) concentrations measured in a range of clinical samples using the in- 
house assay were compared to those measured using the Allegro1* method (Nichols 
Institute) an immunoradiometric assay employing two affinity purified polyclonal
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antisera (Nussbaum et al 1987) and the Magic LiteR system (Ciba-Coming) an 
immunochemiluminometric assay employing an affinity purified polyclonal N- 
terminal antibody and a C-terminal Mab (Brown et al 1987).
The comparison of PTH (1-84) concentrations measured by the in-house method 
and the AllegroR method is shown in Figure 4.35. There is good correlation between 
the methods (r2=0.95) the results using the Allegro method were on average 10% 
higher. The correlation between the the in-house and Magic LiteR methods was also 
good (r2=0.975) with the Magic Lite method results on average 20% lower than 
those from the in-house method (Figure 4.36).
Although on a limited number of samples the results indicate a good correlation 
between the methods across a range of clinical samples (including primary 
hyperparathyroidism and renal failure). The differences in the actual PTH (1-84) 
concentrations observed in the patient samples were also apparent in the standards for 
these methods and reflected differences in primary calibration between the methods.
7 CONCLUSIONS
The sensitivity of the N-terminal Mab to 3B3 to the oxidation state of PTH initially 
caused difficulty in the assay development. It is however a characteristic previously 
described for polyclonal antisera to PTH (Tashijian et al, 1964) and is probably not 
unusual in antisera raised to N-terminal PTH peptides. The fact that this effect is not 
commonly encountered is probably because assay systems employing polyclonal 
antisera - i.e. raised to multiple epitopes on PTH - would not be expected to show the 
same sensitivity to the oxidation state of PTH as a system using a Mab raised to a 
single epitope. It is not possible from the data generated from the present study to 
assess the effect of oxidation on the production of antibodies to PTH. It is likely that 
it plays a role both in the production of an immune response and also in the ability of 
antibody-screening assays to detect the response. The oxidation of samples prior to 
assay to allow quantitation of total oxidised peptide has been described in an assay
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Figure 4 .3 5
The correlation b etw een  the PTH (1-84) concentrations m easured  using the in-house  
a s s a y  with th o se  obtained using the Allegro0 method in a range of clinical sam ples.
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Figure 4 .3 6
The correlation betw een  the PTH (1-84) concentrations m easured  using the in-house  
a ssa y  with th o se  obtained using the Magic Lite0 method in a range of clinical sam ples.
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for the measurement of methionine enkephalin (Clement-Jones et al, 1980). The 
validation studies have shown the assay system developed to give quantitative 
recovery of both oxidised and reduced PTH (1-84).
The assay has also been shown to be sufficiently sensitive to measure circulating 
concentrations of PTH (1-84) in normal subjects. The results of the assay allow 
good discrimination between patients with primary hyperparathyroidism and those 
with hypercalcaemia associated with malignancy. There is likely to be, however, 
some degree of overlap between the PTH (1-84) concentrations in both these groups 
with those found in normal subjects.
The assay is specific for PTH (1-84) in that it is unaffected by an excess of N or C- 
terminal fragments of PTH. In particular the assay has sufficient capacity to cope 
with the high levels of C-terminal fragments found in chronic renal failure.
Thus the performance of the PTH (1-84) IRMA developed compares favourably with 
other published assays (Brown et al, 1986, Nussbaum et al, 1987). In addition, the 
PTH (1-84) concentrations measured using the in-house assay show good correlation 
with those obtained using these methods.
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C H A PTER  5 : STUDIES ON THE CIRCULATING
CONCENTRATIONS OF PTH (1-84) 
1 INTRODUCTION
The development of two-site immunometric assays for PTH (1-84) has been an 
important advance in the laboratory assessment of patients with disorders of calcium 
metabolism and particularly with regard to the differential diagnosis of 
hypercalcaemia. The specificity for PTH (1-84) and the improved sensitivity and 
precision has allowed greater discrimination between clinical groups than could be 
achieved with previous immunoassay methodology (Nussbaum et al, 1987, Brown 
et al, 1987, Logue et al, 1990a).
Similarly studies on the circulating concentrations of PTH in normal and pathological 
states have been limited by PTH immunoassay methodology. N-terminal assays, 
while measuring biologically active PTH, in general lacked the sensitivity to measure 
circulating PTH concentrations in normal subjects (Segre et al, 1975, Armitage 
1986). C-terminal immunoassays, measuring biologically inactive PTH fragments of 
long half life, were not useful in following short term fluctuations in biologically 
active PTH and were markedly influenced by renal function (Di Bella et al, 1978b, 
Armitage 1986).
Thus the ability to measure PTH (1-84), free of interference from PTH fragments, in 
normal subjects and to follow changes within the reference interval with confidence 
offers the potential to study the physiology and control of PTH (1-84) secretion more 
clearly than previously possible.
2 STUDIES ON THE CIRCADIAN SECRETION OF PTH (1-84)
2.1 Introduction
The majority of biochemical, physiological and behavioural phenomena of the human
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organism show profound diurnal variation ie regular changes from day to night 
(Turek 1985, Van Cauter and Aschoff 1989). In nature these diurnal rhythms are 
normally synchronised with 24 h environmental rhythms such as the light-dark cycle. 
However, even under constant environmental conditions, most diurnal rhythms 
persist. This finding has led to the demonstration that these diurnal fluctuations are 
endogenous rhythms and are driven by an internal biological clock (Pittendrigh 
1981). These rhythms are referred to as 'circadian' rhythms, from the Latin circa 
diem, meaning about a day, because their period under constant conditions is close 
to but rarely exactly 24 h. In mammals, the paired suprachiasmatic nuclei (SCN) of 
the hypothalamus have been demonstrated to control the timing of a large variety, if 
not all, circadian rhythms. So far no other circadian 'clock' has been anatomically 
identified in mammals (Turek 1985).
The secretion of many hormones has been shown to be strongly modulated by 
circadian rhythmicity eg melatonin, cortisol, testosterone and the anterior pituitary 
hormones adrenocorticotrophic hormone (ACTH), growth hormone, thyroid 
stimulating hormone (TSH) and prolactin (Desir et al, 1981, Van Cauter and 
Honinckx 1985, Weeke and Gunderson 1978, Linkowski et al, 1987).
A series of studies were carried out to investigate the characteristics and control of the 
circadian rhythm of PTH (1-84) secretion. Prior to reporting the results a description 
of the general design of the studies and the methods employed is given in Sections
2.2 and 2.3.
2.2 G eneral Study Design
Subjects were studied over a 24 h period. Venous blood samples were obtained 
through indwelling cannulae at 30 minute intervals. Timed urine collections were 
taken every 4 h during the day, one sample prior to retiring to bed and one sample on
awakening in the morning.
113
Within an experiment all subjects ate identical diet on the day of sampling, with 
meals being consumed at fixed times. The meals content for the normal subjects was 
intended to represent approximately their usual diet. All patients were hospitalised 
during the study and ate hospital diet at identical times.
Throughout the periods of study subjects and patients were ambulent but avoided 
exercise. Within an experiment the subjects and patients lay down to sleep at the 
same time. Ethical committee approval was obtained for the study, and all patients 
gave informed consent before inclusion in the study.
2.3 M ethods
A ssays
Intact PTH (1-84) was measured using the in-house IRMA (Logue et al, 1990a). 
Plasma cAMP was measured using a commercial kit (Amersham International). 
Urinary cAMP was measured using an in-house RIA method (O'Reilly et al, 1986). 
Nephrogenous cAMP was calculated by the method of Broadus et al, (1977). Serum 
total calcium, phosphate, albumin and creatinine were measured on a Hitachi 704 
using standard methodologies, and calcium was adjusted for albumin concentration 
(Gardner et al, 1981).
Prolactin, HGH, TSH and LH were measured using immunometric assays:-
Prolactin : IRMA (NETRIA, St Bartholomews, London) with a detection limit of 30 
mU/1 and a working range of 60-3500 mUA.
HGH: in-house IRMA with a detection limit of 0.1 mUA and a working range of 0.5- 
200 mUA.
TSH: in-house IRMA with a detection limit 0.2 mU/1 and working range of 0.5-150 
mU/1.
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LH: DELFIA (Pharmacia) with a detection limit of 0.12mU/l and working range of 
0.4 to 250 mU/1.
All samples from an individual subject were analysed in the same assay batch.
Statistical analysis of data
Statistical analysis was performed using a paired difference t-test to analyse 
significant changes within 24 h profiles. The Mann-Whitney U-test was used to 
analyse differences between groups.
Cosinor analysis: Statistical analysis of circadian rhythm parameters was carried out 
using the Cosinor technique (Nelson et al, 1979). In this procedure a cosine curve 
with a period of 24 h is fitted to the data for each individual using the method of least 
squares. An F statistic was then used to test the zero amplitude hypothesis for a 
circadian rhythm. The following parameters were calculated: the mesor (rhythm 
adjusted mean), the amplitude (half the total extent of the predicted change) and the 
acrophase (crest time of the best fit cosine function, in relation to local midnight).
The mean cosinor data were then plotted on a polar coordinate graph. The mean 
amplitude and acrophase of the rhythm were displayed by means of the length and 
angle of the vector. The envelope representing the bivariate statistical confidence 
region was also derived.
Cross-Correlation Analysis: the PTH (1-84) and prolactin data for each individual 
over the 24 h period were smoothed using a 3 sample moving average technique to 
minimise perturbations due to either pulsatile secretion or assay noise. Cross - 
correlation coefficients, the correlation between the PTH (1-84) data of an individual 
versus successive lags of their prolactin data (llag = sample interval = 30min) were 
estimated using the Statsgraphics Package (Statistical Graphics Corporation 
Rockville MD 20852).
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2.4 The circadian rhythm of intact PTH (1-84) and in nephrogenous 
cAMP in normal subjects and patients with primary 
hyperparathyroidism
Introduction
Previous studies on the secretion of PTH over a 24 h period in normal subjects 
using assays mainly specific for the biologically inactive C-terminal region of PTH 
have reported nocturnal rises in immunoreactive PTH concentrations (Jubiz et al,
1972, Sinha et al, 1975) which may also be sleep related (Kripke et al, 1978).
The biological action of PTH is mediated by cyclic adenosine monophosphate 
(cAMP). The measurement of the nephrogenous component of urinary cAMP 
(NcAMP) has been shown to be a good index of PTH bioactivity in vivo (Broadus et 
al, 1977). Studies on cAMP metabolism have reported both the presence (Murad and 
Pak 1972, Sagel et al, 1973) and the absence (Shaw et al, 1977) of circadian 
variation in total urinary cAMP excretion. There have been no reports of circadian 
variation in NcAMP.
Patients with primary hyperparathyroidism have inappropriately detectable or 
elevated serum concentrations of PTH (1-84) in the presence of hypercalcaemia 
(Nussbaum et al, 1987, Blind et al, 1988, Chu and Chu 1988) and elevated 
NcAMP in the majority of cases (Broadus et al, 1977, 1978). Some of the available 
evidence indicates that in primary hyperparathyroidism the adenomatous parathyroid 
tissue functions autonomously whilst other evidence suggests that the gland is not 
totally autonomous and an alteration in the set-point for PTH secretion exists (Parfitt 
1969a, Brown 1983, Gardin et al, 1988).
Thus we might expect that the circadian rhythm of PTH (1-84) and NcAMP observed 
in normal subjects could be lost in primary hyperparathyroidism. Studies measuring 
N and C terminal PTH have shown either the existence (Sinha et al, 1975, Lo
Cascio et al, 1982) or absence (Riggs et al, 1971, Jubiz et al, 1972) of a circadian 
rhythm of PTH in primary hyperparathyroidism.
In this study the circadian secretion of PTH (1-84), NcAMP, serum calcium and 
phosphate in normal adult male and premenopausal female volunteers is investigated 
and compared to the results obtained in patients with primary hyperparathyroidism.
Subjects
Adult males:
Six healthy male volunteers (aged 29-40; mean 33 years) were studied over the same 
24 h period. The study period was from 1400 to 1330 h the following day, with food 
being consumed at 1800, 2300, 0800 and 1300 h. The male subjects lay down at 
0100, were asleep by 0200 and were awakened at 0700 h.
Premenopausal females:
Three premenopausal female healthy volunteers (aged 27-45 yrs) were studied for a 
24 h period from 1900-1900 h (due to the timing of the study period the female 
subjects ate their evening meal 2-3 h later than the male subjects). The female 
subjects lay down at midnight were asleep by 0100 and were awakened at 0800 h. 
Hyperparathyroid patients:
Six patients (three male, three female) with primary hyperparathyroidism (surgically 
proven with histological diagnosis age 47-58 years). All patients were hospitalised 
during the study, they ate hospital diet at similar times to the normal subjects. The 
patients lay down at 1100 were asleep by 1200 and were awakened at 0700 h.
Results
The mean 24 h profiles of PTH (1-84) and NcAMP in the six male subjects are 
shown in Figure 5.1. PTH (1-84) rose from 0130 h in a broad peak through the 
night. The concentrations from 0200 to 0600 h were significantly (P<0.05) elevated 
compared to baseline (1400-1800 h). The PTH (1-84) concentrations in all subjects
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The m ean  (±  SEM) concentrations of PTH(1-84) and NcAMP in six normal m ale 
su b jec ts  sam p led  at 30  minute intervals over a 24  h period. The dotted lines 
indicate the reference intervals for normal male subjects
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returned to baseline values by 1000 h although the rate of fall varied markedly 
between individuals. The mean intra-individual CV between 0630 and 1000 h was 
30% (range 12.9-42.5) compared to 17% (12.6-23.6) in the basal period.
The mean cosinor analysis for PTH (1-84) in the male subjects is shown in Figure 
5.2. The polar co-ordinate plot indicates the tight phase and frequency 
synchronisation in the PTH (1-84) of the six subjects over the 24 h period. The 
results confirm a significant circadian rhythm in PTH (1-84) of mean amplitude 0.72 
from a mesor concentration of 3.3 pmol/1 with the acrophase occurring at 0405 h.
The mean NcAMP concentrations in the male subjects rose throughout the night in 
parallel to the PTH (1-84). The NcAMP concentrations at eight of the eleven time 
points during the period 1200 to 0700 h were significantly (P<0.05) elevated 
compared to the baseline individual means. The mean cosinor data for NcAMP in the 
six male subjects is shown in Figure 5.3. Although there is phase synchrony in the 
NcAMP concentrations of the six subjects occurring at 0524 h, the inter-individual 
variability is such that the mean amplitude of 5.9 from the mesor concentration of 25 
nmol/1 glomerular filtrate is not statistically significant at the 5% level.
The 24 h profiles of PTH (1-84) and NcAMP concentrations in the female subjects 
are shown compared to the mean profile for male subjects in Figure 5.4. The PTH 
(1-84) concentrations are higher throughout the 24 h period than the corresponding 
profile in male subjects (mean 24 h PTH (1-84) in female subjects was 5.0 vs 3.3 
pmol/1 in the males P<0.001). Similarly the NcAMP concentrations are higher in the 
female subjects than in the males (24 h mean NcAMP 28.6 vs 24.8 nmol/1 GF 
p<0.01). It is apparent that the difference in PTH and NcAMP concentrations 
between the males and females is most evident in the late afternoon and early 
evening.
Cosinor analysis of the data from the female subjects confirms a significant circadian 
rhythm in PTH (1-84) of mean amplitude 0.69 pmol/1 from a mesor concentration of
Cosinor analysis of the PTH (1-84) concentrations
in normal male subjects over a 24 h period
0000 h
0405 h
1800 h 0600 h
1200 h
Acrophase :0405 h 
Mesor : 3.3 pmol/l 
Amplitude : 0.72 pmol/I (p < 0.05)
Figure 5.2: Mean cosinor analysis of intact parathyroid hormone 
concentrations for the six normal subjects during the 24 h 
period. Polar co-ordinate plot.
The mean amplitude of the circadian rhythm is plotted, as 
distance from the origin, against the angle from 0000 h 
corresponding to the time of mean acrophase (-x). The shaded 
area represents the statistical confidence (95%) limits of the 
estimated mean parameters. The amplitude and acrophase 
for the individual subjects are also indicated (a ).
Cosinor analysis of the NcAMP concentrations in
normal male subjects over a 24 h period
0000 h
C 3; i524 h
1800 h 0600 ha
1200 h
Acrophase : 0524 h 
Mesor : 25.0 nmol/l GF 
Amplitude : 5.9 nmol/l GF
Figure 5.3: Mean cosinor analysis of nephrogenous cyclic
adenosine monophosphate concentrations for 
the six normal subjects over the 24 h period. 
Polar co-ordinate plot. The shaded area 
represents the statistical confidence limits.
(GF = glomerular filtrate)
Comparison of 24 h profiles of PTH(1-84) and NcAMP 
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Figure 5 .4
The m ean  (± SEM) concentrations of PTH (1-84) and NcAMP in three normal 
p rem enop ausal fem ales sam pled at 30 minutes over a 24  h period are shown  
com pared  to the m ean profiles obtained for the normal male subjects. Fem ale 
su b jects w ere studied from 1900-1830 h, the male subjects from 1400-1300  h
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5.0 pmol/1 with the acrophase occurring at 0302 h (p<0.05). The mean amplitude of 
3.55 from a mesor NcAMP concentration of 28.6 nmol/l GF occurring at an 
acrophase of 0736 h was not statistically significant at the 5% level.
PTH (1-84) and NcAMP values showed a wide scatter in the patients with 
hyperparathyroidism therefore for clarity of presentation the results were expressed 
as percentage of the individual's 24 h mean. The 24 h profiles for PTH (1-84), 
NcAMP (both expressed as percentage of the individual 24 h mean), adjusted serum 
calcium and serum phosphate for normal subjects and patients with primary 
hyperparathyroidism are shown in Figures 5.5 and 5.6 respectively. The measured 
PTH (1-84) and NcAMP concentrations throughout the 24 h period are summarised 
and compared to those found normal male subjects in Table 5.1. The results of the 
cosinor analysis of the data for the four measurements in both of these groups are 
shown in Table 5.2.
The circadian rhythm observed for PTH (1-84) in the normal subjects with a 
significant rise in PTH (1-84) overnight, the acrophase occurring at 0405 h, was lost 
completely in the patients with primary hyperparathyroidism with no synchronised 
rise in PTH (1-84) observed throughout the 24 h period. In normal subjects the 
greatest variability in serum PTH (1-84) concentrations occurs between 0630- 
1000 h. In patients with primary hyperparathyroidism PTH (1-84) concentrations 
occasionally fell within the reference range and in one patient these results coincided 
with normal values for adjusted calcium.
Similarly the significant rise in NcAMP observed in in the normal subjects was 
abolished in patients with primary hyperparathyroidism. In two patients values for 
NcAMP within the reference range were obtained intermittently throughout the 24 h 
period.
The three male patients with primary hyperparathyroidism had the highest 
concentrations of PTH (1-84) and NcAMP (Table 5.1). As these patients also had the
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Figure 5 .5
The m ean  (± SEM) 24 h profiles (expressed  a s % of the individuals 24  h m ean) of PTH 
(1-84), NcAMP, adjusted calcium and phosphate in the six normal subjects.
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Figure 5 .6
The m ean  (+ SEM) 24 h profiles (expressed  a s % of the individuals 24  h mean) of PTH 
































































































































































































































































































Cosinor analysis of 24 h profiles
Acrophase Mesor Amplitude
Normal Subjects 
PTH(l-84) 0405 3.3 0.72 (p <0.05)
N-cAMP 0524 25.0 5.9 ns
Adjusted calcium 2003 2.4 0.02 ns
PO4 0155 1.2 0.14 (p <0.001)
Hyperparathyroid
Patients
PTH(l-84) 2339 14.2 0.80 ns
N-cAMP 1804 58.0 5.6 ns
Adjusted calcium 1613 2.9 0.03 ns
PO4 0116 0.8 0.07 ns
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highest concentrations of adjusted calcium this probably reflects the severity of the 
condition rather than a fundamental difference in PTH (1-84) secretion between men 
and women.
Adjusted calcium concentrations varied little during the 24 h period in both groups.
In the normal subjects a transient statistically significant (p<0.05) decrease 
(compared to the individual means between 1400-1800 h) in mean adjusted calcium 
from 2.44 to 2.40 mmol/1 was observed at 0130 h. There was also a small but 
significant drop in adjusted calcium from 2.42 to 2.38 mmol/1 (p<0.05) observed at 
1230 h (relative to mean levels between 0600 and 0800 h). In the hyperparathyroid 
patients a decrease from 2.94 to 2.84 mmolA (p<0.05) at midnight (relative to the 
individual mean between 1400-1800 h) was observed. Predictably the mean adjusted 
calcium concentration in the patient group was higher than that in the normal subjects 
throughout the 24 h period (p<0.001).
Serum phosphate was significantly lower in the primary hyperparathyroid patient 
group throughout the 24 h (p<0.001). A marked synchronised rhythm in phosphate 
consisting of a transient decrease following the evening meal a significant nocturnal 
rise and then an early morning fall was observed in both groups. The percentage 
change in phosphate was greater in normal subjects than in the patients with primary 
hyperparathyroidism.
D iscussion
In normal male subjects both serum PTH (1-84) and NcAMP concentrations rise 
significantly during the night, with mean values above the day-time reference ranges 
for these analytes. The cosinor analysis confirms a significant circadian rhythm in 
PTH (1-84), with an acrophase at 0405 h. This is consistent with the night-time rise 
in immunoreactive PTH previously reported using C-terminal specific assays (Jubiz 
et al, 1972, Sinha et al, 1975) and also with the hypothesis that the rise may be 
sleep related (Kripke et al, 1978). The circadian variations in PTH (1-84) are
120
accompanied by parallel variations in NcAMP levels. This strongly supports the 
conclusion that the PTH (1-84) released through the night is physiologically active.
The circadian rhythm of PTH (1-84) seen in male subjects is also present in 
premenopausal females. The pattern of secretion however shows some notable 
differences between the male and female subjects. The PTH (1-84) concentrations 
are set higher throughout the 24 h period in the females and in particular during the 
early evening. This is reflected in the cosinor analysis which confirms a higher mesor 
concentration in the females but similar amplitude of rhythm to the male subjects. In 
contrast to our data no sex based difference in PTH (1-84) 24 hour profiles was 
noted in a previous study (Calvo et al, 1988). A more recent study has however 
shown that a low calcium and high phosphate diet causes a persistent elevation in 
PTH (1-84) secretion throughout a 24 h period (Calvo et al, 1990). The increase in 
the early evening PTH (1-84) concentrations relative to the nocturnal peak seen in our 
female subjects is more consistent with studies in both males and females carried 
out in USA which showed biphasic profiles (Markowitz et al, 1988, Calvo et al,
1988). It has been postulated from these and our own studies that there are dietary 
influences on the secretion of PTH (1-84) particularly in the early evening.
The protocol adopted for these studies involved the subjects following a standard 
regime of eating times and approximate meal content within each experiment. The 
choice of food was intended however to reflect the usual diet of the subjects. Thus it 
is probable that the differences between the pattern of secretion of PTH (1-84) in 
female and male subjects seen in this study reflect differences in diet and food intake 
between the groups. The data on the female group is however based on only three 
subjects and further studies which take account of dietary influences are required to 
define the parameters of the circadian secretion of PTH (1-84) in female subjects.
Although the NcAMP concentrations rose significantly m both male and female 
subjects, the cosinor analysis failed to detect a significant phase and frequency
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synchronised rhythm. This is probably related to the small number of subjects and 
the inherent variability in this parameter which is calculated from four separate 
measurements (cAMP and creatinine both in plasma and urine). It is of interest 
however that the NcAMP concentrations remained elevated (0600-0700 h) after the 
main peak of PTH (1-84).
The circadian rhythm of PTH (1-84) is not present in patients with primary 
hyperparathyroidism. This loss of PTH (1-84) rhythm is reflected in the absence of 
the circadian rhythm for NcAMP in primary hyperparathyroidism.
These observations raise important questions for the control of PTH (1-84) secretion 
in normal and abnormal states. Previous studies have demonstrated a fall in ionised 
calcium during the night in both normal subjects and patients with 
hyperparathyroidism (Lo Cascio et al, 1982). In this study we have also shown a 
transient but significant lowering of adjusted calcium in both groups between 
midnight and 0200 h. The aetiology of such a transient fall in calcium is unclear.
A reduction in ionised calcium might be expected to trigger a compensatory surge in 
PTH (1-84) secretion and therefore provide a mechanism for the nocturnal rise in 
PTH (1-84) in normal subjects. However this explanation appears to be an 
oversimplification for it is known that continuous infusion of calcium into normal 
subjects at a dose just sufficient to obliterate the nocturnal fall in serum calcium does 
not eliminate the nocturnal rise in PTH. Predictably infusion of calcium at higher 
doses leads to decreased nocturnal PTH secretion (Jubiz et al, 1972, Sinha et al,
1975). Clearly therefore factors other than changes in ionised calcium concentration 
are important in the circadian rhythm of PTH (1-84) in normal subjects.
Patients with primary hyperparathyroidism have been shown to respond to the 
lowering of serum calcium with increased PTH secretion (Murray et al, 1972, 
Lockefeer et al, 1974). It has been further suggested that the basis of primary 
hyperparathyroidism is an alteration in the calcium-PTH set point rather than
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autonomous secretion of PTH by the parathyroid gland (Brown 1983, Parfitt 1969a, 
Gardin et al, 1988). In this study we have shown the absence of a synchronised 
nocturnal increase in PTH (1-84) in the hyperparathyroid patients despite the 
detection of a transient lowering in adjusted calcium consistent with previous data on 
ionised calcium (Lo Cascio et al, 1982). Although the precise incremental fall in 
serum calcium required to produce a response in hyperparathyroid patients has not 
been defined this is further evidence against the fall in calcium being the main trigger 
to circadian changes in PTH (1-84).
If changes in calcium concentration do not fully explain the circadian rhythm of PTH 
(1-84) then the influence of phosphate must also be considered. This study 
demonstrates a pronounced circadian rhythm of phosphate in normal subjects. A 
small decrease in phosphate which may be due to the movement of phosphate 
intracellularly to support carbohydrate metabolism occurs following the evening 
meal. This is followed by a much larger increase in phosphate prior to the nocturnal 
surge of PTH (1-84). This increase could be regarded as the stimulus for PTH (1-84) 
release, which in turn would cause phosphaturia and the observed fall in serum 
phosphate. However it has been reported that the phosphate circadian rhythm can be 
abolished by prolonged fasting but that the nocturnal rise in PTH persists in these 
individuals (Jubiz et al, 1972). Furthermore, suppression of PTH secretion by 
infusion of an appropriate dose of calcium results in an exaggerated phosphate 
circadian rhythm (Jubiz et al, 1972, Sinha et al, 1975). Thus it would appear that 
phosphate has little or no effect on the secretion of PTH during the night but that the 
PTH status of the individual may well influence the extent of the phosphate circadian 
rhythm. Further support for this latter conclusion is obtained from the phosphate 
results in the hyperparathyroid patients in this study for the phosphate rhythm is 
attenuated in the presence of consistently elevated PTH (1-84) concentrations.
An important incidental observation from this study is that the discrimination between 
normal subjects and patients with primary hyperparathyroidism is time dependent.
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The elevated night-time PIH  (1-84) concentrations had returned to basal values in ah 
subjects by 1000 h. However the the fall to baseline concentrations varied between 
individuals, which gave rise to increased intra-individual variation between 0630 and 
1000 h. These results have implications for the assessment of the PTH (1-84) 
concentrations in an individual. Early morning samples, such as those typically 
collected from hospital in-patients, may give spuriously elevated concentrations.
Thus using PTH (1-84) as the discriminant the optimal time of sampling is 1000- 
1600 h when the variability within and between subjects is at its minimum. Similarly 
the optimal time for sampling using NcAMP as discriminant is between 1100 and 
1500 h and not first thing in the morning as recommended by previous authors 
(Broadus et al, 1977, Holmegaard 1982).
Combining the available data leads to the conclusion that changes in calcium and 
phosphate either alone or in combination can not fully explain the circadian rhythm of 
PTH (1-84) secretion in normal subjects. It remains to be established whether the 
rhythm is modified by the age or sex of the subject, but is tempting to speculate that 
neuroendocrine factors from the hypothalamus or other higher centres may exert 
influence on PTH (1-84) secretion as well as on the the hormones of the anterior 
pituitary. Further work is required to establish whether the loss of circadian rhythm 
of PTH (1-84) in primary hyperparathyroidism is an early event in the natural history 
of the disease or whether it is a secondary consequence of increases in the plasma 
ionised calcium beyond critical threshhold concentrations.
These findings may be of physiological significance for it has been shown in animal 
models that continuous infusions of PTH are not effective in promoting bone growth, 
increased bone formation requires a regimen resulting in transient rises in PTH by 
daily injections (Podbesek et al, 1983, Malluche et al, 1982). Thus the night time 
rise in PTH (1-84) may be essential to normal bone physiology. Further studies on 
the control of the circadian secretion of PTH (1-84) are required, particularly in 
female subjects, to evaluate the possible role of neuroendocrine factors in the
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pathogenesis of bone disorders such as osteoporosis.
2.5 The circadian secretion of PTH (1-84): Temporal correlation with 
the secretion of prolactin, HGH, TSH and LH.
Introduction
Studies on PTH (1-84) secretion have demonstrated the circadian rhythm in intact 
PTH (1-84) and its association with parallel changes in nephrogenous cyclic 
adenosine monophosphate (NcAMP), a measure of the biological activity of PTH, in 
normal subjects (Calvo et al, 1988, Markowitz et al, 1988, Logue et al, 1989). It 
has further been shown that the synchronised circadian rhythm in both PTH (1-84) 
and NcAMP is absent in patients with primary hyperparathyroidism (Logue et al, 
1990b). The mechanism responsible for the PTH (1-84) rhythm remains unclear and 
it has been concluded from these and previous studies (Kripke et al, 1978) that the 
PTH (1-84) rhythm cannot be accounted for by changes in serum calcium or 
phosphate concentrations and therefore that the central nervous system may play a 
role either directly or indirectly in modulating normal PTH (1-84) secretion.
The secretion of many hormones has been shown to be strongly modulated by 
circadian rhythmicity eg melatonin, cortisol, testosterone and the anterior pituitary 
hormones adrenocorticotrophic hormone (ACTH), growth hormone (HGH), thyroid 
stimulating hormone (TSH) and prolactin (Desir et al, 1981, Van Cauter and 
Honinckx 1985, Weeke and Gunderson 1978). It was interest therefore to investigate 
whether there was any commonality between the secretion of PTH (1-84) and other 
circadian hormones over a 24 h period. Prolactin because of its noted association 
with calcium metabolism was of particular interest.
In the light of evidence that exogenous PTH can stimulate prolactin in normal 
subjects (Issac et al, 1978) and that prolactin has been reported to stimulate PTH 
release in  v i t r n  (Maggliola et al, 1981) a possible inter-relationship between these
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two hormones has been postulated. Previous studies employing basal serum 
samples have failed to confirm a relationship between PTH and prolactin (Raymond 
et al, 1982, Fiore et al, 1984).
In view of the evidence of a relationship between PTH (1-84) and prolactin and the 
well defined circadian rhythm of prolactin secretion it was decided to investigate if 
there was any commonality of secretion between these hormones over a 24 h period 
in normal subjects and hyperparathyroid patients. The secretion of other anterior 
pituitary hormones known to be elevated during the night HGH, TSH and LH was 
also investigated.
Subjects and Methods
The samples from the normal subjects and patients with hyperparathyroidism 
obtained in the study on the circadian secretion of PTH (1-84) and NcAMP (Section 
2.4) were assayed for prolactin. The samples from the normal male subjects were 
also assayed for HGH, TSH and LH.
The assay methods are as described in Section 2.3. The data from individuals was 
analysed using cross correlation analysis as described in section 2.3.
Results
The 24 h profiles for serum PTH (1-84) and prolactin in the six individual male 
subjects are shown in Figures 5.7 and 5.8. On visual examination of the profiles 
there is a strikingly similar pattern in PTH (1-84) and prolactin concentrations 
throughout the 24 h period. Two main periods of increased secretion in the six male 
subjects occur at 1600-1900 h and 0200-0600 h for PTH (1-84) and 2000-2200 h 
and 0400-0800 h for prolactin. Although there is variation in the relative height and 
duration of both peaks between subjects they are closely associated for both PTH (1- 
84) and prolactin within each individual with increases in PTH (1-84) occurring 
before those in prolactin in every case.
Correlation between PTH (1-84) and prolactin in
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2 4  h profiles for PTH (1-84) and prolactin (sm oothed using a three sam ple moving average) 
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Figure 5 .8
24  h profiles for PTH (1-84) and prolactin (sm oothed using a three sam ple moving 
average) in normal m ale subjects. Associated with each  profile is a plot of the cross-  
correlation coefficients for the PTH (1-84) data vs su ccess iv e  lags of the prolactin data 
(1 lag = sam pling interval = 30 min).
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Table 5.3
Cross-correlation analysis of 24 h profiles of PTH (1-84), prolactin 
and adjusted calcium in normal men.
PTH v Prolactin PTH v Adjusted calcium
Maximum r Lag time (h) Maximum r Lag time (h)
Subject
1 0.73 -2.0 -0.43 4.0
2 0.83 -3.5 -0.58 0.0
3 0.66 -0.5 -0.66 9.5
4 0.62 -2.0 -0.36 2.5
5 0.81 -1.0 -0.46 0.5
6 0.68 -2.0 -0.49 10.5
The data from each individual were smoothed using a method of three-sample 
running means. A series of correlation coefficients were calculated between the 
PTH(l-84) data of an individual versus successive lags [1 lag = 30 min] of their 
prolactin and adjusted calcium data. The maximal correlation obtained and the 
corresponding lag time are shown for individual subjects.
Mean Prolactin concentrations over the 24 h period
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Associated with the 24 h profiles in Figures 5.7, 5.8 is a plot of the estimated cross- 
correlations for the PTH (1-84) versus successive lags of the prolactin data in each of 
the male subjects. This analysis confirms a strong temporal relationship between 
PTH (1-84) and prolactin secretion with maximal correlation coefficients of 0.73, 
0.83, 0.66, 0.62, 0.81, and 0.68 in the six subjects, respectively. The maximum 
cross-correlation coefficients and the corresponding lag times obtained for the PTH 
(1-84) versus the prolactin data in each of the male subjects are shown in Table 5.3. 
Also shown for comparison are the same parameters for PTH (1-84) versus serum 
adjusted calcium.
The mean concentrations of prolactin in the male subjects, premenopausal females 
and hyperparathyroid patients over the 24 h period are shown in Figure 5.9. The 
prolactin profiles are qualitatively similar in males and females although the prolactin 
concentrations are consistently higher and the sleep related prolactin peak is of 
greater amplitude in women (24 h mean in female subjects = 339 vs 127 mU/1 in 
males p<0.01). Cross correlation analysis confirms a similar temporal relationship 
between PTH (1-84) and prolactin in the female subjects,with a mean maximal 
r=0.67 (range 0.61-0.78) occurring at a mean lag time of -1.7 h (range -0.5 to -4.0), 
to that observed in the male subjects.
The mean prolactin 24 h profile in hyperparathyroid patients is also qualitatively 
similar to that of the normal male subjects both showing the early evening rise and 
the nocturnal peak shortly after the onset of sleep. The mean correlation coefficient 
between PTH (1-84) and prolactin concentrations in the hyperparathyroid patients 
however was 0.19 (range -0.61 to 0.43) with a mean lag time of 0.9 h (range -2.0 to 
7.0).
The mean 24 h profiles for HGH, TSH and LH in the six normal male subjects are 
shown in Figures 5.10. The maximal correlation coefficients and the corresponding 
lag times for the PTH (1-84) data versus successive lags of HGH, TSH and LH data
Mean concentrations of HGH, TSH and LH over the 24 h period
in the normal male subjects
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in the individual subjects are shown in Table 5.4. Also included for comparative 
purposes is the data for adjusted calcium and prolactin. PTH (1-84) secretion over 
the 24 h period shows the strongest temporal correlation with prolactin secretion 
(mean r — 0.72, mean lag time = -1.8 h (-3.5 to -0.5)). There is also a good 
correlation between PTH (1-84) secretion and that of HGH (mean r=0.58; mean lag 
time -0.42 h (-2.5 to 1.0)) and TSH ( mean r = 0.55: mean lag time -2.6 h (-4.5 to 
-1.5)). By comparison the correlation with adjusted calcium is weaker (mean r =
-0.49) within widely varying lagtimes (0.0 to 10.5 h). PTH (1-84) shows no 
correlation with LH secretion (mean r = -0.06; lag times -10.0 to 7.0 h).
D iscussion
The analysis of the individual PTH (1-84) profiles, smoothed using the three sample 
moving average, shows the early evening rise in PTH (1-84) more clearly than does 
the mean data (Section 2.4, Figure 5.1). This indicates that the early evening rise in 
PTH (1-84) is less synchronised between subjects than is the nocturnal rise.
The individual profiles from the six normal men reveal two periods of increased PTH 
(1-84) secretion (1600-1900 h - 0200-0600 h ). The broad rise in intact PTH (1-84) 
through the night (0200 - 0600 h) is in agreement with earlier work detailing the 
nocturnal rise in immunoreactive PTH (Jubiz et al, 1972, Knpke 1978). The timing 
of the earlier peak is consistent with more recent studies on immunoreactive PTH in 
which biphasic PTH profiles were observed, although in contrast to our data, the 
early evening peak was more pronounced being similar in terms of height and 
duration to the rise through the night. This may reflect either the influence of dietary 
calcium and phosphate on the early evening rise or the differences in PTH assay 
methodology (Calvo et al, 1988, Markowitz 1988, Calvo et al, 1990).
The prolactin profiles in the male subjects showing two main peaks of increased 
secretion at 2000-2200 h and 0400-0800 h in each subject are in agreement with 
published data. (Desir et al, 1982). The patterns of prolactin secretion between
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female and male subjects are qualitatively similar. The amplitude of the night time rise 
is higher in the female subjects which is also consistent with earlier studies 
which found nocturnal peak levels in women up to two fold higher than in men 
(Sassin, 1972). The mean 24 h profile for prolactin in the hyperparathyroid patients 
also shows good qualitative agreement with that of the normal subjects. However 
the loss of circadian rhythm of PTH (1-84) in hyperparathyroid patients (Section 2.4 
above, Logue et al, 1990b) means that there is no consistent cross correlation 
between PTH (1-84) and prolactin secretion in these patients.
The most significant finding from the present study is that over a 24 h period there is 
a strong temporal correlation (range 0.62-0.83) between PTH (1-84) and prolactin 
secretion in individual normal subjects with changes in PTH (1-84) occurring 
approximately 2 h before those in prolactin (lag range 0.5-3.5 h). By comparison the 
negative correlation between PTH (1-84) and serum adjusted calcium is weaker 
(range 0.36-0.66) with variable lag times (lag range 0-10 h) - an observation that 
both challenges the view that PTH (1-84) and plasma ionised calcium are always 
inversely linked and also suggests that other factors may be implicated in the control 
of tonic PTH (1-84) secretion.
The controlling mechanism for the circadian rhythm in PTH (1-84) remains unclear.
In accordance with previous studies (Markowitz et al, 1988, Mallette 1989) we 
observed a small fall in adjusted calcium occurring at 1230 h prior to the early 
evening rise in PTH (1-84) seen in the individual subjects. Similarly we found a 
small transient drop in adjusted calcium at 0130 h prior to the nocturnal rise (Section 
2.4 above, Logue et al, 1990b). While it is tempting to speculate a fall in calcium 
acting as trigger to rises in PTH (1-84) this appears to be an over simplification. The 
nocturnal rise in PTH has been shown to persist during continuous infusion of 
calcium (Jubiz et al, 1972) and it has been noted that the nocturnal rise in PTH (1- 
84) occurs at a time when ionised calcium is rising (Markowitz et al, 1988). It is 
noteworthy that separate studies find falling ionised or adjusted calcium around
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midday which suggests either dietary influence or an endogenous circadian rhythm of 
calcium. In addition the fall in adjusted calcium around midday is 3 to 4 h prior to 
the noted early evening peak in PTH whereas studies using EDTA infusion indicate 
a much more rapid response in PTH (1-84) to a lowering of serum calcium 
(Hackeng et al, 1986).
Prolactin has been shown to play a definite role in calcium metabolism only in aquatic 
habitat vertebrates . However prolactin can stimulate avian renal 25-OH-Vitamin 
D3 -I a-hydroxylase (Spanos et al, 1976 a) and increase 1,2540H)2-Vitamin D3
levels in the hen (Spanos 1976b). In addition ovine prolactin has been reported to 
stimulate PTH release from bovine parathyroid cells in v i tro  (Magliola et al, 1981) 
and exogenous PTH has been shown to stimulate prolactin release in normal men 
(Issac et al, 1978). It has been postulated from these acute experiments at non- 
physiological concentrations that prolactin may play a role in the regulation of 
calcium metabolism through a direct effect on calcitropic hormone concentrations 
(Fiore et al, 1984). However studies measuring PTH and prolactin concentrations 
on basal samples from normal and hyperprolactinaemic subjects have produced 
conflicting results that have failed to confirm a direct inter-relationship between these 
two hormones (Raymond et al, 1982, Fiore et al, 1984).
The results of the present study demonstrate that the secretion of PTH (1-84) and 
prolactin are, however, highly correlated over a 24 h period within individual 
normal subjects. Thus while previous evidence from the acute experiments might 
suggest a direct positive feedback loop between PTH (1-84) and prolactin the data 
from this study indicates that while PTH (1-84) may be affecting the secretion of 
prolactin the reverse is unlikely. Our data are more suggestive of a common 
controlling factor and indirect coupling of the secretion of these hormones possibly 
via the neural network of the suprachiasmic nuclei which are responsible for the 
timing of circadian rhythms (Turek 1985). Inconsistencies with previous studies 
probably reflect differences in hormonal effects at pharmacological and pathological
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concentrations.
It appears therefore that the circadian changes in PTH (1-84) in normal subjects are 
entrained to an endogenous circadian clock which is temporally coupled to prolactin 
secretion. The nocturnal rise in prolactin is known to be sleep-related (Sassin et al, 
1973) and there is also evidence that the nocturnal rise in PTH (1-84) is sleep related 
(Knpke et al, 1978) raising the possibility of neuroendocrine control mechanisms 
common to both PTH (1-84) and prolactin.
In addition to the strong temporal relationship found between PTH (1-84) and 
prolactin the 24 h profile of PTH (1-84) in the six normal male subjects also shows 
a better correlation and more consistent lag times with TSH and HGH secretion than 
with variations in adjusted calcium. The 24 h profile for TSH has been shown to 
result from the interaction of sleep and circadian rhythmicity. The evening rise in 
TSH occurring well before the onset of sleep and reflects circadian timing (Parker et 
al, 1976). During sleep an inhibitory influence is exerted on TSH secretion (Parker 
et al, 1987) such that during sleep deprivation the evening rise of TSH is prolonged 
and enhanced. Similarly while HGH secretion is strongly associated with sleep such 
that adult males typically show a single HGH pulse coincident with sleep there 
evidence for a weak circadian rhythm modulating the occurrence of and height of 
HGH secretory pulses (Van Cauter and Refetoff 1985).
The lack of correlation between the PTH (1-84) and LH secretion reflects the more 
pulsatile characteristics of the LH profile.The secretion of LH is known to be 
strongly pulsatile in naturej and while there is circadian variation in the pulse 
frequency in children at puberty resulting in higher LH levels during the nigh^ in 
males reaching adulthood the circadian variation is dampened and becomes 
undetectable (Turek and Van Cauter 1988). In the majority of male adults the 
secretion remains pulsatile and may vary considerably between individuals (Veldhuis
1987).
Based on observations in animal models that continuous infusions of PTH are not 
effective in promoting bone growth and that increased bone formation requires a 
regimen resulting in transient rises in PTH by daily injections (Podbesek et al, 1983, 
Malluche et al, 1982) it has been postulated that the night time rise in PTH (1-84) 
may be an important factor in normal bone physiology (Calvo et al, 1988, Logue et 
al, 1990b). Further studies on the control of the circadian secretion of PTH (1-84) 
and its relationship to prolactin secretion are required, particularly in female 
subjects, to evaluate the possible role of neuroendocrine factors in the pathogenesis 
of bone disorders such as osteoporosis. It is also of importance to establish whether 
manipulation of the circadian PTH (1-84) profile may have a role in the treatment of 
such disorders.
2.6 Control of the circadian rhythm of PTH (1-84) secretion - 
evidence from a sleep shift experiment.
Introduction
The profile of PTH (1-84) secretion in normal man is characterised by a late 
aftemoon/early evening rise and a nocturnal surge through the night (Section 2.4 
above, Logue et al, 1989). The mechanism responsible for the PTH (1-84) rhythm 
remains unclear and it has been concluded from these and previous studies (Knpke 
et al, 1978, Markowitz et al, 1988) that the PTH (1-84) rhythm cannot be 
accounted for by changes in serum calcium or phosphate concentrations and therefore 
that the central nervous system may play a role either directly or indirectly in 
modulating normal PTH (1-84) secretion.
Prolactin secretion follows a similar pattern over a 24 h period in normal male 
subjects with an early evening rise and a major night time elevation occurring shortly 
after the onset of sleep (Sassin 1973, Desir et al, 1982). Cross correlation analysis 
of the 24 h profiles confirmed a strong temporal correlation between PTH (1-84) and
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prolactin secretion in normal male and female subjects with the changes in prolactin 
secretion occurring approximately 2 h after those in PTH (1-84) (Section 2.5 above, 
Logue et al, 1990c). It has been postulated therefore that there may be 
neuroendocrine control common to PTH (1-84) and prolactin secretion.
The overall circadian characteristics (excluding food intake or dietary effects) of a 24 
h hormonal profile generally result from the effects of circadian rhythmicity (intrinsic 
effects of time of day irrespective of the sleep or waking state), sleep (intrinsic effects 
of sleep irrespective of the time of day) and pulsatile secretion occurring at 
frequencies of minutes or hours. To delineate the relative roles of circadian and sleep 
effects, strategies based on the fact that circadian rhythmicity needs several days to 
adapt to abrupt shifts of the sleep-wake cycle have been employed. Thus by shifting 
the sleep times by 7-12 h, masking effects of sleep on circadian inputs are removed 
and the effects of sleep at an abnormal circadian time can be revealed.
Studies have shown prolactin secretion to be strongly associated with sleep in that 
daytime naps are associated with rises in prolactin (Parker et al, 1973) and acute 
reversal or delay of the the sleep-wake cycle is accompanied by prolactin elevation 
during daytime sleep (Sassin et al, 1973). There is also evidence that the nocturnal 
surge in PTH is sleep related (Kripke et al, 1978). A sleep-shift experiment in 
which the time of sleep was delayed by 7 h was carried out on six normal male 
subjects to asses the relative roles of circadian and sleep effects on the 24 h profile of 
PTH (1-84) secretion.
Subjects and methods
Six normal male subjects aged 30-41 yrs were studied on two separate occasions. In 
study A (circadian) (samples from circadian study in Section 2.4 above) the subjects 
slept from 0100-0800 h and in study B (sleep shift) the subjects were awake through 
the night and slept from 0800-1400 h.
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Results
The 24 h profiles for PTH (1-84), prolactin and NcAMP during the circadian and 
sleep shift studies are shown in Figures 5.11. For clarity of presentation the mean 
profiles have been smoothed using the three sample moving average technique and 
error bars have been omitted.
The timing of the nocturnal rise in PTH (1-84) appears unaltered despite the shift in 
the sleep-wake cycle although it appears that the start of the PTH (1-84) peak is 
attenuated (2300-0300 h). The NcAMP rises in parallel to the PTH (1-84) in both 
studies but the rise during the sleep shift experiment is reduced, mean NcAMP from 
0130 to 0700 h during the sleep shift study was 23.8 nmol/1 GF compared to 31.9 
(p<0.01) in the circadian study. The nocturnal prolactin peak seen in the circadian 
study is absent in the sleep shift study. However a rise in prolactin occurs coincident 
with the time of delayed sleep in the sleep shift study.
There were no significant differences observed in the 24 h profiles for adjusted 
calcium or phosphate between the studies.
D iscussion
Early studies using this type of experimental design demonstrated that the secretion 
of some hormones is primarily modulated by circadian rhythmicity, eg cortisol and 
melatonin, while others such as prolactin and growth hormone are strictly sleep 
dependent. The complete distinction between circadian dependent or sleep-related 
rhythms was the basis of a two-oscillator model for the generation of circadian 
rhythms (Moore-Ede et al, 1982). The model postulated two separate, but interacting 
pacemakers, one (referred to as X) driving deep circadian rhythmicity and the other 
(referred to as Y) driving the rest activity-cycle. According to this model the sleep- 
related rhythms were assumed to be controlled by the Y oscillator and the circadian 
rhythms would be driven by the master circadian pacemaker X.
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Figure 5.11
A com parison  of the 24  h profiles (smoothed using a three sam ple moving average) 
for PTH (1-84), NcAMP and prolactin between the circadian and sleep  shift studies in
the normal m ale subjects.
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The shift in the timing of the prolactin peak seen in this acute sleep shift experiment is 
consistent with early studies on prolactin secretion which had shown that daytime 
naps are associated with increases in prolactin (Parker et al, 1973) and that acute 
reversal or delay of the sleep wake cycle is accompanied by an increase in prolactin 
during daytime sleep (Sassin et al, 1973). These studies lead to the conclusion that 
the prolactin secretion was primarily controlled by sleep without inherent circadian 
rhythmicity. However more recent studies on repeated sleep-shifts as part of a jet- 
lag study had shown a splitting of the prolactin peak revealing an endogenous 
circadian component to prolactin secretion in addition to the sleep-related component. 
(Desir et al, 1982). It is now accepted that sleep effects and circadian effects interact 
to produce the overall temporal pattern of the majority of hormones and that different 
portions of the wave shape of the hormonal pattern adapt at different rates to 
manipulations of the sleep wake-cycle. The data on prolactin is consistent with a 
circadian control strongly influenced by sleep but with some underlying circadian 
modulation (Van Cauter and Refetoff 1985).
Nocturnal PTH concentrations have been shown previously to be temporally 
correlated with cycles of stage 3 and 4 sleep (Kripke et al, 1978). In this acute 
sleep-shift experiment the timing of the main nocturnal PTH (1-84) rise did not alter 
significantly from the normal circadian pattern. However it appears that the early part 
of the peak (2300-0300 h) is suppressed. Thus the PTH (1-84) data would be 
consistent with a primarily circadian rhythm which may be modified by sleep. 
Another example of this type of control is that of TSH which is primarily circadian 
but suppressed by sleep such that in sleep deprivation experiments the evening rise in 
TSH is enhanced and prolonged (Parker et al, 1987).
Therefore while the secretion of PTH (1-84) and prolactin follow well defined 
circadian patterns in normal subjects such that there is a strong temporal correlation 
between these hormones over a 24 h period the mechanism by which they are
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entrained to the biological clock appears to be fundamentally different.
However, the evidence linking prolactin to PTH and calcium metabolism remains 
(Spanos et al, 1976, Magliola et al, 1981, Fiore et al, 1984). The recent finding 
that prolactin can stimulate parathyroid hormone related peptide in breast milk 
(Thiede and Rodan 1988) adds weight to the association of prolactin and calcium 
metabolism. The comparison of the NcAMP profiles between the studies indicates 
that while the NcAMP peak remains coincident with the PTH (1-84) peak in the sleep 
shift experiment it is reduced in size. It is interesting to speculate whether the night 
time rise in NcAMP during the normal sleep wake cycle has a prolactin dependent 
component, perhaps related to the production of parathyroid hormone related peptide.
Thus while the results of sleep shift experiment argue against a direct neuroendocrine 
link between PTH (1-84) and prolactin secretion the circadian studies so far 
demonstrate that these hormones are maintained by the circadian clock in a distinct 
phase relationship throughout a 24 h period in normal subjects. Given the postulated 
role of prolactin in calcium metabolism it may be that this high degree of temporal 
organisation allows concerted metabolic effects between these hormones.
2.7 Control of the circadian rhythm of PTH (1-84) secretion -
preliminary evidence of modification of the rhythm by a 96 h
fast. 
Introduction
The secretion of PTH (1-84) in normal subjects follows a defined circadian rhythm.
Over a 24 h period the PTH (1-84) concentrations in normal subjects follow a 
biphasic pattern of an early evening rise and a nocturnal peak. (Markowitz et al,
1988, Calvo et al, 1988, Logue et al, 1989). However the mechanism responsible 
for the circadian rhythm remains unresolved.
i-pt . i • u- <-irrr»nrrVir»nt onr studies and those of others is thatThe most consistent relationship throughout ou
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between PTH and serum phosphate concentrations. The rhythm in serum phosphate 
is qualitatively similar and coincident with that of PTH (1-84) (Markowitz et al,
1988, Calvo 1988, Logue et al, 1990b). The strongest evidence against a direct link 
between the circadian secretion of PTH (1-84) and phosphate is that of Jubiz et al, 
(1972) where it was shown that the circadian rhythm in serum phosphate was 
abolished by a 96 h fast while the PTH rhythm was unaffected.
It was decided therefore to re-evaluate the association between the secretion of PTH 
(1-84) and phosphate by investigating the effect of a prolonged fast in normal 
subjects. The preliminary results from three male volunteers are presented below.
Subjects
Three male subjects ( aged 35-41 yrs) who had also participated in the circadian 
study (Section 2.4) were fasted (water only) for four days. They were sampled every 
30 minutes from the third (1500 h) to the fourth (1430 h) day of fasting. 
Throughout the study the subjects were ambulant but avoided exercise and followed 
a normal sleep wake cycle.
Results
The mean 24 h concentrations of PTH (1-84), adjusted calcium and serum phosphate 
found in the fasting study are shown compared to the profiles obtained in the 
circadian study (Section 2.4) in Figure 5.12.
PIH  (1-84) concentrations were higher compared to the fed state (mean of 5.2 vs 3.3 
pmol/1 p<0.01) and were outwith the reference range for normal subjects (1-5 pmol/1) 
for much of the 24 h. The synchronised nocturnal peak between subjects is not 
present in the fasting study. PTH (1-84) secretion appears more pulsatile in nature 
with concentrations being highest in the afternoon.
The mean 24 h adjusted calcium was decreased compared to the circadian study (2.33 
versus 2.22 mmol/1. p<0.01).
Comparison of the 24 h profiles of PTH(1-84), adjusted calcium and phosphate 
between the circadian and fasting studiesiu n
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The serum phosphate concentrations were reduced and the rhythm attenuated on 
fasting; fasting mean 1.07 mmol/l (range 0.97-1.15) compared to 1.23 mmol/l (range 
0.91 -1.43) in the fed state. ^
D iscussion
The results of this study are based on the first three of six subjects and therefore 
should be regarded as preliminary.
The decrease in serum adjusted calcium is in agreement with previous data on fasting 
(Statland et al, 1973, Elia et al, 1984). Dietary manipulation has been shown to 
have a major impact on the circadian phosphate rhythm (Jubiz et al, 1972). The 
reduction in serum phosphate concentrations observed on fasting is consistent with 
the previously reported loss of circadian rhythm in phosphate under these conditions 
(Jubiz et al, 1972). Comparison of the 24 h profiles in this study however suggests 
a markedly attenuated rhythm rather than a complete loss. This probably reflects the 
increased sampling frequency in this study.
However in contrast to the unaltered PTH circadian rhythm reported by Jubiz et al,
(1972) the PTH (1-84) profile was markedly different between the fasting and fed 
states. The PTH (1-84) concentrations were elevated during the day and appeared 
pulsatile in nature with marked between subject variability such that the synchronised 
nocturnal peak was not detected. The differences between the studies most probably 
reflect the combination of improved methodology, allowing the measurement of 
intact PTH (1-84) rather than immunoreactive PTH, and the increased sampling 
frequency employed in this study.
The marked attenuation of the serum phosphate rhythm produced on fasting in this 
study is therefore also accompanied by an elevation in PTH (1-84) concentrations 
and loss of circadian rhythmicity in PTH (1-84). Thus it is no longer appropriate to 
exclude an interaction between the circadian changes in serum phosphate and those of
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PTH (1-84) on the basis of the dissociation of these rhythms during a prolonged 
fast. Simplistically it could be argued that if under normal conditions the circadian 
rhythm in PTH (1-84) were triggered by increases in serum phosphate the attenuated 
phosphate rhythm observed on fasting would result in a reduction in PTH (1-84) 
concentrations. The elevated PTH (1-84) concentrations seen in this study are 
therefore probably secondary to the reduction in serum calcium. While it is not 
possible from this study to evaluate the role of serum phosphate and calcium in the 
circadian secretion of PTH (1-84) under normal conditions the data from this study 
are more consistent with the postulate that the PTH (1-84) status may modulate the 
phosphate rhythm (Jubiz et al, 1972, Markowitz et al, 1988, Logue 1990b). Recent 
studies on the effect of dietary manipulation on PTH (1-84) secretion have also 
shown persistently elevated PTH (1-84) concentrations in response to a high 
phosphorous, low calcium diet (Calvo et al, 1990). Thus it is clear that both diet and 
food intake have a marked influence on the circadian profile of PTH (1-84).
While full analysis of the pulsatile nature of the PTH (1-84) must await the 
completion of this study (with more subjects) there appears to be an increase in the 
pulsatility of PTH (1-84) secretion on fasting. Growth hormone is known to to 
increase during fasting (Cahill et al, 1966) and it has recently been shown that there 
is a significant increase in both the frequency and amplitude of the pulsatility of 
growth hormone secretion with the appearance of ultradian frequencies (Ho et al,
1988). It has been postulated from these and animal studies that the function of the 
signal mode, ie continuous versus pulsatile secretion, can mediate differential 
metabolic actions of growth hormone, and therefore play a role in the switch from 
the predominantly gluconeogenic to the lipolytic source of metabolic fuel with 
prolonged fasting. Similarly the pattern of secretion has been linked to differential 
effects of PTH (1-84) concentrations on type 1, cAMP mediated, and type 2, inositol 
phosphate mediated, receptors (Hesch et al, 1988). It is possible therefore that the 
pulsatile secretion of PTH (1-84) represents an adaptation to the fastmg state perhaps
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facilitating the mobilisation of calcium as it has been calculated that approximately 
half the quantities of calcium and phosphate excreted in urine during a prolonged fast 
had been mobilised from bone (Elia et al, 1984).
Despite the increased PTH (1-84) concentrations during the day the night time 
concentrations are not significantly different between the fasting and circadian 
studies. Therefore although the PTH (1-84) concentrations did not show a 
synchronised night time rise from the elevated basal concentrations it remains 
possible the neuroendocrine or sleep related factors are responsible for PTH (1-84) 
secretion during the night. It is also possible that fasting p e r  s e  suppressed the 
expected nocturnal surge in PTH (1-84) as has been shown for TSH (Romijn et al,
1990).
In conclusion the preliminary analysis of the effects of a four day fast in normal 
subjects has shown that while the serum phosphate rhythm is greatly reduced the 
circadian rhythm of PTH (1-84) does not remain unaltered as previously reported.
This has implications for the investigation of the control of PTH (1-84) secretion as a 
possible role for serum phosphate has been excluded on the basis of previous studies 
on fasting (Jubiz et al, 1972).
2.8 Conclusion
There is general agreement that serum calcium concentration is the main regulator of 
PTH (1-84) secretion. There is little evidence however that this relationship is 
dominant within the physiological range and it is has been postulated that non-ionic 
influences such as intrinsic pulsatility and adrenergic activity under the control of the 
central nervous system are of importance in modulating PTH (1-84) secretion 
particularly during sleep (Kripke et al, 1978, Markowitz et al, 1988). The improved 
sensitivity and specificity of the two-site immunometric assay has allowed the 
definition of the circadian rhythm of PTH (1-84) secretion in normal subjects. The 
studies of this project have indicated that the circadian secretion of PTH (1-84) could
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not fully be explained by changes in serum adjusted calcium. There is a strong 
correlation between changes in serum phosphate and PTH (1-84) concentrations 
under normal conditions. The overall results are consistent with the postulate that the 
PTH status modulates the rhythm in serum phosphate, however, the fasting study 
has indicated that a possible role for phosphate in the generation of the circadian 
profile of PTH (1-84) cannot be excluded.
The secretion of PTH (1-84) over a 24 h period is strongly correlated with other 
hormones which are entrained to the circadian 'clock' and are elevated through the 
night, most notably prolactin which has a known association with calcium 
metabolism. These results were suggestive of neuroendocrine control common to 
PTH (1-84) and prolactin especially as evidence had suggested that the nocturnal 
PTH (1-84) peak was, like that of prolactin, sleep related. The dissociation of the 
secretion during sleep shift indicated however that these hormones are entrained to 
the circadian 'clock' by different mechanisms. PTH (1-84) secretion appears to have 
an underlying endogenous rhythm which may be modified by sleep whereas 
prolactin is strongly associated with sleep but has been shown to have an 
endogenous component. Nevertheless under normal conditions the PTH (1-84) 
concentrations are maintained in a defined phase relationship to those of prolactin 
over a 24 h period. The secretion of PTH (1-84) particularly during the night is 
therefore likely to have a component of neuroendocrine control linking it to the 
pacemaker of circadian rhythms.
In addition to the effects of endogenous rhythmicity and of sleep, discussed above, 
the role of diet and food intake should also be considered. A diet low in calcium and 
high in phosphate has been shown to cause persistently elevated PTH concentrations 
in normal subjects (Calvo et al, 1990). The differences in PTH (1-84) concentrations 
between male and female subjects found in this study was most likely diet related.
The elevated PTH (1-84) concentrations and increased pulsatility seen on fasting may 
represent a positive adaptation to fasting to enable mobilisation of calcium
presumably from bone. It is also possible however that the increased PTH (1-84) 
concentrations reflect an absence of suppression, normally present due to food 
intake, of the tonic secretion of PTH (1-84). Suppression could result from the 
calcium content of the diet or indirectly via other hormones influenced by food 
intake. PTH (1-84) concentrations have been shown to suppress during an insulin 
tolerance test in normal subjects (Fisher et al, 1990). Whether this is a centrally 
mediated stress effect or a direct action of insulin remains to be established.
The profile of PTH (1-84) concentrations over a 24 h period in normal subjects is 
therefore multifactorial in origin. Further studies are required to elucidate the relative 
contributions of endogenous rhythmicity, sleep, diet and food intake to the 
generation of the circadian rhythm of PTH (1-84) secretion in normal subjects and in 
the pathophysiology of calcium metabolism.
3 STUDIES ON THE PULSATILE SECRETION OF PTH (1-84)
3.1 Introduction
The studies on circulating concentrations of PTH (1-84) over a twenty four hour 
period revealed a defined circadian pattern of secretion in normal subjects (Section 2 
above; Logue et al, 1989). Most hormones are secreted as a series of pulses rather 
than continuously and therefore, in addition to circadian, also show ultradian (i.e. 
occurring at intervals shorter than 24 h) variations in serum concentrations. While the 
pulse generators appear anatomically distinct from the neural structures responsible 
for circadian timing (Pohl et al, 1983) interactions between the circadian rhythmicity 
and pulsatility occur via the modulation of the amplitude, frequency and phase of the 
pulses.The circadian pattern of ACTH release has been shown to be obtained by the 
circadian modulation of pulse amplitude and frequency (Van Cauter and Honinckx 
1985). The frequency and amplitude of LH pulses are modulated during the
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nocturnal hours by circadian rhythmicity and/or sleep (Soules et al, 1985).
Virtually all endocrine glands exhibit an episodic rather than continuous pattern of 
hormone secretion (Urban et al, 1988). The resultant pulsatile mode of hormone 
delivery is believed to convey important physiological information to the target cells 
with variations in pulse amplitude and frequency being important modulators of 
target organ response (Gross et al, 1987). The investigation of the pulsatile release 
by the measurement of circulating concentrations of hormones requires sensitive and 
precise assay methodology ideally using small sample volumes and having the 
capability to process large numbers of samples. Previous methodology made the 
study of PTH difficult although studies suggested pulsatility was present in dogs 
(Fox et al, 1981) and in man (Robinson et al, 1982). More recently Dixit et al,
(1987) demonstrated pulsatile release of bioactive PTH in normal subjects with 
pulses occurring every 10-15 minutes and an increase in amplitude and frequency 
following stimulation by EDTA infusion. The development of two-site 
immunometric assays for PTH (1-84) has allowed more detailed studies of ultradian 
variations in the circulation and PTH (1-84) concentrations have been shown to vary 
in a pulsatile fashion with peaks approximately every 10 minutes in normal subjects 
(Harms et al, 1989).
The main reason for investigating the pulsatile release of a hormone is to understand 
its role in disease states. It has been shown that pulse amplitude and frequency 
modulation disturbances can have the same dramatic consequences for the expression 
of an endocrine disease as a glandular defect for example disturbed GnRH secretion 
in polycystic ovarian disease and Klinefelters syndrome (Kazer et al, 1987, Spratt et 
al, 1987). Indeed Harms et al, (1989) reported a decreased PTH (1-84) pulse 
amplitude and frequency in patients with osteoporosis.
A study of the pulsatile nature of PTH (1-84) secretion under basal condiuons and 
following EDTA infusion in normal subjects and patients with primary
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hyperparathyroidism was therefore undertaken.
3.2 Subjects and Methods 
Normal Subjects
Four healthy male volunteers (aged 31-42; mean 35 years) were studied on two 
separate occasions. In the first study the subjects were studied under basal 
conditions for a period of 60 minutes. Venous blood samples were obtained through 
an indwelling cannula at 0.5 minute intervals. The subjects were then studied 
(approximately one year later) before and during an EDTA infusion (24 mg/kg/h). In 
this study the subjects were sampled for 30 minutes (0.5 minute intervals) under 
basal conditions and then infused with EDTA for 90 minutes. Samples were 
withdrawn (0.5 minute intervals) during the last 30 minutes of the EDTA infusion. 
The studies were carried out between 1200 and 1400 h to minimise the effects of 
circadian changes in PTH (1-84) concentrations.
Hyperparathyroid patients: Four patients (two male, two female) were studied with 
primary hyperparathyroidism (subsequently surgically proven with histological 
diagnosis; aged 47-58 years). The patients were studied before and during EDTA 
infusion according to the protocol used with the normal subjects.
Intact PTH (1-84) was measured using the in-house IRMA (Logue et al, 1990a). All 
samples from an individual subject were analysed in the same assay batch.
The PTH (1-84) profiles were analysed by Fourier analysis (Statgraphics package). 
This procedure decomposes the variance of the data into contributions over a range of 
frequencies. The data were analysed using the integrated periodogram technique 
(Statgraphics) to verify non-random variation in the time series.
144
3.3 Results
The PTH (1-84) concentrations found in the normal subjects and patients with 
primary hyperparathyroidism are shown in Table 5.5.
In three of the the normal subjects (DOR, FCL, WDF) the PTH (1-84) 
concentrations were within the reference range (1-5 pmol/1) in both basal periods 
although in two subjects (WDF, FCL) the mean PTH (1-84) concentration was 
significantly lower in the second basal period (3.6 v 2.3 and 4.4 v 2.3 pmol/1 
respectively; p<0.05)). The PTH (1-84) concentration in the fourth subject (GHB) 
was at the upper end of the reference range (5.5 pmol/1) in the first basal study and 
clearly elevated (8.8 pmol/1) in the second basal period. This has been ascribed to a 
severe dietary regime undertaken by the subject prior to the study and is consistent 
with the elevated PTH (1-84) concentrations observed in fasting subjects (Section
2.7 above).
In response to the EDTA infusion the PTH (1-84) concentrations increased in all 
subjects by a mean factor of 5.3 (range 2.7-7.6). The basal PTH (1-84) 
concentrations in the hyperparathyroid patients were in the range 3.5-11.2 pmol/1 
which increased following EDTA by a similar factor to that observed in the normal 
subjects (mean 3.9; range 2.7-7.6).
The statistical analysis, using the integrated periodogram technique, confirmed the 
presence of non-random variation in the PTH (1-84) profiles. Figures 5.13-5.16 
show for each individual normal subject a plot of the PTH (1-84) concentrations 
(smoothed using a three sample moving average technique to minimise effects of 
assay noise) during the initial basal period, the basal pre EDTA period and the EDTA 
infusion. Associated with each of these graphs is a plot of the Fourier analysis of 
the profile. The Fourier analysis estimates the relative contributions to the profile 
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amplitude of the component sinusoids against frequency is derived.
The PTH (1-84) concentrations in the first basal profile in subject 1 (DOR) show a 
pronounced pulsatile pattern with the appearance of pulses at approximately five 
minute intervals. The Fourier analysis confirms the dominant contribution to this 
profile is the sinusoid with a frequency of 12 pulses/h (Figure 5.13). The profile for 
the second basal pre EDTA also shows pulsatile pattern although the frequency of 
pulses is reduced. This is reflected in the Fourier analysis in which shows once again 
a single dominant peak but with a frequency of 6 pulses/h. In addition there are also 
small contributions from higher frequency rhythms. During the EDTA infusion the 
the Fourier analysis indicates a major dominant peak with frequency of 6 pulses/h 
similar to that in the pre EDTA basal but with increased amplitude. There are also 
contributions from higher frequencies.
In subject 2 (WDF) during the initial basal profile a dominant peak with a frequency 
of 12 pulses/ h is observed. There are also contributions from lower frequencies with 
periods in the range 3 to 6 pulses/h (Figure 5.14). The analysis of the pre EDTA 
basal period shows a qualitatively similar pattern but with a shift to higher 
frequencies. The major peak is observed at 24 pulses/h together with lower 
frequencies in the range 6 to 12 pulses/h. There is also a component of higher 
frequencies around 48 pulses/h. During EDTA a qualitatively similar pattern to that 
obtained in the pre EDTA basal is observed with a peak at period 24 pulses/h but 
with increased contribution from the other lower (around 6 pulses/h) and higher 
(around 48 pulses/h) frequencies.
The analysis of the data from subject 3 (FCL) (Figure 5.15) shows the main 
contribution to initial basal profile to be from peaks with periods at 3 to 6 pulses/h 
but there is also a component at 12 pulses/h. The basal pre EDTA shows a similar 
pattern but with additional higher frequency components. During the EDTA infusion 
the pre EDTA pattern is substantially similar but with increased amplitude.
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Figure 5 .1 3
PTH (1-84) concentrations (sm oothed  using a three sam ple m oving average) in subject 1 
(DOR) during the initial basal period, the basal period prior to EDTA (1 year later) and during 
th e EDTA infusion. A ssocia ted  with each  profile is the Fourier analysis of the data.
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Figure 5 .1 4
PTH (1-84) concentrations (sm oothed  using a three sam ple m oving average) in subject 2 
(WDF) during the initial b asal period, the basal period prior to EDTA (1 year later) and during 
the EDTA infusion. A ssoc ia ted  with each  profile is the Fourier analysis of the data.
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Figure 5 .1 5
PTH (1-84) con centration s (sm oothed  using a three sam p le m oving average) in subject 3  
(FCL) during the initial basal period, the basal period prior to EDTA (1 year later) and during 
the EDTA infusion. A ssocia ted  with each  profile is the Fourier analysis of the data.
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Fig u re  5 .1 6
P T H  (1 -8 4 ) concentrations (sm oothed  using a three sam ple moving averag e) in subject 4  
(G H B ) during the initial basal period, the basal period prior to E D TA  (1 year laier) and during 
the E D T A  infusion. Associated with each profile is the Fourier analysis of the data.
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The analysis of the basal profile in subject 4 (GHB) (Figure 5.16) shows a major 
contribution from the peak with in the range 4 to 6 pulses/h. There are however 
additional components across a wide range of frequencies (12-30 pulses/h). The pre 
EDTA profile in this subject shows a complex composition with, in addition to a 
peak at 6 pulses/h, major contributions from a broad range of higher frequencies (24 
to 75 pulses/h). This may to be related to the dietary regime undertaken by this 
subject. During EDTA fusion the pattern is similar to those observed in the other 
subjects with contributions from frequencies in the range 3 to 6 pulses/h and from 
higher frequency components.
By comparison with the normal subjects the analysis of the pre EDTA basal profiles 
in two of the the hyperparathyroid patients (GR, ME) showed a complex mixture of 
frequencies in the range 3 to 30 pulses/h (Figures 5.17 & 5.18). During EDTA 
infusion in these two patients a similar complex mixture of frequencies was observed 
but with increased amplitude. However the data from the other two hyperparathyroid 
patients (MC, DW) showed patterns similar to that of the normal subjects with single 
dominant peaks with period in the range 6 to 12 pulses/h (Figures 5.19 & 5.20). 
During EDTA infusion in these patients an increase in amplitude and higher 
frequency components was observed again similar to the effects seen in the normal 
subjects.
3.4 Discussion
The results of this study confirm pulsatile variation in the circulating concentrations 
of PTH (1-84) in normal subjects. The observation of pulses occurring at 10-15 
minute intervals (4 to 6 pulses/h) as a component common to the profiles from all the 
normal subjects under basal conditions is consistent with previous data on bioactive 
PTH (Dixit et al, 1987) and PTH (1-84) (Harms et al, 1989). However the estimate 
of the frequencies of the components of pulsatility varied both between individuals 
and also within an individual between the two basal profiles. It is notable however
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Figure 5 .1 7
PTH (1-84) con centration s (sm oothed  using a three sam ple m oving average) in 
hyperparathyroid patient 1 (GR) during the basal period prior to E D T A , and during 
the EDTA infusion. A ssoc ia ted  with each  profile is the Fourier analysis of the data.
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Figure 5 .1 8
PTH (1-84) con centrations (sm oothed  using a three sam ple m oving average) in 
hyperparathyroid patient 2 (ME) during the b asa l period prior to EDTA and during 
the EDTA infusion. A ssocia ted  with each  profile is the Fourier analysis of the data.
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Figure 5 .1 9
PTH (1-84) concentrations (sm oothed  using a three sam ple m oving average) in 
hyperparathyroid patient 3 (MC) during th e b asal period prior to EDTA and during 
the EDTA infusion. A ssoc ia ted  with each  profile is the Fourier analysis of th e data.
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Figure 5 .2 0
PTH (1-84) con centrations (sm oothed using a three sam ple m oving average) in 
hyperparathyroid patient 4  (DW) during the basal period prior to EDTA and during 
the EDTA infusion. A ssocia ted  with each  profile is the Fourier an alysis of the data.
that the qualitative pattern of pulsatility was consistent within an individual subject. 
Thus the subjects with pronounced pulsatility (i.e. showing a major dominant peak 
on Fourier analysis) in the initial profile maintained this pattern throughout the study 
despite a shift in the estimate of pulse frequency. Similarly subjects who showed 
more complex contributions to the pulsatile profile also maintained this qualitative 
pattern. There was however good agreement in the estimate of pulse frequencies 
between the pre EDTA basal and the profile during EDTA within individual normal 
subjects. The estimate of pulse frequency therefore shows a close relationship within 
a day but is significantly different between the basal profiles carried out a year apart. 
This shift in pulse frequency may reflect changes in physiological parameters within 
an individual.
The EDTA infusion increased PTH (1-84) concentrations in the normal subjects in 
agreement with previous studies (Hackeng et al, 1986). The effect of EDTA on 
pulsatility appeared to be an amplification of the components present in the pre-EDTA 
profile resulting an increase the amplitudes of the components and in the 
contributions from high frequency rhythms. Thus the response to an EDTA infusion 
in normal subjects involves an elevation in PTH (1-84) concentrations and 
modulation of the amplitude and frequency of pulses.
The pattern of pulsatility in the hyperparathyroid patients during the basal profile was 
not consistent in that two of the patients showed a complex range of component 
frequencies of increased amplitude relative to the normal subjects while the other two 
patients showed pronounced pulsatility with a single dominant peak similar to the 
normal subjects. The patterns were not related simply to either PTH (1-84) or 
calcium concentration but appeared, like those of the normal subjects, consistent 
within an individual patient. The response to EDTA was similar to that observed in 
normal subjects both with respect to the increase in PTH (1-84) and the modulation 
of pulse amplitude and frequency. This is consistent with the concept of an error in 
the set point for calcium in primary hyperparathyroidism in that despite
hypercalcaemia the lowering of serum calcium concentration by EDTA infusion 
produces a response similar to that of observed in normal subjects (Gardin et al, 
1988).
The release of a hormone in a pulsatile manner is thought to maximise the efficiency 
of hormone release and the information content of the signal. In the case of the 
hormones of the hypothalamic pituitary axis, where continued stimulation of the 
secretory cells causes desensitization, the cells are activated to release hormone in 
'bursts'. The silent periods in between the bursts of activity avoids desensitization 
of the secretory cell and provides maximum hormone output (Leng 1988a). The 
bursts of activity can be either limited to within groups of secretory cells producing 
continuous release of hormone as in the case of vasopressin or synchronised across 
the gland producing pulsatile release of hormone as for LH (Leng 1988b).
The pulse generator is thought to be an integral part of the physiology of the 
hypothalamic-pituitary axis acting centrally via the hypothalamus (Lincoln 1988) 
although the pituitary itself has been shown to have intrinsic pulsatility (Robinson 
and Dyer 1988). There is no data on the pulse generator for PTH (1-84) secretion. 
Harms et al, (1989)haveshown the pulsatile variation in circulating concentrations of 
PTH (1-84) to be independent of changes in serum calcium. The parathyroids are 
known to respond to adrenergic stimulii (Heath 1980) but further studies would be 
required to confirm a possible role in pulse generation. Catastrophe theory has 
shown that combinations of simple linear inputs to a feedback control system or 
simple chemical reactions can produce oscillations and provide the basis for pulse 
generation (Leng 1988a). Both cAMP and intracellular calcium have been shown to 
be capable of producing endogenous oscillations in response to neuromodulatory 
agents in cell systems (Gillette 1988). Thus it is also possible that the pulsatility is a 
property either inherent to the cells of the parathyroid glands or arises from the 
feedback control of PTH (1-84) secretion.
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The pulsatile release of a hormone is an important principle in dynamic hormone- 
receptor interactions with the modulation of pulse amplitude and frequency being 
major determinants of end organ response (Spratt et al, 1987, Gross et al, 1987). 
The manipulation of gonadotrophin secretion by GnRH pulse amplitude and 
frequency modulation has been shown to shift testicular function either to hormone 
secretion or spermatogenesis. The underlying mechanism is the preferential 
activation of either the type 1 (cAMP mediated) receptors involved in hormone 
secretion or the type 11 receptors (inositol phosphate mediated) of spermatogenesis 
(Spratt et al, 1987). By analogy it has been suggested that pulse amplitude and 
frequency modulation of PTH (1-84) concentrations governed the expression of 
either type 1 or type 11 receptors and ultimately PTH biological activity. Following 
the finding of reduced pulsatility in patients with osteoporosis disturbed glandular 
PTH (1-84) secretion has been implicated in the pathogenesis of osteoporosis (Hesch 
et al, 1988).
The concept of modulation of pulsatility as a control system is further supported by 
the finding of a loss of circadian rhythm but increased pulsatility in fasting subjects 
(Section 2.7 above) and also by the complex pulsatility found in the subject in this 
study undertaking a severe dietary regime. It is known that fasting increases the 
complexity of the pulsatility of growth hormone secretion which is thought to act in 
mediating the switch from the predominantly gluconeogenic to a lipolytic source of 
metabolic fuel in prolonged fasting (Ho et al, 1989). Similarly the increased 
pulsatility may be involved in the mobilisation of calcium from bone during a fast.
In conclusion it seems clear that in common with many other hormones PTH (1-84) 
is secreted in a pulsatile manner with modulations of amplitude and frequency of 
pulses being an integral part of the control of PTH biological activity. The 
assessment of the components of pulsatility in individuals has indicated that while the 
tendency to either pronounced pulses or a more complex harmonics is characteristic
of the individual the estimate of the component pulse frequency is not consistent 
between experiments. It remains to be established whether the alterations in 
amplitude and frequency of pulses seen in the hyperparathyroid patients contribute to 
or result from the pathogenesis of hyperparathyroidism, further studies are required 
to elucidate the role of pulsatility of PTH (1-84) secretion in normal physiology and 
disease states.
4 STUDIES ON THE PTH (1-84) RESPONSE TO PAMIDRONATE
THERAPY IN PATIENTS WITH PAGET'S DISEASE OF BONE 
AND HYPERCALCAEMIA OF MALIGNANCY
4.1 Introduction
Thebisphosphonates,a group of pyrophosphate analogues, are potent inhibitors of 
osteoclast-mediated bone resorption. Bisphosphonates are used in the treatment of 
diseases associated with increased bone resorption such as Paget's disease (Russel et 
al 1974, Frijlink et al, 1979, Adami et al, 1986, Gray et al, 1987), hypercalcaemia 
associated with malignancy (HCM) (Sleeboom et al, 1983, Singer and Fernandez 
1987, Van Breukelen et al, 1982, Ralston et al, 1985, Cantwell and Harris 1987) and 
involutional osteoporosis (Huaux et al, 1985). Pamidronate (3-am ino-1- 
hydroypropylidene-l,l-bisphosphonate, APD) is one of the more effective 
bisphosphonates in the treatment of Paget's disease and HCM and the effects of APD 
treatment on calcium and phosphate homeostasis have been well documented (Van 
Breukelen et al, 1982, Sleeboom et al, 1985, Singer and Fernandez 1987, Ralston et 
al, 1988, McCloskey et al, 1988).
APD treatment in patients with Paget's disease or HCM has provided the opportunity 
to study PTH secretion from normal or suppressed parathyroid glands in response to 
the lowering of serum calcium (Adami et al, 1982, Sleeboom et al, 1983, Papapoulos 
1986). To date however studies on the response of PTH to APD therapy have been 
limited by PTH assay technology. While responses have been observed with N and
C-terminal immunoassays the results have been inconsistent (Adami et al, 1982, 
Sleeboom et al, 1983). More recently, using homologous immunoradiometric assays 
specific for either the N or C terminal, increases in PTH were observed only when 
the patients became hypocalcaemic (Papapoulos et al, 1986). The development of 
sensitive and specific two-site immunometric assays for PTH (1-84) has allowed 
changes within the reference interval in normal subjects to be demonstrated (Logue et 
al, 1989).
We therefore re-examined the PTH response to APD therapy in Paget's disease and 
HCM. Also included in the study are two indirect measurements of PTH secretion, 
the maximum tubular reabsorption of phosphate per litre glomerular filtrate 
(TmP04/GFR) (Bijvoet 1977) and nephrogenous cyclic adenosine monophosphate 
(NcAMP) (Broadus et al 1977). Through the comparison of these indices with the 
PTH (1-84) it was hoped to identify the role, if any, of PTHrP in the response to 
APD in HCM.
4.2 Patients and Methods
Twelve patients with Paget’s disease (4 M; 8 F; aged 51-63 yrs) were included in the 
study. All had their bone disease confirmed by standard biochemical, radiological 
methods and where appropriate by histomorphometry. All were studied prior to and 
following a single intravenous dose of 45 mg Pamidronate, which was given over 4 
hours in 0.5 litres of 0.9% NaCl.
Twelve patients with HCM (7 M; 5 F; aged 48-78 yrs) were also studied. The origin 
o f the primary tumour in these patients was breast (3), myeloma (2), lung (4); 
lymphoma (2) and genito-urinary tract (1). Standard radionuclide bone scan was 
used to assess the presence and extent of metastatic bone disease. Eight o f the twelve 
patients had metastatic bone disease, and the tumour load was estimated as being 
heavy in two and light in six patients. All patients were rehydrated over a  24 hr 
period with a minimum of 2 litres of intravenous 0.9% N a d  prior to the
administration of a single intravenous dose of 30 mg Pamidronate given over 4 hours 
in 0.5 litres of 0.9% NaCl. Serum creatinine concentrations were within the reference 
range (60-130 |imol/l) in ten patients and elevated in two (150, 180 p.mol/1) 
following rehydration. No patient developed renal failure during the study.
In both groups of patients blood samples were obtained by venesection prior to 
Pamidronate (day 0) and daily thereafter for seven days. All blood specimens were 
collected between 10.00-11.00 hrs, and a timed (2 hour) fasting urine was obtained 
after discarding the first morning urine specimen. Serum, K-EDTA plasma and urine 
were stored at -20°C prior to analysis.
Serum and urinary calcium, albumin, phosphate and creatinine were measured using 
standard automated methods. Serum calcium was adjusted for variations in albumin 
concentration, as describedpreviously(Gardner et al, 1981). Intact PTH (1-84) was 
measured in serum using an in-house immunoradiometric assay (Logue et al, 1990a). 
T111PO4/GFR was determined according to the method of Bijvoet (1977). Plasma 
cAMP was measured with a commercially available kit (Amersham International pic, 
Aylesbury, Bucks, UK); urinary cAMP with an in-house radioimmunoassay 
(O’Reilly et al, 1986) and nephrogenous cAMP calculated by the method of Broadus 
et al (1977). Each series of samples for an individual patient was analysed within a 
single batch.
Statistical analysis was performed using a paired difference t test to compare each 
sample point with the appropriate day zero result for the individual patient.
4.3 Results
The mean (± SEM) results for the parameters measured in the patients with Paget’s 
disease are displayed in Figure 5.21. Prior to therapy, the mean concentration of all 
four parameters was within the appropriate reference interval: adjusted calcium 2 .20- 
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NcAMP 8-28 nmol/L. Following Pamidronate, there was a small but significant fall 
in serum adjusted calcium, within the reference range, on day 2 (p <0.01) which was 
sustained throughout the remainder of the study. A significant increase in PTH (1- 
84) occurred on day 2 (p <0.05). The serum PTH (1-84) concentration continued to 
increase throughout the period of the study, reaching values of more than twice the 
upper limit of the reference interval. The TmPO^GFR fell gradually to a trough on 
day 4 (p <0.001), which persisted thereafter. In keeping with the rise in PTH (1-84) 
NcAMP rose to a peak on day 4 (p <0.01), which was also sustained. These results 
are consistent with a normal PTH response to a Pamidronate induced reduction of 
serum calcium.
The mean (± SEM) results for the parameters measured in the patients with HCM are 
displayed in Figure 5.22. Following rehydration, but prior to Pamidronate, all 
subjects had elevated concentrations of serum adjusted calcium (range 2.85-3.95 
mmol/L). Nine patients had PTH (1-84) concentrations below the assay detection 
limit (0.5 pmol/L), whilst the other three patients had concentrations close to the low 
end of the reference interval (0.9-1.1 pmol/L). Despite this suppression of PTH (1- 
84), the mean TmPO^GFR concentration was below the reference interval and the 
mean NcAMP concentration was significantly elevated.
Following Pamidronate therapy, there was a rapid and continuing fall in the serum 
adjusted calcium in all subjects, with the mean concentration reaching the upper limit 
of the reference interval on day 5. PTH (1-84) concentrations remained suppressed 
for days 1-3 but rose significantly on day 4 (p <0.05) and continued to rise, such 
that the mean concentration was above the reference interval at the end of the study. 
The T1X1PO4/GFR and NcAMP responses to Pamidronate therapy were complex. 
Thus, the initially subnormal TmP04/GFR fell significantly, reaching a nadir on day 
5 (p <0 .001) before rising significantly on the final day of the study (p <0 .01). 
NcAMP concentrations showed the reverse effect, with a significant rise from the 
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APD Study: PTH(1-84) vs Adjusted Calcium Concentrations
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possible to demonstrate a significant increase in PTH (1-84) secretion coincident 
with the fall in serum calcium. The concentration of PTH (1-84) rose progressively 
during APD therapy despite the fact that the serum calcium did not continue to fall 
after day 2 and despite the fact that no patient became frankly hypocalcaemic.
The increased secretion of PTH (1-84) following APD therapy in Paget's disease 
could also be detected by measurement of the indirect parameters of PTH (1-84) 
action. PTH acts via renal tubular receptors and cyclic AMP second messenger to 
reduce the maximal tubular reabsorption of phosphate. Thus the findings of 
decreased serum phosphate, decreased Tm P04 and increased NcAMP following 
APD therapy are consistent with the known biological effects of increased PTH 
(1-84) secretion (Bijvoet 1977, Broadus et al, 1977).
The patients with HCM showed the expected combination of hypercalcaemia and 
suppressed serum PTH (1-84) concentrations prior to therapy with APD. However 
the pretreatment concentrations of TmP04  and NcAMP were decreased and increased 
respectively. These observations are consistent with the recognised existence, in a 
proportion of these patients, of PTHrP a molecule which is structurally distinct from 
PTH (1-84) but which contains striking homology in the N terminal amino acid 
sequence and so binds the renal tubular PTH receptor (Stewart et al, 1983, Ralston et 
al, 1984, Suva et al, 1987).
APD therapy to the patients with HCM produced the expected sharp and prolonged 
decrease in serum adjusted calcium (Van Breukelen et al, 1982, Sleeboom et al 1985,
Singer and Fernandez 1987, Ralston et al, 1988, McCloskey et al, 1988). At the end 
of the study the mean adjusted calcium was within the reference intervals with a 
range 2.25 to 2.80 mmol/1. This study therefore confirms the effectiveness of APD 
as a therapeutic agent in HCM. Of particular interest however, were the PTH (1-84) 
results for these showed a significant rise on day 4 and continued to increase to a 
mean concentration above the reference interval. The initial increase in PTH (1-84)
occurred at a time when the mean serum adjusted calcium was above the reference 
interval, and the elevated PTH (1-84) concentrations occurred when the mean 
adjusted calcium was within the reference interval with no patient hypocalcaemic. 
These observations contrast with previous reports that the PTH secretion occurs only 
as patients become hypocalcaemic (Papapoulos et al 1986) and strongly suggest a 
resetting of the 'trigger point' for PTH secretion in patients with HCM. The concept 
of an altered 'trigger point' for PTH (1-84) secretion may explain a number of 
conditions related to altered calcium homeostasis (Parfitt 1979). Previous studies 
using acute changes in calcium have shown both rate of fall and direction of change 
to be important determinants of the PTH response in normal subjects and patients 
with secondary hyperparathyroidism (Adami et al, 1982, Cunningham et al, 1989). 
However, the data from this study indicate that in HCM the absolute calcium 
concentration is more important in 'triggering' PTH (1-84) secretion than the rate of 
fall in calcium that can be obtained following Pamidronate therapy.
The clinical implication of these results is related to the interpretation of PTH (1-84) 
concentrations in patients receiving APD therapy. Confusion between the two major 
causes of hypercalcaemia (primary hyperparathyroidism or malignancy) may occur in 
HCM if a sample is obtained after treatment with APD as in some cases a modest 
lowering of the serum calcium results in detectable PTH (1-84) secretion.
The observed changes in TmP04/GFR and NcAMP following treatment of HCM 
with APD require careful interpretation. If PTHrP is responsible for the abnormal 
concentrations of these parameters pretreatment in some patients then the 
exacerbation of the abnormality (decreasing TmP04/GFR increasing NcAMP), 
before a significant rise in PTH (1-84), from 2 to 5 days after APD may suggest 
increased secretion of PTHrP at this time, either as a direct consequence of the 
therapy or as a manifestation of the pathophysiology of the disease. The paradoxical 
increase in TmP04/GFR and decrease in NcAMP on day 7 is also interesting for it 
occurs at a time of increasing PTH (1-84) secretion and yet is suggestive of
decreased stimulation of the renal tubular PTH receptor. The explanation of this 
phenomenon must await validated assays for PTHrP as the assays currently available 
give conflicting results in some patient groups depending on methodology and 
specificity (Henderson et al, 1990, Burtis et al, 1990).
5 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN 
HAEMODIALYSIS PATIENTS
5.1 Introduction
Secondary hyperparathyroidism is a consistent feature of advanced renal failure. 
Plasma concentrations of parathyroid hormone become elevated early in renal disease 
and often continue to increase as renal function declines (Reiss et al, 1968, Amaud 
1973). Nearly all patients with renal failure show some degree of secondary 
hyperparathyroidism and this is thought to be an adaptive response to hypocalcaemia 
which occurs because of hyperphosphataemia and reduced calcium absorption (Fuss 
et al, 1976, Avram et al, 1978, Bricker 1972). In addition, skeletal resistance to the 
effects of PTH, and altered sensitivity of the parathyroid glands to feedback 
regulation by calcium, may both play a role (Llach et al, 1975, Brown et al, 1982).
More recently it has been suggested that reduced production of l,25(OH)2D3 in renal 
failure may lead to hyperparathyroidism by a direct effect on the parathyroid gland. 
l ,25 (OD)2D 3 binds to specific receptors on parathyroid tissue and suppresses the 
levels of m-RNA for the synthesis of pre-pro PTH, the biosynthetic precursor of 
PTH (Karmall et al, 1989). Through this mechanism the low plasma concentrations 
of l ,25(OH)2D 3 in advanced chronic renal failure are thought to be an additional 
important cause of PTH hypersecretion (Slatopolsky et al, 1984, Korkor 1987, 
Sherwood 1987, Feinfield and Sherwood 1988, Slatopolsky et al, 1988).
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Calcitriol (l,25(OH)2D3) is effective in the prevention and treatment of secondary 
hyperparathyroidism in uraemic patients undergoing dialysis (Cobum et al, 1977, 
Mason et al, 1980, Baker et al, 1986). However, the occurrence of hypercalcaemia 
limits the dose tolerated in the long term to 0.5 mg/day or less (Cobum et al, 1977, 
Brickman et al, 1980). Furthermore the l,25(OH)2D3 plasma concentrations 
achieved by these doses are likely to be low because of the significant degree of 
Calcitriol metabolism in the gut (Napoli et al, 1983).
Even with optimal serum calcium concentrations many patients treated with Calcitriol 
develop progressive secondary hyperparathyroidism and eventually require subtotal 
parathyroidectomy (Kanis et al, 1976, Shimamatsu et al, 1987, Sharman et al,
1982). Recently Slatopolsky and co-workers have tested the hypothesis that the 
administration of Calcitriol intravenously might achieve better PTH suppression 
(Slatopolsky et al, 1984). They showed that excellent control of PTH secretion 
could be achieved by a thrice-weekly injection of Calcitriol. High doses were 
tolerated without hypercalcaemia occurring and higher plasma concentrations of 
l,25(OH)2D3 were achieved with intravenous compared with oral administration.
In this study we attempted to suppress secondary hyperparathyroidism with high 
doses of oral Calcitriol since the intravenous preparation is generally unavailable, and 
we prevented hypercalcaemia occurring by using a low calcium dialysate. In 
addition we compared the effects of daily vs thrice-weekly administration of 
Calcitriol, since it might be the intermittent dosage regimen rather than the 
intravenous route of administration which led to the better suppression of 
hyperparathyroidism in the study of Slatopolsky et al (1984).
5.2 Patients and Methods
Nineteen patients undergoing regular haemodialysis gave written informed consent to 
enter the study which was approved by the local ethical committees. There were 13
men and 6 women of mean age 40 years (range 19-67 years). These patients were 
dialysed for 4-5 hours thrice-weekly and the mean duration of haemodialysis was 39 
months (range 3-96 months). The original diagnoses were glomerulonephritis in 6 , 
the urological complications of spina bifida in 3, Alport’s syndrome in 2, reflux 
nephropathy in 2, renovascular disease in 2, and mega-ureter, amyloidosis, Fabry’s 
disease and polycystic kidneys in one each. Seven patients were receiving vitamin D 
analogues and five calcium carbonate, but these were stopped prior to the study. 
Twelve patients were receiving aluminium hydroxide in a mean dose of 2400 mg/day 
and this was continued during the study.
All patients had biochemical evidence of secondary hyperparathyroidism with a mean 
PTH (1-84) plasma concentration of 62 pmol/1 (range 15-125),the normal range 
being 1-5 pmol/1. Nine patients had radiological evidence of renal osteodystrophy 
and 9 had elevated serum alkaline phosphatase concentrations (ALP greater than 110 
IU).
Patients were randomly assigned to receive daily (conventional), or thrice-weekly 
(intermittent) therapy with Calcitriol. For 2 weeks (control period) all patients were 
dialysed using a dialysate containing 1.0 mmol/l of calcium instead of one containing 
1.55 mmol/l. For 12 weeks (treatment period) patients received oral Calcitriol and 
continued to dialyse with low calcium dialysate. The conventional group received 
0.25 microgrammes as the single morning oral daily dose with a dosage increment of 
0.25 microgrammes at the beginning of each subsequent week until the serum 
calcium concentration, corrected for albumin, was 2.6-2.7 mmol/l after which the 
dose was maintained at that level. If the serum calcium exceeded 2.7 mmol/l 
Calcitriol was withheld until it had fallen to the desired range and it was then 
recommenced at 0.25 microgrammes less than the previous dose. The intermittent 
group received 0.5 microgrammes orally thrice weekly at the end of each dialysis 
with a dosage increment of 0.5 microgrammes at the end of each subsequent week 
until the serum calcium concentration was in the range 2.6-2.7 mmol/l. If the serum
calcium exceeded 2.7 mmol/l, Calcitriol was withheld until the calcium fell to the 
desired range, after which it was recommenced at 0.5 microgrammes less than the 
previous dose. Calcium carbonate (Titralac) was prescribed if there was no rise in 
serum calcium after several weeks of Calcitriol therapy.
Predialysis serum calcium, phosphate, albumin and alkaline phosphatase were 
measured twice weekly. During the control period and during the last 2 weeks of 
therapy serum aluminium and magnesium, plasma PTH (1-84) and serum 
l,25(OH)2D3 were measured twice weekly and for the rest of the study once weekly. 
All bloods were taken pre-dialysis which meant that l,25(OH)2D3 concentrations 
were measured 1-6 hours after the morning Calcitriol dose in the conventional group 
and 44-68 hours after the last post-dialysis Calcitriol dose in the intermittent group.
Analytical Methods
Calcium, phosphate, alkaline phosphatase (ALP) and albumin were measured by 
standard automated techniques. Magnesium and aluminium were measured by 
atomic absorption spectroscopy.
Intact PTH (1-84) was measured using the two-site immunometric assay with a 
sensitivity of 0.5 pmol/1 and a range of 1.5-250 pmol/1. It has an intra-assay 
coefficient of variation less than 10%. The normal range is 1-5 pmol/1 and the assay 
is unaffected by a 200 molar excess of C-terminal fragments (Logue et al, 1990a).
l,25(OH)2D3 was measured using the method of Rheinhardt et al (1984) but using 
high performance liquid chromatography (HPLC) in the final purification of vitamin 
D metabolite from serum. The intra-assay coefficient of variation is less than 10% 
and the normal range 30-100 pmol/1. The sensitivity of the assay is 5 pmol/1 and for 




Paired pre- and post-treatment changes in PTH, l,25(OH)2D3, calcium and alkaline 
phosphatase were assessed by the Wilcoxon Signed Rank Test. The relative effects 
of the 2 different dosage regimens on these parameters were compared using the 
Wilcoxon Rank Sum Test.
5.3 Results
The treatment was well tolerated, but one patient in the intermittent group complained 
of gastric fullness and dyspepsia for 24 hrs after each dose of Calcitriol and he was 
withdrawn from the study after 11 weeks. Two other patients were withdrawn from 
the study after 12 weeks following renal transplantation and urological surgery. The 
results of all patients are included in the analysis.
All but three patients achieved a net rise in serum calcium and all but one patient 
achieved a net fall in PTH (1-84). Nine patients had their dose of Calcitriol reduced 
because of hypercalcaemia (adjusted serum calcium greater than 2.7 mmol/l), but in 
no patient was this associated with symptoms and in all cases it resolved within 2-4 
days. Seven patients (4 conventional, 3 intermittent) required calcium carbonate 
supplements to facilitate a rise in serum calcium.
The mean dose of Calcitriol at the end of the study was 2.0 microgrammes/day 
(range 1-3 microgrammes/day) in the conventional group and 2.6 microgrammes 
post-dialysis (range 1-4 microgrammes post-dialysis) in the intermittent group.
The biochemical results are displayed in Figures 5.24 and 5.25 and Tables 5.6 and 
5.7. The mean plasma PTH (1-84) concentration fell from 62 pmol/1 (range 15-125 
pmol/1) during the control period to 39 pmol/1 (range 5-120 pmol/1) in the first month 
of treatment (p <0.01). The mean PTH (1-84) concentration then fell further to 22 
pmol/1 (range 1-70 pmol/1) at the end of the treatment period (Figure 5.24). The
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Table 5.6
Comparison between control and final mean values for phosphate, 




2.11 (1.17-3.47) 2.22 (1.33-3.26) N .S.
ALP
(IU)
144 (48-461) 123 (61-346) p <0.05
Aluminium
(p.mol/1)
1.45 (0.8-2.9) 1.51 (0.4-2.6) N .S.
Magnesium
(mmol/l)
1.07 (0.62-1.38) 1.11 (0.78-1.81) N .S.
Table 5.7
Comparison between initial and final mean values for adjusted 
calcium, PTH (1-84) and ALP in the conventional and intermittent 
therapy groups
INITIAL FINAL
Adjusted calcium conventional 2.33 (2.19-2.45) 2.45 (2.26-2.62)
(mmol/l) intermittent 2.33 (2.05-2.55) 2.58 (2.34-2.62)
PTH (1-84) conventional 64 (15-125) 26 (1-70)
(pmol/1) intermittent 61 (20-125) 18 (4-41)
ALP conventional 163 (48-461) 138 (61-346)
(iu/1) intermittent 128 (70-245) 108 (72-155)
mean serum calcium concentration during the control period was 2 .3 3  mmol/l (range 
2.05-2.55 mmol/l) and after one month of Calcitriol was 2.36 mmol/l (range 2.09- 
2.59 mmol/l). At the end of the treatment period the mean serum calcium 
concentration had risen to 2.52 mmol/l (range 2.26-2.67 mmol/l) (p < 0.01 (Figure 
5.24)). The mean serum alkaline phosphatase concentration fell from 144 IU/1 
(range 48-461IU/1) to 123 IU/1 (range 61-346 IU/1) at the end of the treatment period 
(p <0.05) (Table 5.6). There were no significant changes in the mean serum 
phosphate, magnesium or aluminium concentrations during the study (Table 5.6). 
Sixteen patients were taking aluminium hydroxide at the end of the study in a mean 
dose of 2500 mg/day.
Ten patients were entered in the intermittent group and 9 patients in the conventional 
group. There were no significant differences in the biochemical changes between the 
two treatment regimens (Table 5.7), apart from serum l,25(OH)2D3 concentrations. 
Mean l,25(OH)2D3 concentrations in the control period were low in both patient 
groups (Figure 5.25). The l,25(OH)2D3 concentrations measured 1-6 hours after 
Calcitriol increased from a mean of 5 pmol/1 (<5-17) in the control period to 114 
pmol/1 (<5-225) at week 10 in the conventional group (p <0.01). The mean serum 
concentrations measured 44-68 hours post-dose in the intermittent group rose from 
13 pmolA (<5-43) in the control period to 48 pmol/1 (<5.-71) at week 1 0  (p <0 .0 1 ) 
(Figure 5.25).
5.4 Discussion
This study shows that in patients with moderately severe secondary 
hyperparathyroidism, even after many years of renal replacement therapy, medical 
treatment can achieve marked parathyroid suppression. The combination of high oral 
doses of Calcitriol and low calcium dialysate was well tolerated and achieved much 
higher serum concentrations of l,25(OH)2D3 without causing hypercalcaemia than 
oral Calcitriol therapy alone (Slatopolsky et al, 1984). There was strong evidence of
a direct effect of l,25(OH)2D3 on the parathyroid gland since PTH (1-84) 
concentrations fell significantly during the first month of active treatment despite 
static serum calcium concentrations. An additive suppressive effect of PTH (1-84) 
secretion was observed when the serum calcium had increased in the latter two 
months with higher doses of Calcitriol.
There was no difference in the degree of PTH (1-84) suppression between patients 
receiving daily Calcitriol and those receiving it thrice-weekly. Studies in the rat 
demonstrate that maximal inhibition of PTH m-RNA synthesis occurs at 
concentrations of l,25(OH) Vit D around 50-100 pmol/1 (Silver et al, 1986) which is 
similar to the concentrations measured 44-68 hrs after Calcitriol at the end of this 
study. A ‘therapeutic range’ for l,25(OH)2D3 concentrations in chronic renal failure 
in man has not yet been determined nor have the relative importance of high ‘peak’ or 
sustained ‘trough’ concentrations. However, we have clearly achieved 
concentrations sufficient for a good clinical response in both groups.
The semm l,25(OH)2D3 concentrations were low or undetectable at the beginning of 
the study and were significantly increased after 1 0  weeks in both treatment groups. 
The serum l,25(OH)2D3 concentrations were not directly comparable between the 
two groups because of the different times of sampling. However, serum 
concentrations measured 44-68 hrs after the last dose in patients in the intermittent 
group were well within the normal range and this demonstrates that the gut 
metabolism of Calcitriol after oral treatment is not a significant impediment to the 
attainment of physiological semm l,25(OH)2D3 concentrations (Napoli et al, 1983).
Calcitriol has been shown to increase phosphate as well as calcium absorption 
leading to hyperphosphataemia (Ramirez et al, 1986, Demantis et al, 1986, Fournier 
et al, 1987). Mean phosphate and aluminium concentrations did not rise during the 
study, but there was a modest increase in the requirement for aluminium containing 
phosphate binders. The overall control of phosphate in these patients was poor from
164
the beginning of the study, despite thrice-weekly dialysis and advice about dietary 
restriction and phosphate binding therapy. As a result the mean Ca/P0 4  product was 
high at 4.87 mmol/l (2.87-8.44) and increased with the rise in calcium to 5.56 
mmol/l (3.48-8.45) at the end of the study. The risk of metastatic calcification is 
proportional to the level of Ca/PC>4 (Parfitt 1969b) and we would therefore not 
suggest attempting to increase the serum calcium level in longer term studies of PTH 
(1-84) suppression unless the serum phosphate was well controlled.
The mean calcium loss was calculated (by measuring pre- and post-dialyser dialysate 
calcium concentrations, dialysate flow rates and dialysis time) at 6 .3  mmol/l (250 
mg) per dialysis. Seven patients required supplementary oral calcium carbonate to 
facilitate a rise in serum calcium during the treatment period. In these patients the 
dietary calcium intake was presumably inadequate and a higher dialysate calcium 
could have been used without causing hypercalcaemia (Raman et al, 1976).
We have achieved a 65% reduction in PTH (1-84) levels in patients with moderately 
severe secondary hyperparathyroidism over 12 weeks. This is comparable to the 
effects of intravenous Calcitriol reported by Slatopolsky et al (1984). Regimens 
utilising high doses of Calcitriol may offer considerable clinical benefits if these 
effects can be shown to be sustained in longer term studies. The combination of high 
doses of oral Calcitriol and hypocalcaemia dialysate has advantages over intravenous 
Calcitriol in that it is more readily available, cheaper, and more applicable to patients 
treated by CAPD.
Furthermore, we have shown that thrice-weekly Calcitriol therapy is as effective as 
daily therapy. This may have implications for simplifying treatment regimens and 
suggests that even wider spacing of doses should be investigated.
CHAPTER 6  
GENERAL DISCUSSION
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CHAPTER 6  : GENERAL DISCUSSION
The production of antibodies useful in diagnostic PTH assays has traditionally been 
difficult. The immune response to PTH (1-34) in mice has been shown to be under 
genetic control (Nussbaum et al, 1985) and the antibody responses to PTH (1-34) 
obtained in this study are consistent with a species and strain specific response. In 
this project the strategy of using chemically synthesised peptides to generate site 
specific monoclonal antibodies was successful in producing N-terminal, but not C- 
terminal monoclonal antibodies. It is interesting that other groups produced by 
similar strategies C-terminal, but not N-terminal monoclonal antibodies. This may 
reflect in part differences in the selection and preparation of the immunogens and in 
immunisation schedules. The production of monoclonal antibodies is totally 
dependent, however, on the selection procedure and as such the antibody screening 
assay is central to the process.
As radiolabelled (hence oxidised) PTH (1-34) was employed in the antibody 
screening assay in this study, it is therefore perhaps not surprising that monoclonal 
antibodies which recognised oxidised PTH (1-34) preferentially were selected. It 
may also contribute to the failure to detect a response in the CBA mouse strain 
which had been identified as a high responder to PTH (1-34) (Nussbaum et al, 
1985). Similarly the screening assay, using radiolabelled PTH (53-84), may have 
played a part in the failure to detect C-terminal monoclonal antibodies. Thus it is 
possible that the successful production of either C-terminal or N-terminal antibodies 
may be a consequence of the assay methods used for antibody screening by the 
various groups.
Nevertheless by combining the monoclonal antibodies produced the primary aim of 
the work of this thesis, the development of a two-site immunometric assay specific 
for intact PTH (1-84), has been successfully achieved. In addition the original 
design specifications, that the assay should measure PTH (1-84) in all normal
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subjects and be free of interference from PTH fragments, have also been met. The 
performance of the PTH (1-84) assay developed, in terms of limit of detection and 
assay precision, compares favourably with other methods (Nussbaum et al, 1987, 
Brown et al, 1987).
However the loading of the assay with C-terminal monoclonal antibody to avoid 
interference from C-terminal fragments requires the large scale production of this 
antibody - in this laboratory alone, on present usage, 1 g of purified monoclonal 
antibody is required per year. This is has significant cost implications. It is possible 
with alternative assay design in two-site IRMA methods to avoid the requirement for 
a gross excess of C-terminal monoclonal antibody by employing N-terminal ‘capture’ 
followed by a wash step to remove the C-terminal fragments before the addition of 
the radiolabelled antibody. The assay development studies while identifying the best 
combination of monoclonal antibodies to be 3B3 and ESQ1, also showed however 
that these antibodies did not function as well in this preferred configuration. 
Subsequently a two-site IRMA for PTH (1-84) in the preferred configuration of N- 
terminal capture, to avoid interference from C-terminal fragments, has been 
developed using the 6E3 monoclonal antibody, also produced in this project, in 
combination with an affinity purified polyclonal antibody to C-terminal PTH. This 
method, while involving an extra wash step, substantially reduces the volumes of 
reagents required with comparable assay performance (Greig et al, 1990).
This preferred configuration relies on the current evidence from clearance studies that 
N-terminal fragments are not produced in excess relative to intact PTH (1-84) 
(Bringhurst et al, 1988). There is some evidence, however, that significant amounts 
of N-terminal fragments are produced in some pathological situations, particularly 
end stage renal failure (Goltzman 1986). The monoclonal antibody 4G3 produced in 
this project was shown to be specific for PTH (1-34) in that it recognises PTH (1- 
84) poorly. It has been possible to develop a two-site IRMA for PTH (1-34) using 
4G3 in combination with radiolabelled 3B3. The assay measures low picomolar
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concentrations of PTH (1-34) and shows less than 0.2% cross reactivity with PTH 
(1-84). Studies are now in progress to identify whether significant amounts of N- 
terminal fragments may be produced in  v i tr o  or appear in the circulation in  v iv o .
The second aim of the work of this thesis was the application of the assay to the 
physiology and pathophysiology of calcium homeostasis. The main clinical 
application of PTH (1-84) assays is in the differential diagnosis of hypercalcaemia.
The PTH (1-84) results from this assay allow good discrimination between normal 
subjects and patients with primary hyperparathyroidism. The potential for overlap 
between these groups noted for this assay is similar to results obtained with 
published PTH (1-84) assays (Nussbaum et al, 1987, Brown et al, 1987, Frolich et 
al, 1990). The studies on the circadian secretion of PTH (1-84) have described a 
defined rhythm in normal subjects with PTH (1-84) rising both in the early evening 
and in a broad peak through the night. There was considerable variation in the return 
to baseline concentrations between subjects with the greatest variability between 
subjects was in the period from 0600 to 1000 h. Thus, PTH (1-84) concentrations in 
early morning samples, such as those typically collected from in-patients, may 
therefore appear to be elevated spuriously. An important observation from these 
studies is that the discrimination between normal subjects and patients with primary 
hyperparathyroidism is time dependent. Thus for optimal discrimination based on 
PTH (1-84) concentrations samples should be taken, and reference ranges 
established, between 1000 and 1600 h. Further, while the synchronised circadian 
rhythm is lost in patients with primary hyperparathyroidism the PTH (1-84) 
concentrations vary markedly about the patient’s 24 h mean concentration. Thus 
potential for overlap between these groups probably accurately reflects the 
pathophysiology of this condition such that patients with mild primary 
hyperparathyroidism may have PTH (1-84) concentrations within the reference range 
(Logue et al, 1990b).
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The PTH (1-84) concentrations in patients with hypercalcaemia of malignancy were 
well separated from those in patients with primary hyperparathyroidism with most 
HCM patients having undetectable PTH (1-84) concentrations. Studies using intact 
PTH (1-84) assays have shown a higher proportion of HCM patients to have 
detectable PTH (1-84) concentrations (Nussbaum et al, 1987, Brown et al, 1987) 
than observed with the assay developed in this project. The most probable 
explanation for this observation lies in the selection of the HCM patients. The APD 
study has shown that in treated HCM patients a relatively small decrease in serum 
calcium can produce a rise in PTH (1-84) even though the patient remains 
hypercalcaemic (Fraser et al, 1990). Thus the finding of detectable PTH (1-84) in 
HCM patients may reflect decreases in calcium due to either a response to the 
initiation of treatment or perhaps fluctuations in the course of the underlying 
malignant condition. PTH (1-84) concentrations in samples collected after the 
initiation of treatment, such as rehydration or APD, should therefore be interpreted 
with caution in the light of these observations.
It was not possible to make a direct comparison of the performance of the PTH (1- 
84) IRMA with that of the N-terminal specific assay previously employed in this 
laboratory due to lack of reagents for the latter method. However, recent studies 
comparing the performance of intact PTH (1-84) IRMA with that of the best 
’research' mid-molecule RIA methods have reported either equivalent (Endres et al,
1989) or superior performance of the intact PTH (1-84) methods (Wheeler et al,
1990) in the differential diagnosis of hypercalcaemia. In addition, given that the 
interpretation of mid-molecule assay results is difficult in renal failure, the ability of 
the PTH (1-84) IRMA to follow the suppression of secondary hyperparathyroidism 
as seen in the study in haemodialysis patients (Van Der Merwe et al, 1990) makes the 
PTH (1-84) IRMA the method of choice for the laboratory assessment of patients 
with disorders of calcium metabolism.
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In common with most other hormones PTH (1-84) concentrations in the circulation 
vary in a manner consistent with pulsatile secretion. The pulsatile release of 
hormones is an important principle in dynamic hormone-receptor interaction with the 
the modulation of pulse amplitude and frequency being major determinants of end 
organ response.
The information that can be obtained from studies on the dynamics of hormone 
secretion is directly related to the frequency of sampling. A sampling frequency of 
four to five samples for every cycle to be observed and a sampling period sufficient 
to observe four to five cycles has been recommended to avoid problems with 
interpretation due to aliasing phenomen a (Mathews 1988). Obviously an overriding 
consideration is that blood-loss in the subjects should be kept within ethical limits. 
The sampling period and frequency employed in this study were chosen specifically, 
with these considerations in mind, in the light of a previous report on the pulsatile 
nature of bioactive PTH (Dixit et al, 1987). The results confirmed a similar 
frequency of pulsatility, with pulses every 10-15 minutes, between intact PTH (1-84) 
and that reported for bioactive PTH. This supports the concept of PTH (1-84) being 
the major bioactive form of PTH in the circulation. Nevertheless more extensive 
sampling periods with appropriate sampling frequencies would be required both to 
establish the variation in pulsatility over a 24 h period and to investigate pulsatility at 
lower frequencies, for example, in the range of 2-4 h which have been demonstrated 
for other hormones.
There is general agreement that some form of objective analysis of the hormone 
profiles generated is required to enable valid comparison of the pulsatile secretion of 
hormones. The method chosen for this study is a standard mathematical technique in 
the analysis of time-series data. The method provides a good estimate of the 
dominant harmonics present taking account of the variance of the data. However 
analysis techniques specifically designed for the investigation of hormone pulsatility
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have been developed( Urban et al, 1988). The use of such techniques would provide 
a more rigourous analysis of the data generated in this study as parameters of 
hormone secretion (half-life, clearance) and assay performance (dose-related 
precision) would also taken into account.
The significance of the study of patterns of hormone pulsatility lies in the 
observations that modulation of amplitude and frequency can have dramatic effects 
on end organ response. Such changes may be seen in response to a change in 
metabolic state or in disease states. In this study the PTH (1-84) pulsatility, at the 
frequencies studied, appeared to be characteristic of the individual and did not 
correlate with the presence of primary hyperparathyroidism. On the other hand, in 
the investigation of the circadian secretion of PTH (1-84), where the sampling period 
was 24 h and sampling frequency 0.5 h, major changes were seen in the pattern of 
secretion in normal subjects on fasting. This pattern was qualitatively similar to that 
observed in hyperparathyroid subjects in whom the circadian rhythm of PTH (1-84) 
is absent. This may indicate that pulsatility with frequencies in the range 2-4 h may 
play a part in the response to metabolic changes and be associated with primary 
hyperparathyroidism. Studies are underway on the analysis of the underlying 
pulsatility in the data from the circadian studies.
It has been shown that the profile of the circadian secretion hormones, such as 
ACTH and TSH, are generated by modulation of the amplitude and frequency of the 
underlying pulsatile secretion (Veldhuis et al, 1990, Rossmanith et al, 1988). These 
observations further emphasise the inter-relationship between pulsatile and circadian 
secretion of hormones.
The most significant finding of the circadian studies is that the PTH (1-84) 
concentrations in normal subjects over a 24 h period show a stronger temporal 
correlation with other circadian hormones, notably prolactin, than with adjusted 
calcium concentrations. This both challenges the view that PTH (1-84) and plasma
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ionised calcium concentrations are inversely related and also suggests that other 
factors may be implicated in the tonic control of PTH (1-84) secretion. However, 
while the secretion of PTH (1-84) and prolactin follow a well defined circadian 
pattern such that there is a strong correlation between these hormones over a 24 h 
period the sleep-shift study indicated that the mechanism by which they are entrained 
to the biologically clock are fundamentally different. Nevertheless the evidence 
suggests that the control of PTH (1-84) secretion has a neuroendocrine component.
In addition it was notable that the NcAMP output of the subjects in the sleep-shift 
experiment suggested decreased PTH bioactivity. PTH (1-84) concentrations in 
normal subjects are maintained in a distinct phase relationship with those of prolactin 
and other circadian hormones over a 24 h period. It may be that this high degree of 
temporal organisation allows concerted metabolic effects between these hormones 
especially through the night.
The most consistent relationship throughout the circadian studies is that between 
PTH (1-84) and serum phosphate concentrations. The rhythm in serum phosphate is 
qualitatively similar and coincident with that of PTH (1-84). In the fasting study 
both rhythms were markedly altered. Thus a role for serum phosphate in the 
generation of the circadian profile of PTH (1-84) could not be excluded, as had 
been done previously, based on the dissociation of these rhythms during fasting.
From the observation that continuous infusions of PTH are not effective in 
promoting bone growth and that increased bone formation requires a regimen 
resulting in transient rises in PTH by daily injections (Podsbeck et al, 1983, 
Malluche et al, 1982) it has been postulated that the nocturnal rise in PTH (1-84) is 
an important factor in normal bone physiology. Further it has been suggested that 
abnormalities of the PTH (1-84) secretion rhythm may play a part in the aetiology of 
osteoporosis. This concept has been strengthened by the finding of reduced 
pulsatility of PTH (1-84) secretion in osteoporotic patients (Harms et al, 1989). It is 
of note also that abnormalities have been demonstrated in osteoporotic compared to
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normal elderly women in the response of PTH and 1,25 dihydroxyvitamin D to 
provocative testing with a phosphate challenge (Silverberg et al, 1989). In addition 
a survey of the effect of ageing on parameters of bone metabolism in a healthy elderly 
population revealed that the only major difference between males and females was in 
the regulation of the phosphate set-points with age (Sherman et al, 1990). Thus it 
would be possible to postulate a role in the bone loss associated with osteoporosis 
for alterations in the PTH (1-84) secretion rhythm which may be either directly 
related to, or merely reflected by, abnormal phosphate metabolism.
Proposals for future work
1. The original aims of this thesis in terms of the performance of the PTH (1-84) 
assay developed have been successful. The assay sensitivity may potentially be 
improved by the development of a non-isotopic label system. Whilst the clinical 
studies have shown that the sensitivity of the assay, using the iodine125  
radiolabel, has not been been limiting the development of a more sensitive 
assay will allow equivalent performance to be attained with a smaller sample 
volume - thus enabling greater sampling frequencies to be employed in studies 
of the dynamics of PTH (1-84) secretion.
2. The development of an assay system for parathyroid hormone related peptide 
(by the application of a similar strategy that employed for PTH (1-84)) will 
allow the elucidation of the relative roles of PTH (1-84) and PTHrP in the 
aetiology and treatment of hypercalcaemia of malignancy and permit an 
understanding of the role of PTHrP in normal physiology.
3. Further work is required to evaluate the relative contributions of ionised 
calcium, phosphate and neuroendocrine factors to the control of the circadian 
rhythm of PTH (1-84) secretion.
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4. It is increasingly possible that subtle alterations in the fine control of PTH (1- 
84) contribute to the aetiology of both type 1 and 11 osteoporosis. In order to 
examine this possibility it will be necessary to assess both the pulsatility and the 
circadian rhythm of PTH (1-84) secretion in well defined patient groups and in 
control subjects matched for age, sex and dietary intake.
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